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ABSTRACT 
G. SEVGİ BAĞIŞLAR 
PhD in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Mehmet Öztürk 
August 2009, 123 Pages 
 
Genetic and epigenetic aspects of cellular senescence and immortality in hepatocellular 
carcinoma (HCC) are poorly elucidated. The aim of our thesis was to characterize 
senescence and immortality gene network (SIGN) involved in these cancers. We also 
wished to explore epigenetic changes associated with senescence and immortality of 
HCC cells. First, we identified differentially expressed genes in immortal, pre-senescent 
and senesce-arrested Huh7 clones. Our microarray analysis revealed 6390 probesets 
significantly changing among groups. Moreover, the significant gene signature could 
successfully discriminate both replicative senescent cells, and oncogene-induced 
senescent cells from their immortalized counterparts. E2F1 targets, stem-cell related 
genes, DNA repair, RNA splicing and cell cycle related gene sets were enriched 
specifically in immortal cells, whereas immune function, stress response, electron 
transporter activity, protein modification, metabolism, chromatin biogenesis related gene 
groups were significantly up-regulated in senescent clones. Next, we integrated gene 
expression data from senescence-programmed and immortal HCC cells with the data 
from cirrhosis and HCC tissues to generate a SIGN signature. This signature identified 
several HCC classes, including one “normal-like”, and two with increased expression of 
immortality genes. Senescence-to-immortality transition was accompanied by hepatic 
dedifferentiation and increased expression of cell proliferation, chromosome modification 
and DNA damage response genes. Finally, we identified a large set of upregulated DNA 
damage checkpoint and DNA repair genes that showed significant associations with some 
SIGN classes of HCC tumors. As retinoblastoma/E2F pathway plays a key role in cellular 
senescence, we also analyzed E2F and DP family members in senescent and immortal 
hepatocellular carcinoma cells. E2F1, E2F5, E2F7, E2F8 and DP1 were up-regulated in 
immortal hepatocellular carcinoma (HCC) cell lines as compared to senescent cells, 
whereas E2F3a and DP-2 expressions were downregulated. Upregulation of DP2 
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expression in senescent cells correlated with increased DP2 protein expression, as tested 
with TGF-beta induced senescence models. Finally, we demonstrated important 
epigenetic changes associated with hepatocellular immortality and senescence. Among 
histone methyltransferases and demethylases, MLL3, FBXL11, SUV420H1, UTX, 
SMYD2, SETD2, JMJD2B, JMJD3, JARID1B and ASH1L genes were up-regulated, and 
EZH2 was down-regulated in senescent cells. These changes were accompanied with 
changes in histone methylation patterns. Of particular interest, H3K27me1, H3K27me3, 
H4K20me3, H3R2me2a and H4R3me2a forms of methylated histones displayed 
increased expression in both Huh7 and MRC5 senescent cells, as compared to their 
immortal forms. Finally, H3K27me3, H4K20me3, H3K36me3, H3R17me2a, H4R3me2a 
also showed decreased expression in some cirrhotic liver and primary HCC tumors. In 
conclusion, we demonstrated that a large set of senescence and immortailty genes were 
dysregulated in HCC. This profound change in gene expression was associated with 
differential expression of histone modifying enzymes, as well as histone methylation 
status. Thus, the immortalization of hepatocytes during hepatocellular carcinogenesis is 
accompanied with global gene expression changes probably mediated by a major 
modification of their epigenetic program via histone demethylation.  
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ÖZET 
İMMORTAL VE HÜCRE YAŞLANMASI PROGRAMLI KARACİĞER KANSER 
HÜCRELERİNDE GENETİK VE EPİGENETİK ANALİZİ 
G. SEVGİ BAĞIŞLAR 
Doktora Tezi, Moleküler Biyoloji ve Genetik Bölümü 
Danışman: Prof. Dr. Mehmet ÖZTÜRK 
Ağustos 2009, 123 Sayfa 
Hepatoselüler karsinomda (HCC), hücre yaşlanması ve immortalitesinin genetik ve 
epigenetik özellikleri henüz zayıf olarak açıklanmıştır. Tezimizin amacı; karaciğer 
kanserinde rol alan hücre yaşlanması ve immortalite gen ağını karakterize etmektir. 
Ayrıca, hücre yaşlanması ve immotral HCC hücrelerinin epigenetik değişikliklerini de 
incelemek istedik. İlk önce, immortal, erken hücre yaşlanması ve hücre yaşlanması Huh7 
klonlarında gen ifade farklılıklarını bulduk. Mikroarray çip çalışmamız sonucunda 6390 
prob seti, bu gruplar arasında değişiklik gösterdi. Daha fazlası, bu anlamlı gen seti; hem 
replikatif hücre yaşlanması hem de oncogen indüklenmiş hücre yaşlanması modellerini, 
bunların immortalize edilmiş karşılıklarından başarı ile ayırdı. Biyolojik fonksiyon 
gruplama çalışmaları; E2F1 hedef genlerinin, kök hücre ilişikli genlerin, DNA tamir, 
RNA splicing ve hücre döngüsü ilişik gen gruplarının özellikle immortal hücrelerde 
ifadesinin arttığını gösterdi. Öte yandan, immün sistem, stres cevabı, elektron taşınımı, 
protein modifikasyonu, metabolizma ve kromatin biyogenezi ile ilgili grupları yaşlanmış 
hücre klonlarında ifade gösteriyordu. Ayrıca, immortal ve hücre yaşlanması programlı 
hücre datasıyla siroz ve HCC doku datasını birleştirerek, ortak değişen “hücre yaşlanması 
ve immortal gen ağı (SIGN) listesini elde ettik. SIGN gen seti, farklı HCC alt gruplarını 
birbirinden ayırmayı başardı. SIGN gen setinde hücre yaşlanmasından immortale doğru 
anlamlı olarak değişen gruplar; hepatic de-differensiye genleri, hücre döngüsü, 
kromozom modifikasyonu ve DNA hasarına cevap veren gen grupları idi. Ayrıca, geniş 
bir sayida DNA tamir genlerinin tümor oluşumu ve ilerlemesi ile alakalı olduğunu 
belirledik.  
Retinoblastoma/E2F yolağı hücre yaşlanmasında önemli bir rol oynamaktadır, biz de bu 
yüzden E2F ve DP protein ailesi üyelerinin yaşlanmış ve immortal programlı 
hepatoselüler karsinomlarında analiz ettik. E2F1, E2F5, E2F7, E2F8 ve DP1 genlerinin 
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ifadesi immortal hücrelerde artış gösterdi. Öte yandan E2F3a ve DP2 genlerinin ifadesi 
azalmıştı. DP-2 ifadesinin senesens Huh7 hücrelerde artışı; DP2 protein artışı ile 
ilintilendirildi ve aynı artış TGF-beta indüklenmiş hücre yaşlanmasında da gözlendi.  
Son olarak, hepatoselüler immortalite ve yaşlanmış hücrelerinde önemli epigenetik 
değişiklikler gösterdik. Histone metiltransferaz ve demetilazlar arasında; MLL3, FBXL11, 
SUV420H1, UTX, SMYD2, SETD2, JMJD2B, JMJD3, JARID1B ve ASH1L genlerinin 
hücre yaşlanmasında artış gösterdiğini ve EZH2 geninin azalış gösterdiğini gözlemledik. 
Bu değişiklikler eşliğinde, histon metilasyon seviyeleri de değişikliğe uğruyordu. 
Yaşlanmış Huh7 ve MRC5 hücrelerde immortal eşdeğerlerine göre, H3K27me1- and 3, 
H4K20me3, H3R2me2a ve H4R3me2a rezidülerinin artış gösterdiğini gözledik. 
H3K27me3, H4K20me3, H3K36me3, H3R17me2a, ve H4R3me2a rezidüleri bazı sirotik 
karaciğer ve HCC tümörlerinde azalan bir ifade gösterdi.  
Sonuç olarak, geniş sayıda immortal ve hücre yaşlanması genlerinin HCC de de 
değiştiğini göstermiş olduk. Histon modifiye eden genleri ve histon metilasyon seviyesi 
de değişikliğe uğruyordu. Yani, hepatositlerin immortalizasyon süreçleri global gen ifade 
değişikliği ile oluyor ve, büyük ihtimalle, bu değişim epigenetik program tarafından 
yönlendiriliyor.   
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CHAPTER 1. INTRODUCTION 
 
1.1 Hepatocellular malignancy 
The liver is a vital organ present in vertebrates and some other animals; it has a wide range of 
functions, a few of which are detoxification, protein synthesis, and production of 
biochemicals necessary for digestion. The liver plays a major role in metabolism and has a 
number of functions in the body, including glycogen storage, decomposition of red blood 
cells, plasma protein synthesis, hormone production, and detoxification. It lies below the 
diaphragm in the thoracic region of the abdomen. It produces bile, an alkaline compound 
which aids in digestion, via the emulsification of lipids. It also performs and regulates a wide 
variety of high-volume biochemical reactions requiring highly specialized tissues, including 
the synthesis and breakdown of small and complex molecules, many of which are necessary 
for normal vital functions (Anthea et al, 1993).  
Primary cancer of the liver is the fourth most common cause of death from cancer 
(estimated mortality is more than 600,000 deaths per year) and the third most common 
malignancy in human (Ferlay et al, 2001),  (1). The lethality of liver cancer stems in part from 
its resistance to existing anticancer agents, a lack of biomarkers that can detect surgically 
resectable incipient disease, and underlying liver disease that limits the use of 
chemotherapeutic drugs (2). There are two main kinds of primary liver cancer, hepatoma and 
cholangiocarcinoma. Hepatoma is cancer of the hepatocytes, the main functioning liver cells. 
Cholangiocarcinoma originates in the bile ducts. Hepatoblastoma (HB) is the most common 
pediatric liver malignancy, comprising approximately 1% of all pediatric cancers (3). Liver 
angiosarcoma is a very rare type of primary liver cancer developing from the cells of blood 
vessels within the liver. Hepatocellular carcinoma (HCC) is one of the most common 
malignant liver tumors (83% of all cases) in the world with a high prevalence in Asia and sub-
Saharan Africa (4). Recent studies have shown that the incidence of HCC has substantially 
increased in the USA as well as in other areas including Japan and Europe (El-Serag and 
Mason, 1999), (Taylor-Robinsonet al., 1997). HCC is one of the few human cancers in which 
an underlying etiology can often be identified in most cases. Hepatocarcinogenesis nearly 
always develops in the setting of chronic hepatitis or cirrhosis; conditions in which many 
hepatocytes are killed, inflammatory cells invade the liver and connective tissue (5).  
Development of HCC is a multistep process and slow. The sequential events leading to HCC 
may be summarized in five steps: chronic liver injury that produces inflammation, cell death, 
cirrhosis and regeneration, DNA damage, dysplasia, and finally HCC (Figure 1.1) (6), (2).  
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Figure 1.1: Multistage process of hepatocarcinogenesis (2). 
  
1.2   Pathogenesis of hepatocellular carcinoma 
HCC affects all segments of the world population, although significant differences in HCC 
incidence in various countries reflect the regional differences in the prevalence of specific 
etiological factors as well as ethnicity (American Cancer Society. Cancer Facts and FIGS 
2005. American Cancer Society [online], http://www.cancer.org/docroot/home/index.asp 
(2005)). The most prominent factors associated with HCC include chronic hepatitis B and C 
viral infection, chronic alcohol consumption, aflatoxin-B1-contaminated food and virtually all 
cirrhosis-inducing conditions (Figure 1.2) (7). Other etiological factors have also been 
proposed to lead to HCC, albeit at a lower frequency; such as certain metabolic disorders, 
diabetes, non-alcoholic fatty liver disorders. In addition, gender can also influence the risk 
and behavior of HCC, with males accounting for a larger  fraction of cases (8). 
 
1.2.1 Viral-induced hepatocarcinogenesis 
Hepatitis B virus (HBV) infects approximately 2 billion individuals worldwide and causes an 
estimated 320,000 deaths annually. Approximately 30–50% of HBV-related deaths are 
attributable to HCC (9). The impact of HBV infection on HCC development is reflected by 
the correlation between increased incidences of HCC in patients with increasing levels of 
HBV DNA in serum (10). Hepatitis C virus (HCV) infects approximately 170 million 
individuals worldwide (11). Approximately 20% of chronic HCV cases develop liver 
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cirrhosis, and 2.5% develop HCC (12). The viral-associated mechanisms driving 
hepatocarcinogenesis are complex and involve both host and viral factors. 
HBV is a non-cytopathic, partially double-stranded hepatotropic DNA virus classified 
as a member of the hepadnaviridae family. The HBV genome encodes several viral proteins 
essential to its life cycle, including a reverse transcriptase/DNA polymerase (pol), the capsid 
protein known as hepatitis B core antigen (HBcAg), and the L, M and S envelope proteins 
that associate with the endoplasmic reticulum (ER) membrane as part of their replication 
process. HBV also encodes a number of proteins whose functions are not fully understood, 
such as protein x (HBx) (13).  
 Several lines of evidence support the direct involvement of HBV in the transformation 
process. First, HBV genome integration has been associated with host DNA microdeletions 
(14) that can target cancer-relevant genes including telomerase reverse transcriptase (TERT), 
platelet-derived-growth-factor receptor-β (PDGFRβ ), PDGFβ and mitogen activated protein 
kinase 1 (MAPK1), among others (15). Second, HBx transcriptional activation activity can 
alter the expression of growth-control genes, such as SRC tyrosine kinases, Ras, Raf, MAPK, 
ERK, JNK and others (16), (17). Finally, HBx can bind and inactivate the tumor suppressor 
p53 in vitro, therefore increasing cellular proliferation and survival and compromising DNA-
damage checkpoints (18), (19). The hepatocarcinogenic potential of HBx has been genetically 
validated in HBx transgenic mice, of which 90% develop HCC (20). 
 Host–viral interactions seem to contribute to hepatocarcinogenesis in several ways. A 
robust T-cell immune response is presumably elicited to combat viral infection, however, this 
response contributes to hepatocyte necrosis, inflammation and consequently regeneration, 
leading to carcinogenesis (13).  Such continuous replication of hepatocytes might enable the 
propagation of oncogenic lesions and telomere erosion with consequent genomic instability. 
Another proposed mechanism of HBV-induced hepatocarcinogenesis might stem from viral–
ER physical interactions, that provoke ER stress and ultimately the induction of oxidative 
stress (21), which can stimulate growth- and survival-signaling pathways, cause mutations 
through the generation of free radicals and activate stellate cells (22). 
 HCV is a non-cytopathic virus of the flaviviridae family. The HCV positive-stranded 
RNA genome encodes non-structural proteins (NS2, NS3, NS4A, NS5A and NS5B), which 
associate with the ER membrane to form the viral replicase and viral envelope proteins (E1 
and E2). An important recent advance has been the establishment of a cell-culture model 
supporting efficient HCV replication and infectious particle production (23) (24), enabling the 
molecular dissection of these processes for the first time. 5–10% of HCV-infected patients 
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develop liver cirrhosis after 10 years of infection, a frequency that is approximately 10–20-
fold higher than HBV, a highly relevant association as cirrhosis is a significant correlate of 
HCC development (25).  
 Both viral and host factors are thought to contribute to HCC development in the 
setting of HCV infection, analogous to HBV (13). One theory for HCV-induced 
hepatocarcinogenesis posits that the continuous cycles of hepatocyte death caused by the 
immune response to the virus and subsequent regeneration provide a context for the 
accumulation and propagation of mutations. HCV RNA and/or core proteins have been 
suggested to impair dendritic cell functions that are important for T-cell activation (26). In 
addition, HCV core proteins have been shown to interact with components of the MAPK 
signaling pathway (such as ERK, MEK and Raf) and therefore modulate cell proliferation 
(27). NS5A has also been shown to interact with and inactivate p53 by sequestration to the 
perinuclear membrane, thereby affecting the p53-regulated pathways that control cell-cycle 
progression, cellular survival, response to hypoxic and genotypic stresses, and tumor 
angiogenesis (28).  
 
1.2.2 Alcohol-induced hepatocarcinogenesis 
Chronic alcohol intake has been implicated in causing the production of proinflammatory 
cytokines through monocyte activation and provoking increased concentrations of circulating 
endotoxin, activating Küpffer cells which release many chemokines and cytokines (including 
TNFα, interleukin-1β (IL1β), IL6 and prostaglandin E2) with adverse effects on hepatocyte 
survival (29). In the setting of chronic ethanol exposure, hepatocytes show increased 
sensitivity to the cytotoxic effects of TNFα, which sets the stage for chronic hepatocyte 
destruction–regeneration, stellate cell activation, cirrhosis and ultimately HCC (29). 
 Alcohol also damages the liver through oxidative stress mechanisms. Alcoholic 
hepatitis shows increased isoprostane, a marker of lipid peroxidation (30). Oxidative stress 
might contribute to hepatocarcinogenesis in several ways; promoting fibrosis and cirrhosis via 
activation of stellate cells, actin on HCC-relevant signalling pathways, such as the 
documented reduction in tyrosine phosphorylation of STAT1, and causing accumulation of 
oncogenic mutations. 
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Figure 1.2 Mechanisms of hepatocarcinogenesis (2).  
 
1.2.3 Aflatoxin-B1-induced hepatocarcinogenesis 
Ingestion of the fungal toxin, aflatoxin B1, also poses an increased risk for the development of 
HCC. Aflatoxin B1 seems to function as a mutagen, and is associated with a specific p53 
mutation (codon 249, G to T mutation) (31). 
 
1.3        Genetic and epigenetic events in HCC 
The neoplastic evolution of HCC proceeds through a multi-step histological process that is 
less well defined than that of other cancer types (Figure 1.2). The molecular analysis of 
human HCC has shown many genetic and epigenetic alterations that result in the deregulation 
of key oncogenes and tumor-suppressor genes including TP53, β-catenin, ErbB receptor 
family members, MET and its ligand hepatocyte growth factor (HGF), p16(INK4a), E-
cadherin and cyclooxygenase 2 (COX2). 
 
1.3.1 The p53 tumour suppressor 
Although it is widely accepted that p53 deficiency participates in the development of HCC, 
whether p53 mutation contributes to cancer initiation, progression or both remains an area of 
active investigation. In humans, analyses of HBV- and HCV-related HCCs have shown a 
greater frequency of p53 mutations in advanced malignancies (43%) than in regenerative 
nodules (~7%) (32). In the context of aflatoxin B1, regions of high aflatoxin B1 exposure 
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show frequent p53 mutations in early-stage HCC lesions, whereas regions of low aflatoxin B1 
exposure show p53 mutations in much later stages of HCC (33).  
 
1.3.2 β-catenin and AXIN1 
β-catenin is a crucial downstream component of the Wnt signalling pathway. When Wnt 
signalling is engaged, the adenomatosis polyposis coli (APC) and Axin proteins no longer 
bind β-catenin, with consequent β-catenin stabilization and translocation to the nucleus where 
it associates with the Tcf family of transcription factors. This transcription factor complex 
trans-activates a host of target genes governing cancer-relevant processes, including MYC, 
cyclin D1, COX2, and matrix metalloproteinase 7 (MMP7) (34).  
 β-catenin mutations and increased nuclear expression have been detected in human 
HCC (35). In some reports, β-catenin over-expression and mutations have been related to 
early-stage HCCs (5) and in others to HCC progression (36). Over-expression and mutations 
of β-catenin occur more frequently in HCV-related HCCs compared with HBV-related HCCs 
(37).  
Aberrant accumulation of beta-catenin is observed at high frequency in many cancers 
(38). This accumulation correlates with either mutational activation of CTNNB1 (beta-catenin) 
or mutational inactivation of APC and Axin1 genes in some tumors. In addition to mutations 
in the beta-catenin gene, mutations in the Axin1 and Axin2 genes may alter the Wnt signaling 
pathway, resulting in accumulation of beta-catenin in HCC. In literature; there are studies 
indicating that Axin1 mutation is observed in a specific portion of HCC cases (10%-25% in 
different studies) (39), (40). Somatic mutations of exon 3-5 of AXIN1 have been observed in 
25% of HCC patients. Moreover, reduced or absent expression of axin was seen in 66.7% 
HCCs tested. The abnormal expression of beta-catenin and axin proteins was closely 
correlated with mutations of AXIN1 and beta-catenin (P < 0.0001 and P = 0.008, respectively). 
The researchers suggest that mutation of AXIN1 gene is a frequent and late event for HCC, 
associated with cirrhosis, and is correlated significantly with abnormal expression of axin and 
beta-catenin. Transduction of the wild-type Axin gene (AXIN1) induces apoptosis in HCC 
cells as well as in colon cancer cells. 
 
1.3.3 ErbB receptor family  
The examination of these receptor tyrosine kinases has documented the overexpression of 
ERBB1 (also known as epidermal growth factor receptor (EGFR)) in 68% of HCC cases, 
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ERBB3 in 84%, ERBB2 (also known as HER2) in 21% and ERBB4 in 61% (but at a lower 
level) (41).   
 
1.3.4 MET and HGF 
Overexpression of the MET receptor has been reported in advanced human HCCs (42). The 
role of MET signalling in HCC development has been confirmed in mouse models, whereby 
mice transgenic for the MET ligand HGF, one of the most potent hepatocyte mitogens, 
develop HCCs by 1.5 years of age (43).  
 
1.3.5 Methylation of cancer-relevant genes 
Aberrant DNA methylation patterns have been reported in human HCC (44). Methylation has 
been detected in the earliest stages of hepatocarcinogenesis, and to a greater extent in tumor 
progression (45). Specific hypermethylation events in HCC have targeted p16(INK4a), E-
cadherin, COX2, apoptosis-associated speck-like protein (ASC) and deleted in liver cancer 1 
(DLC1), among others (18). 
Studies have reported methylation at p15, SOCS1, RIZ1 and CASP8 in HCC (46). 
Methylation status of RASSF1A, SOCS1 and CASP8 in 97 tumors found to be 
hypermethylated in 30.9, 33.0 and 15.5%, respectively. Moreover, methylation status of 
RASSF1A but not the other 2 genes predicted the outcome of HCC (47). In an other study, 
Okochi et. al. detected that aberrant methylation of the SOCS-1 gene in 30 of 50 (60%) HCC 
specimens. No corresponding nontumorous liver tissues have showed SOCS-1 methylation. 
Subsequent Northern analysis proved that methylation of the SOCS-1 promoter inactivated 
translation and diminished expression of SOCS-1 mRNA. They analyzed the correlation 
between the clinicopathological data and SOCS-1 aberrant methylation and found that HCC 
derived from liver cirrhosis had a significant relationship with SOCS-1 methylation (P = 
0.0207) (48). 
 
1.3.6 c-Myc 
Recently, Kaposi-Novak et. al. identified that the MYC oncogene as a plausible driver gene 
for malignant conversion of the dysplastic nodules. They showed that induction of MYC 
target genes occurred ubiquitously during malignant conversion (49). 
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1.4      Liver cirrhosis and senescence 
Liver cirrhosis, the irreversible terminal stage of chronic liver disease, characterized by 
widespread fibrous scarring, serious complications of liver cirrhosis includes those: 
accumulation of fluid in the abdomen (ascites), bleeding disorders (coagulopathy), increased 
pressure in the blood vessels (portal hypertension), and confusion or a change in the level of 
consciousness (hepatic encephalopathy). Regenerative nodules are characteristic lesions of the 
cirrhotic liver. Dysplastic foci, which are smaller than 1 mm, can be found in regenerative 
nodules. There are two types of dysplastic foci in cirrhotic livers, small cell-dysplasia (SCD) 
and the large cell-dysplasia (LCD), according to the nuclear/cytoplasmic ratio. 
Hepatocyte telomere shortening and senescence are general markers of human liver 
cirrhosis, and correlates with progression of fibrosis in cirrhosis samples (Wiemann SU.et al., 
2002). Additionally, Paradis V et al. observed an increasing percentage of replicative 
senescent liver cells from normal liver to chronic hepatitis and HCC (Paradis V. et al., 2002). 
 
1.4.1 Cellular senescence 
The term ‘‘cellular senescence” was initially used by Hayflick and colleagues to define cells 
that ceased to divide in culture (50). Today, cellular senescence is recognized as a response of 
proliferating somatic cells to stress and damage from exogenous and endogenous sources. It is 
characterized by permanent cell cycle arrest. Senescent cells also display altered morphology 
and an altered pattern of gene expression, and can be recognized by the presence of 
senescence markers such as senescence-associated b-galactosidase (SABG), p16INK4A, 
senescence-associated DNA-damage foci and senescence-associated heterochromatin foci 
(51). This cellular response has both beneficial (anti-cancer) and probably deleterious (such as 
tissue aging) effects on the organism. 
Upstream checkpoint kinases, such as ATM or ATR are activated in response to DNA 
damage in the form of double-stand breaks. These kinases phosphorylate downstream factors 
including CHK1 and CHK2 that in turn phosphorylate p53. Phosphorylation of p53 results in 
its activation by the displacement of the MDM2 protein. Critical involvement of this p53 
activating pathway has been reported for both telomere-dependent, and oncogene-induced 
senescence (52). Most cells senesce owing to engagement of the p53 pathway, p16–pRB 
pathway, or both (Figure 1.3). 
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Figure 1.3 Senescence controlled by the p53 and p16–pRB pathways (51).  
 
1.4.1.1 Replicative senescence 
Human chromosome telomere ends which are composed of TTAGGG repeats (5–20 kb) in a 
DNA-protein complex formed by six telomere-specific proteins, called ‘‘shelterin” (53) 
prevent genomic instability and the loss of essential genetic information by ‘‘capping” 
chromosome ends. They are also indispensable for proper recombination and chromosomal 
segregation during cell division. Telomeres become shorter with every cell division in somatic 
cells, because of replication complex’s inability to copy the ends of linear DNA, which also 
makes them a ‘‘cell cycle counter” for the cell (54). Telomeres are added to the end of 
chromosomes with a complex containing the RNA template TERC and the reverse 
transcriptase TERT (55). Most somatic cells lack telomerase activity because the expression 
of TERT is repressed, in contrast to TERC expression. It is now well known that telomere-
dependent senescence is induced by a change in the protected status of shortened telomeres, 
whereby the loss of telomere DNA contributes to this change (56). At least two other forms of 
telomere-independent senescence are presently known: (1) oncogene-induced senescence; and 
(2) reactive oxygen species (ROS)-induced senescence (Figure 1.4). 
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Figure 1.4 Senescence pathways (52). 
 
1.4.1.2 Oncogene and ROS-induced senescence   
Oncogene-induced senescence had initially been identified as a response to expression of Ras 
oncogene in normal cells, accompanied by accumulation of p53 and p16INK4a. In addition to 
Ras, other oncogenes including Raf, Mos, Mek, Myc and Cyclin E also induce senescence 
(57). Similar to telomere-dependent senescence, oncogene-induced senescence is also 
primarily a DNA damage response (Figure 1.3).  
  ROS-induced senescence, the other telomere-independent senescence pathway is 
gaining importance, also. Experimental induction of ROS accumulation in cells (for example 
by mild H2O2 treatment or glutathione depletion) induces senescence-like growth arrest in 
different cell types, whereas anti-oxidant treatment can inhibit senescence (58). More 
importantly, ROS have been identified as critical mediators of both telomere-dependent and 
oncogene-induced senescence (52). 
 
1.4.2 Senescence as an anti-tumor mechanism in hepatocellular carcinoma 
Recent findings indicate that senescence induction is a powerful mechanism of HCC 
regression. Xue et al. expressed H-ras oncogene and suppressed endogenous p53 expression 
in mouse hepatoblasts which produced massive HCCs upon implantation into livers of 
athymic mice (59). However, these tumors regressed rapidly upon restoration of p53 
expression. Tumor regression was due to differentiation and massive senescence induction, 
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followed by immune-mediated clearance of senescent cells. These observations may indicate 
that oncogene-induced senescence is also involved in HCC. On the other hand, HCCs induced 
by tet-regulated c-Myc activation in mouse liver cells differentiate into mature hepatocytes 
and biliary cells or undergo senescence (60). Thus, senescence induction may also be relevant 
to oncogene inactivation in HCC. So far, all the reported examples of senescence induction in 
HCC cells are in the form of a telomere-independent permanent cell cycle arrest. Until 
recently, it was unknown whether replicative senescence could also be induced in immortal 
cancer cells. Our group reported recently that immortal HCC cells can revert spontaneously to 
a replicative senescence phenotype (61). HCC cells generated progeny that behaved, in vitro, 
similar to normal somatic cells. Such senescence-programmed progeny (C3 and G12 clones) 
lacked telomerase activity due to TERT repression (probably mediated by SIP1 gene), and 
displayed progressive telomere shortening in cell culture, resulting in senescence arrest. On 
the other hand, immortal clones (C1 and G11) had indefinite proliferation capacity with high 
tumorigenic capacity.   
 
1.4.3 Cyclin-dependent inhibitors as common mediators of senescence arrest    
Most if not all senescence pathways result in the activation of cyclin-dependent kinase 
inhibitors (CDKIs) in order to induce permanent cell cycle arrest. Senescent cells accumulate 
at G1 phase of the cell cycle due to an inability to enter into S phase in order to initiate DNA 
synthesis. The transition of proliferating cells from G1 to S phase requires the release of E2F 
factors from their inhibitory partner retinoblastoma protein (pRb) following phosphorylation 
by cyclin-dependent kinases (CDKs), in particular by CDK4/CDK6 and CDK2 at this stage of 
the cycle (62). The senescence arrest is mediated by inhibition of pRb phosphorylation by 
CDK4 and CDK2. The activities of these enzymes are controlled by different mechanisms, 
but the major proteins involved in the control of senescence arrest are CDKIs. Almost all 
known CDKIs have been reported to be implicated in senescence arrest, but three of them are 
best characterized: p16INK4a and p15INK4b which inhibit CDK4/CDK6, and p21Cip1 which 
inhibits CDK2 (Fig. 2). p21Cip1 is one of the main targets of p53 for the induction of cell 
cycle arrest following DNA damage (63). Pathways that generate DNA damage response and 
p53 activation use p21Cip1 as a major mediator of cellular senescence to control pRb protein 
(64). Exceptionally, p21Cip1 can be activated by p53-independent pathways to induce 
senescence (65).  
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1.5       Expression Profiling Using Affymetrix GeneChip Microarrays 
The approximately 25,000 genes in mammalian genomes can be transcribed at different 
levels. Measurements of gene expression for ten thousands of genes in parallel give the most 
comprehensive picture of steady-state levels of transcripts and is used in basic and applied 
research. Microarrays are the most frequently used technology for genome-wide expression 
profiling; from the various available microarray platforms, Affymetrix GeneChips are most 
frequently used for expression profiling and over 3,000 scientific publications describe results 
of this technology. In medical research, expression profiling by microarrays holds great 
promises for better understanding of diseases, identification of new therapeutic targets, and 
subclassification of diseases to identify individualized treatment strategies (66). Microarray 
studies provide evidence that a large set of growth control genes is deregulated in HCC (1). 
A typical microarray experiment involves the hybridization of an mRNA molecule to 
the DNA template from which it is originated. Many DNA samples are used to construct an 
array. The amount of mRNA bound to each site on the array indicates the expression level of 
the various genes. This number may run in thousands. All the data is collected and a profile is 
generated for gene expression in the cell (67).  
Affymetrix microarray technology uses oligonucleotides consisting of 25 bases. A 
special technique called photolithographical array production is applied to sequence or 
synthesize the oligonucleotides on a glass support. Each gene (or transcript) is represented by 
22 different oligonucleotide fragments that are attached to a tiny section of the chip (density 
of up to 500 000 sections per 1.6 cm2). Each section carries 22 different oligonucleotide 
sequences (11 matches and 11 mismatches). Thus, the expression of a gene is given by 11 
signal intensities (compared to 1 signal for cDNA microarrays). The 11 mismatch strands 
serve to determine the specificity of measured signal. The production of target DNS includes 
some further steps. After the isolation of mRNA and the reverse transcription to cDNA, the 
cDNA strands are converted to double stranded DNA molecules. After this step, the DNA is 
converted to cRNA molecules using a special polymerase (T7 polymerase) and fluorescently 
labelled. This cRNA is hybridised to the microarray. Unbound cRNA are washed away and 
signal intensities are scanned. The Affymetrix GeneChip Human Genome U133 set is made 
up of over 1,000,000 unique oligonucleotide features covering over 39,000 transcript variants 
which represent 33,000 of the best characterized human genes. Sequences used in the design 
of array were selected from GeneBank, dbEST, and RefSeq.  
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1.6   Rb/E2F pathway 
The Rb-E2F pathway links growth-regulatory pathways to a transcription program involved in 
DNA synthesis, cell-cycle progression, cell division, apoptosis, DNA repair, differentiation 
and senescence (68). This transcription program is repressed when hypophosphorylated pRb is 
bound to E2F proteins or recruit co-repressors to the proteins, and active when pRb is 
phosphorylated by CDK4/6, which frees E2F proteins to function as transcription factors via 
forming heterodimers with DP proteins. Eight E2F genes encode nine major proteins that 
share a related DNA-binding domain and are classified as either ‘activating’ or ‘repressor’ 
E2Fs (69). E2F1, E2F2 and E2F3a localize to the promoters of target genes in the G1/S phase 
and activate transcription of these genes; whereas E2F4, E2F5 and, most probably, E2F3b 
bind their target promoters in association with Rb family members in the G0/G1 phase 
coincident with their repression (70). E2Fs 1-5 have pocket-protein binding domains that 
enable them to interact with pRb and its homologs p107 and p130. E2Fs 6-8 lack this domain, 
and repress transcription via other mechanisms; for example, E2F6 exerts its effect by binding 
to the Polycomb group’s transcriptional repressors.  The E2F proteins, except E2F7 and 8, 
form heterodimers with DP (or TFDP), which enhances their DNA binding, transactivation 
and pRb-binding activities DP1 and DP2 (which is the human equivalent to murine DP3) 
proteins are 70% homologous and each form functional dimers with any E2F protein (71). The 
other DP family protein, DP4, which has been recently characterized, shares 90% homology 
with DP1 and heterodimerizes with E2F (72). DP proteins have a DNA-binding domain that 
shares sequence homology with the E2F DNA-binding domain (73). As pRb protein is the key 
player in cell-cycle progression, it is not surprising that it and its upstream regulators, such as 
Cyclin D1, cyclin-dependent kinase 4 and p16INK4a are frequently mutated in numerous types 
of human tumours (73). And thus, attention has focused on the involvement of downstream 
regulators of pRb in tumourigenesis, of which E2F/DP transcription factors are the best 
characterized set. Increased levels of E2F1 have been associated with tumorigenesis and a 
poorer outcome of melanoma, small-cell lung carcinoma, breast and pancreas carcinomas 
both in vitro and in vivo, whereas decreased E2F1 expression has resulted in more aggressive 
disease progression in colon cancer, bladder cancer and diffuse large B-cell lymphoma (74), 
(75), (76), (77).  
It is becoming apparent that the function of any given E2F/DP family protein in 
regulating cell proliferation, apoptosis, quiescence or senescence is more complex than 
previously thought and most probably dependent on cell type and context (78). The Rb 
pathway is among the pathways most frequently disrupted in HCC. RB1 is inactivated by 
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direct mutation or loss of the RB1 gene, and phosphorylation of the pRb protein is deregulated 
through aberrant cdk activity (via loss of p16INK4a expression or cyclin-D1 amplification) (5). 
Up-regulation of pRb-free E2F1-DP1 and E2F2-DP1 heterodimers is found to be a major 
cause of aberrant G1-S transition in c-myc/TGF-β-dependent HCC models (79). Also, 
Hepatitis B viral core protein (HBc) has been found to interact with E2F1 and reduce the 
DNA-binding ability of E2F1 to the p53 promoter (80). Mutations of E2F4 have been detected 
in HCC (81). Yasui et al. showed that the DP1 gene was located at 13q34, a frequent 
amplification site in HCC, and that over-expression of this gene was correlated with large 
tumour size (82). Nonetheless, the involvement of different DP subunits (including splice 
variants) and different E2F-DP heterodimers in the oncogenic and tumor suppressor 
mechanisms (such as immortality and senescence) in HCC are not completely understood. 
 
1.6.1 DP-2 (TFDP2) 
Human cells express at least three DP2 isoforms (of 55, 48 and 43 kDa) (83). Despite being 
identified more than 13 years ago (84), the DP2 gene remains underexplored, particularly in 
terms of its role in tumorigenesis.  
An increase in DP2expression has been reported in a smal set of HCC tissues by RT-PCR 
(85).  
 It has been reported that the expression of DP2 is controlled during tissue 
development (86), (87) and cell cycle (88). Moreover, the expression of DP2 in adult tissues is 
highly variable, detected in some tissues - including liver - but not in others. Differential 
expression of DP2 was also observed in cancer cell lines (71). 
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Figure 1.5   E2F/DP family (89). 
 
1.7   Chromatin modifications and hepatocellular carcinoma 
The term epigenetics refers to changes in gene expression or phenotype caused by 
mechanisms other than changes in the underlying DNA sequence, hence the name epi- 
(Greek: over; above) -genetics. These changes may remain through cell divisions for the 
remainder of the cell's life and may also last for multiple generations. 
 
1.7.1 DNA methylation 
The 5' cytosine of CpG dinucleotides within mammalian genomes can be methylated by 
denovo DNA methyltransferases such as DNMT3A and DNMT3B. Maintenance of DNA 
methylation is performed by DNMT1, utilizing hemimethylated DNA as a substrate. This 
provides a mechanism to propagate the epigenetic mark following DNA replication. The 
methyl groups serve as docking sites for gene silencing proteins. In general, DNA methylation 
correlates with increased chromatin condensation and gene silencing (90). 
 There are several ways in which altered patterns of DNA methylation lead to disease. 
Alterations in methylation patterns are responsible for several congenital diseases that affect 
growth through the misregulation of imprinted genes. In addition to alterations in the patterns 
of DNA methylation, loss of DNA methyl transferase also leads to disease. Given that 
mutations within DNA methyltransferase genes are associated with disease, it follows that 
mutations within genes encoding proteins that bind to methylated cytosines also result in 
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disease. MeCP2 (methyl-CpG-binding protein 2) is a member of a class of DNA methyl 
binding proteins (MBDs) that specifically recognize methylated cytosine residues. These 
binding proteins function by recruiting histone deacetylases (HDACs) to silencetarget genes. 
Mutations in the X-linked gene encoding MeCP2 are responsible for approximately 95% of 
classic Rett syndrome cases (RTT, OMIM 312750) (91).  
 
1.7.1.1    DNA methylation and cancer 
CpG dinucleotides are generally methylated in normal cells, with the exception of 
hypomethylation at CpG “islands” located upstream of many active genes. In contrast, cancer 
cells exhibit a global hypomethylation and CpG island hypermethylation (92) (Fig. 1.6 and 
1.7). This shift in the pattern of DNA methylation frequently results in inappropriate silencing 
of genes. Global DNA hypomethylation (also known as demethylation) is associated with 
activation of protooncogenes, such as c-JUN, c-MYC, and c-Ha-Ras, and generation of 
genomic instability. Hypermethylation on CpG islands located in the promoter regions of 
tumor suppressor genes results in transcriptional silencing and genomic instability. For 
example, expression of the serine protease inhibitor family member maspin is reduced due to 
methylation of promoter sequences in many advanced forms of cancer (93). 
 
Figure 1.6  Epigenetic Alterations in Tumor Progression, skin tumor as a model (94). 
A growing number of genes undergoing aberrant CpG island hypermethylation in 
HCC have been discovered, suggesting that de novo methylation is an important mechanism 
underlying malignant transformation in the liver. Epigenetic silenced genes are involved in 
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important molecular pathways of carcinogenesis e.g., cell cycle regulation, apoptosis, DNA 
repair or cell adhesion (45). The genes frequently found to be methylated in HCC are APC, 
GSTP1, RASSF1A, p16, COX-2, CCND2, SPINT2, RUNX3, CFTR, HINT1, RIZ1 and E-
cadherin (45). Furthermore, a combination of RASSF1A, CCND2 and SPINT2 showed 89-
95% sensitivity, 91-100% specificity and 89-97% accuracy in discriminating between HCC 
and non-HCC tissues, and correctly diagnosed all early HCCs (95). Also, it was shown that one 
of the regulation mechanisms of hTERT promoter was DNA methylation (96). Some miRNA’s were 
also shown to be silenced by DNA methylation and play a role in hepatocellular 
carcinogenesis, for example micro-RNA 1 (97). Also, methylation of Tip30 promoter was 
associated with poor prognosis in human hepatocellular carcinoma (98). Yan et. al. associated 
the promoter methylation and reduced T-cadherin expression (40% HCC) with the 
development and progression of hepatocellular carcinoma. 
Calvisi et. al. showed that the extent of global DNA hypomethylation and CpG 
hypermethylation correlates with biologic features and clinical outcomes of HCC. They 
suggested that aberrant methylation is a major event in both early and late stages of liver 
malignant transformation and might constitute a critical target for cancer risk assessment, 
treatment, and chemoprevention of HCC (99).  
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Figure 1.7 DNA methylation differences in some cancers (Esteller M, Epigenetics in 
cancer, NEJM, 2008). 
1.7.2 Histone modifications 
The nucleosome is the fundamental unit of chromatin and it is composed of an octamer of the 
four core histones (H3, H4, H2A, H2B) around which 147 base pairs of DNA are wrapped. 
The core histones are predominantly globular except for their N-terminal ‘‘tails,’’ which are 
unstructured. A striking feature of histones, and particularly of their tails, is the large number 
and type of modified residues they possess. These modifications serve to alter charge 
interactions of the histone tails with DNA, thereby influencing chromatin packaging. In 
addition, these modifications serve as binding sites for specific factors that “read” a proposed 
histone code. In most cases, specific modifications correlate with biological functions such as 
chromatin condensation, transcriptional regulation and DNA replication. Generally speaking, 
two kinds of enzymatic activities impinge on chromatin structure. One family involves mainly 
ATP hydrolysing enzymes that can re-model chromatin by ‘shuffling’ nucleosomes. Another 
family includes a set of enzymes that are able to modify histones covalently, at specific 
residues, located most commonly at the histone tails (100). There are at least eight distinct 
types of modifications found on histones. We have the most information regarding the 
modifications include acetylation, phosphorylation, methylation and ubiquination. Although 
these modifications have been known for many years to occur on histones, their function is 
only recently being recognised. There are over 60 different residues on histones where 
modifications have been detected either by specific antibodies or by mass spectrometry. 
However, this represents a huge underestimate of the number of modifications that can take 
place on histones. Extra complexity comes partly from the fact that methylation at lysines or 
arginines may be one of three different forms: mono-, di-, or trimethyl for lysines and mono- 
or di- (asymmetric or symmetric) for arginines (101). The timing of the appearance of a 
modification will depend on the signaling conditions within the cell.  
Whereas lysine acetylation almost always correlates with chromatin accessibility and 
transcriptional activity, lysine methylation can have different effects depending on which 
residue is modified. Methylation of histone H3 lysine 4 (H3K4) and H3 lysine 36 is 
associated with transcribed chromatin. In contrast, methylation of H3 lysine 9 (H3K9), H3 
lysine 27 (H3K27), and H4 lysine 20 (H4K20) generally correlate with repression. Distinct 
histone modifications can influence each other and may also interact with DNA methylation, 
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in part through the activities of protein complexes that bind modified histones or methylated 
cytosines (102). (Fig. 1.8).  
 
1.7.2.1 Histone modifying enzymes  
Most modifications have been found to be dynamic, and enzymes that remove the 
modification have been identified (Fig. 1.9).  
  
Figure 1.8  Histone modifications (Upstate) 
Of all the enzymes that modify histones, the methyltransferases and kinases are the 
most specific. This is perhaps the reason why methylation is the most characterized 
modification to date. In some cases, the specificity of enzymes that modify histones can be 
influenced by other factors: complexes in which enzymes are found (103); proteins that 
associate with the enzyme may affect its selection of residue to modify (104), or the degree of 
methylation (mono-, di-, or tri-) at a specific site (105). Proteins are recruited to modifications 
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and bind via specific domains. Methylation is recognized by chromo-like domains of the 
Royal family (chromo, tudor, MBT) and nonrelated PHD domains, acetylation is recognized 
by bromodomains, and phosphorylation is recognized by a domain within 14-3-3 proteins. 
 
Figure 1.9 Histone modifying enzymes (101).  
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Also, recently Chang et. al. identified that the Jumonji domain-containing 6 protein (JMJD6) 
was a JmjC-containing iron- and 2-oxoglutarate-dependent dioxygenase that demethylates 
histone H3 at arginine 2 (H3R2) and histone H4 at arginine 3 (H4R3) in both biochemical and 
cell-based assays (106).  
 The abundance of modifications on the histone tail makes ‘‘crosstalk’’ between 
modifications very likely. Mechanistically such communication between modifications may 
occur at several different levels. Firstly, many different types of modification occur on lysine 
residues. This will undoubtedly result in some form of antagonism since distinct types of 
modifications on lysines are mutually exclusive. Secondly, the binding of a protein could be 
disrupted by an adjacent modification. The best example of this is that of phosphorylation of 
H3S10 affecting the binding of HP1 to methylated H3K9 (107). Thirdly, the catalytic activity 
of an enzyme could be compromised by modification of its substrate recognition site; for 
example, isomerization of H3P38 affects methylation of H3K36 by Set2 (108). Fourthly, an 
enzyme could recognize its substrate more effectively in the context of a second modification; 
the example here is the GCN5 acetyltransferase, which may recognize H3 more effectively 
when it is phosphorylated at H3S10 (109).  
 
1.7.2.2 Histone methylation and cancer 
Hypermethylation of the CpG islands in the promoter regions of tumor-suppressor genes in 
cancer cells is associated with a particular combination of histone markers: deacetylation of 
histones H3 and H4, loss of H3K4 trimethylation, and gain of H3K9 methylation and H3K27 
trimethylation. The presence of the hypo-acetylated and hypermethylated histones H3 and 
H465 silences certain genes with tumor-suppressor–like properties, such as p21WAF1, despite 
the absence of hypermethylation of the CpG island (94). In human tumors generally, 
modifications of histone H4 entail a loss of monoacetylated and trimethylated forms (110). 
These changes appear early and accumulate during the development of the tumor. The losses 
occur predominantly at the monoacetylated Lys16 and trimethylated Lys20 residues of 
histone H4 in association with hypomethylated repetitive DNA sequences. They have been 
found in breast and liver cancer (111); (112). In prostate cancer, weak immunohistochemical 
staining of two histone modifications (the dimethylation of lysine 4 and the acetylation of 
lysine 18 of histone H3) has been proposed as a marker of a high risk of recurrence. 
Expression patterns of histone modifying enzymes distinguish cancer tissues from their 
normal counterparts, and they differ according to tumor type. In leukemias and sarcomas, 
chromosomal translocations that involve histone-modifier genes, such as histone 
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acetyltransferases (e.g., cyclic AMP response-element-binding protein [CREB]–binding 
protein–monocytic leukemia zinc finger [CBP-MOZ]) and histone methyltransferases (e.g., 
mixed-lineage leukemia 1 [MLL1], nuclear-receptor binding SETdomain protein 1 [NSD1], 
and nuclear-receptor binding SET-domain protein 3 [NSD3]), create aberrant fusion proteins 
(113). In solid tumors, there is amplification of genes for histone methyltransferases such as 
EZH2, mixed-lineage leukemia 2 (MLL2), or NSD358,69 or a demethylase (e.g., Jumonji 
domain-containing protein 2C [JMJD2C/GASC1]).  
 
1.7.2.2.1 H3K27 methylation 
The H3K27 methylation mark is primarily governed by the polycomb group (PcG) proteins 
that are initially genetically defined in Drosophila melanoganster. Two polycomb repressor 
complexes (PRC1 and PRC2) have been characterized. PRC1, comprising core components of 
BMI-1, Ring-1, HPH and HPC, recognizes trimethylated H3K27 and mediates the 
maintenance of the silent state. PRC2, comprising of enhancer of zeste homologue 2 (EZH2), 
suppressor of zeste 12 (SUV12) and embryonic ectoderm development (EED), mediates the 
initiation of gene repression via association with HDACs and DNA methyltransferases 
(DNMTs) (114).  
 
1.7.2.2.1.1 EZH2  
EZH2, a SET domain methyltransferase for H3K27, plays essential roles in embryonic 
development and stem cell renewal (114). Overexpression of EZH2 has been observed and 
positively correlates with the progression of multiple malignancies, including prostate cancer, 
breast cancer, lymphoma, myeloma, colorectal cancer, endometrial cancer, bladder cancer and 
melanoma and liver (90). Ectopic overexpression of EZH2 leads to increased cell proliferation 
and transformation independent of growth factors in multiple myeloma, whereas decreased 
expression of EZH2 by RNAi leads to growth arrest in prostate cancer cells. The 
methyltransferase activities of both EZH2 and HDAC recruited by EED are required for cell 
proliferation and invasion mediated by EZH2. The fact that the PRC2 complex recruits 
DNMTs to the promoters of EZH2 target genes and induces their silencing in tumor cells 
suggests that EZH2 might selectively induce the silencing of tumor-suppressor genes during 
cancer cell evolution (115). However, direct evidence supporting EZH2-mediated silencing of 
tumor-suppressor genes remains to be established. Alternative mechanisms of oncogenesis 
have been proposed. For example, cytoplasmic EZH2 controls actin polymerization and cell 
signaling upstream of the small GTPase CDC42 (116).  
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1.7.2.2.1.2 BMI1 
BMI1 is recruited to trimethylated H3K27 (H3K27me3) as part of the PRC1 complex via the 
interaction between HPC and H3K27me3. It was originally identified as a protooncogene that 
cooperates with Myc to promote B-cell lymphoma development in mouse models (117). It is 
also overexpressed in lymphoma, leukemia, medulloblastoma, neuroblastoma and non-small-
cell lung cancer (NSCLC). BMI1 inhibits Myc-induced apoptosis through repression of the 
CDKN2A locus (118). In addition, BMI1 harbors crucial activities in maintaining proliferative 
capacities of both normal stem cells and leukemic stem cells, suggesting that BMI1 might 
promote tumorigenesis by misdirecting tumor cells toward a stem cell fate (118).  
 
1.7.2.2.2 H3K9 methylation 
 
1.7.2.2.2.1 HP1 – an H3K9 methylation ‘reader’ 
HP1 proteins (HP1a, HP1b, HP1g) bind to methyl-H3K9 and are crucial for the formation of 
heterochromatin and gene silencing. Decreased HP1a and HP1b expression has been observed 
in metastatic breast tumors, melanoma and other metastatic tumors. Ectopic expression of 
HP1a reduces invasion of breast cancer cells, whereas inhibition of HP1a leads to increased 
invasion without affecting cell growth, implicating its role in tumor metastasis suppression. 
However, either an increase or reduction in HP1 levels can lead to chromosome instability 
and aneuploidy (90); (119).  
 
1.7.2.2.2.2 SUV39H and RIZ1 – H3K9 methylation ‘writers’ 
SUV39H1 and SUV39H2, mammalian homologues of Drosophila SU(VAR)3–9, are SET 
domain HMTs for H3K9. Whereas SUV39H1-/- and SUV39H2 -/- mice are viable with no 
clear phenotype, SUV39H1-/-/SUV39H2-/- mice exhibit severely compromised viability, 
increased chromosomal instability and increased risk of B-cell lymphoma. These phenotypes 
were associated with chromosomal mis-segregation, abnormally long telomeres and 
significant reduction of di- and tri-methylation of H3K9 and loss of HP1 binding at 
pericentric heterochromatin and telomeres (120). Biochemically, SUV39H1 and HP1 interact 
with pRb and mediate gene silencing of –pRb targets. SUV39H1 also prevents Ras-induced 
tumorigenesis by promoting senescence. Despite these observations, the role of 
SUV39H1inhuman cancer is not defined because there have not been any SUV39H1 
mutations or losses reported in human cancers. RIZ1/PRDM2, another family of SET domain 
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H3K9 methyltransferase, was originally identified as a pRb-binding protein. Inactivation of 
RIZ1 by mutations and silencing via promoter hypermethylation are observed in many human 
cancers, including hepatocellular, colon, breast and gastric cancers, suggesting a 
tumorsuppressive role. Furthermore, missense mutations that abolish the HMT activity of 
RIZ1 are found in human cancers (121), (122).  
 
1.7.2.2.2.3 JMJD2C – an H3K9 methylation ‘eraser’ 
Jumonji-domain-containing proteins (JMJD) have recently been characterized as histone 
lysine demethylases. JMJD2C, initially identified as gene amplified in squamous cell 
carcinoma 1 (GASC1), is also frequently amplified and overexpressed in esophageal 
squamous cell carcinoma, lung sarcomatoid carcinoma and desmoplastic medulloblastoma. It 
removes the methyl group from tri- and di-methylated H3K9. Overexpression of 
JMJD2C/GASC1 induces reduction of global H3K9 triand di-methylation levels and 
delocalization of HP1, which might contribute to tumorigenesis (123), (124).  
 
1.7.2.2.3 H3K4 methylation 
Initial genetic analysis in D. melanoganster defines the functional roles of the trithorax group 
(Trx-G), the ‘writers’ for the H3K4 methylation mark, during development. Conserved from 
flies to mammals, Trx-G proteins maintain the epigenetic activation of homeodomain genes, 
whereas PcG proteins mediate their silencing. These two antagonistic groups of proteins 
control important aspects of differentiation and proliferation during embryogenesis (124).  
 
1.7.2.2.3.1 MLL and SMYD3 – H3K4 methylation ‘writers’ 
The mixed lineage leukemia (MLL) protein, a mammalian Trx-G protein, is a SET domain 
H3K4 methyltransferase and maintains activation of Hox gene expression during 
development. In several leukemia subtypes, several genetic events have been observed to 
involve the MLL gene. Indeed, AF10, an MLL fusion partner, binds the H3K79 HMT 
hDOT1L, linking H3K79 methylation to leukemogenesis and persistent activation of Hox-A 
protooncogenes. However, the mechanism of MLL fusion involving other partners remains to 
be elucidated. SET- and MYND-domain-containing protein 3 (SMYD3), another 
methyltransferase for H3K4, is found to be frequently upregulated in colorectal and 
hepatocellular carcinoma cell lines. SMYD3 interacts with RNA helicase HELZ and RNA 
polymerase II and mediates transcriptional activation of targets, including oncogenes, 
homeobox genes and cell-cycle regulatory genes. Overexpression of SMYD3 enhances cell 
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growth and promotes transformation, whereas inhibition of SMYD3 expression represses cell 
growth in cancer cell lines (125).  
 
1.7.2.2.3.2 ING proteins – H3K4 methylation ‘readers’ 
Mammalian ING family proteins, INGs 1–5, are putative tumor suppressors and have been 
observed to cooperate with p53 to mediate growth arrest, cellular senescence and apoptosis. 
Reduced expression, somatic mutations and allelic loss of ING proteins (especially ING1, 
ING3 and ING4) are observed in breast cancer, gastric cancer, melanoma, glioma and head 
and neck squamous cell carcinoma (HNSCC) (126).  
 
1.7.2.2.4 H3K36, H4K20 and H3K79 methylation 
 
1.7.2.2.4.1   H3K36, H4K20 and H3K79 methylation ‘writers’ 
The nuclear-receptor-binding SET-domain-containing protein 1 (NSD1), initially identified as 
a fusion partner of nucleoporin 98 (NUP98) in t(5;11)(q35;p15.5)-containing pediatric AML, 
is a methyltransferase for H3K36, and to a lesser degree for H4K20. NSD1 mediates cellular 
context-dependent gene silencing and activation. NUP98-NSD1 translocation leads to 
hematopoietic transformation and leukemia, at least partly as a result of the activation of Hox-
A genes via the H3K36 methyltransferase activity of NSD1. Heterozygous mutation or loss of 
heterozygosity (LOH) of NSD1 causes Sotos syndrome, a childhood overgrowth syndrome 
exhibiting increased risk (2%–7%) for hepatocellular carcinoma, leukemia and 
neuroblastoma. hDOT1L is a human non-SET-domain methyltransferase for H3K79. 
hDOT1L has been shown to interact with AF10, one of the MLL fusion partners in AML. In 
leukemias caused by MLL-AF10 and clathrin-assembly protein-like lymphoid-myeloid 
(CALM)-AF10 fusion proteins, hDOTL is mistargeted to the Hox-A9 and Hox-A5 loci, 
respectively; subsequent H3K79 hypermethylation at these loci and upregulation of Hox-A 
genes are thought to be responsible for leukemogenesis (127). 
 
1.7.2.3 Histone lysine acetylation and cancer  
Several lines of evidence support the connection between HAT dysregulation and 
oncogenesis. The viral oncoproteins E1A (adenovirus) and large T-antigen (SV40) primarily 
target p300, CBP and PCAF (p300/CBP-associated factor) and inhibit their function (128). 
Bi-allelic mutations of p300 and CBP have been observed in colorectal, gastric, hepatocellular 
and breast cancers. Chromosomal translocations resulting in fusion proteins of HATs, 
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including MLL-CBP, MLL-p300, MOZ-CBP, MOZ-p300 and MOZ-TIF2 (transcriptional 
intermediary factor 2), have been identified in leukemia and myelodysplastic syndrome, and 
the leukemogenic potential has been confirmed in murine models in the case of MLL-CBP. 
 In cell lines and murine models of colon cancer, HDAC2 is upregulated upon loss of 
adenomatosis polyposis coli (APC), and the expression of HDAC2 is required for 
tumorigenesis, presumably via its aberrant repressive activities. Recently, HDAC inhibitors 
(HDACis) have been shown to be a class of promising anti-cancer agents, exhibiting a range 
of observed cellular effects, including growth arrest, differentiation and apoptosis in a variety 
of cancers in clinical trials. Similarly, overexpression of HDAC1–3 and 6 has also been 
observed in prostate, gastric, breast and cervical cancer (129). 
 
1.7.2.4 Histone methylation and senescence 
Certain types of cells exhibit senescent arrest that is accompanied by senescence-associated 
heterochromatic focis (SAHFs), a new type of facultative heterochromatin (130). Such drastic 
chromatin rearrangement can also be observed during some types of cellular differentiation, 
another state of stable cell cycle arrest (Francastel et al, 2000). Very little is known about the 
effector mechanism of cellular senescence, but the global chromatin reorganisation may not 
simply be a senescence marker, but rather play a key role in the senescence mechanism. In 
fact, there is a strong correlation between SAHF formation and the irreversibility of the 
senescence phenotype (131), (130), (132).  
 The kinetics of the accumulation of SAHF-positive cells after triggering senescence by 
ras is well correlated with that of other indicators of senescence, such as SA-b-gal activity, 
p16 induction, Rb hypo-phosphorylation and cell cycle arrest; and SAHFs and DNA synthesis 
are mutually exclusive events (130). Senescence-associated heterochromatic focis are 
enriched for markers of heterochromatin, such as heterochromatin protein 1 (HP1) and Lys9 
tri-methyl (K9me3) of histone H3 (which confers a docking site to HP1), and exclude 
euchromatic markers, such as histone H3 K9 acetyl and K4me3 (130). Interestingly, SAHF 
formation is largely dependent on the p16/Rb pathway in ras-induced senescence, although 
the impact of p53 on SAHF is marginal (130). The experiments revealed that high-mobility 
group A (HMGA) proteins are senescence-associated chromatin binding proteins and that 
HMGA proteins are essential structural components of SAHFs. Furthermore, HMGA-
dependent SAHF formation contributes to the stable senescence arrest (130), (132). 
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1.7.2.5 Histone variants 
In higher organisms each histone subtype, with the possible exception of histone H4, is 
represented by a family of genes encoding multiple non-allelic primary-sequence variants. 
The presence of replacement variants that, unlike most other histones, are expressed 
throughout the cell cycle and serve as a source of chromatin components needed during repair 
or recombination of DNA or to replace histones lost through turnover in quiescent cells. 
Because different histone variants can contribute to a distinct or unique nucleosomal 
architecture, this heterogeneity can be exploited to regulate a wide range of nuclear functions, 
and evidence is accumulating that histone variants do indeed have distinct functions (133).   
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CHAPTER 2. OBJECTIVES AND RATIONALE 
The molecular pathogenesis of HCC largely remains unsolved. Genetic mutations are 
apparently limited to a few genes such as TP53 and CTNNB1 occurring in distinct subsets of 
HCC. In contrast, expression changes such as induced expression of telomerase reverse 
transcriptase (TERT) and epigenetic silencing of CDKN2A gene, affecting >80% and >50% of 
HCCs respectively, are quite common (134). Inactivation of TP53 and CDKN2A and 
reactivation of TERT provide strong evidence for the bypass of cellular senescence as a key 
event involved in HCC (52). Adult hepatocytes, like other somatic cells, are programmed for 
senescence, a mechanism that blocks excessive cell proliferation by a telomere-dependent 
mechanism. Telomere-independent forms, such as oncogene-induced and DNA 
damageinduced senescence are also observed, both in normal and cancer cells. p16INK4a- 
and p21Cip1-dependent pathways leading to retinoblastoma protein (pRb) activation and 
permanent G1 arrest are involved as mediators in the senescence arrest (135). Cellular 
senescence appears to play a major role in liver diseases. Chronic liver diseases are associated 
with progressive telomere shortening leading to the cellular senescence that is observed 
frequently in cirrhosis, but also in some HCCs (136). But, there was no experimental evidence 
for spontaneous reprogramming of replicative senescence in immortalized cancer cells. Using 
hepatocellular carcinoma (HCC)-derived Huh7 cells as a model system, our group have 
shown that cancer cells with replicative immortality are able to spontaneously generate 
progeny with replicative senescence (61). To investigate the mechanism of spontaneous 
senescence in HCC-derived cells, we performed whole genome expression microarray 
analysis in immortal, senescent committed and pre-senescence stage clones. We tested our 
significant gene set on previously published senescence models. We obtained differentially 
expressed gene sets and biological pathways that can play a major role in reprogramming-
senescence and immortality.  
 Experimental animal models also provide strong evidence for a critical role of cellular 
senescence in HCC (59). However, the role of cellular senescence and immortality in human 
HCC remains elusive. We integrated immortal and senescence-programmed Huh7 data and 
malignant and non-malignant human liver tissue data to define a senescence and immortality 
gene network (SIGN) to predict and classify the progressive steps of human hepatocellular 
carcinogenesis and molecular subtypes of HCC. 
 The Rb pathway is among the pathways most frequently disrupted in HCC (137). The 
Rb-E2F pathway links growth-regulatory pathways to a transcription program involved in 
DNA synthesis, cell-cycle progression, cell division, apoptosis, DNA repair, differentiation 
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and senescence (138). We performed unsupervised hierarchical cluster analysis of E2F/DP 
family genes using our immortal and senescence-programmed Huh7 microarray data. We 
studied expression profiles of E2F/DP family members in immortal and senescence-arrested 
HCC cells. Our results prompted us to further investigate DP-2 gene and protein in HCC. 
 Classical genetics alone is not able to explain all the changes of a tumor cell. It is 
apparent that cancer is also a disease that is driven by ‘epigenetic changes’ — patterns of 
altered gene expression that are mediated by mechanisms that do not affect the primary DNA 
sequence. These epigenetic alterations occur within a larger context of extensive alterations to 
chromatin in neoplastic cells in comparison with the normal cells from which they are 
derived. These involve both losses and gains of DNA methylation as well as altered patterns 
of histone modifications (139). Recent studies indicate that epigenetic alterations might 
initiate the expansion of pre-malignant cells during the early stages of tumorigenesis. During 
the earliest steps of development of principal tumour types, a subset of these pre-malignant 
cells undergo genetic alterations that allow them to mediate tumour progression and growth. 
The early epigenetic changes that occur in these cells 
might determine the subsequent genetic changes and thereby foster progression of these 
clones. In the search of most significantly changing gene sets between senescence and 
immortal clones of Huh7, we identified that chromatin binding proteins, especially chromatin 
modifying enzymes are changing between these groups. We grouped the significant 
chromatin modifying enzymes with unsupervised hierarchial cluster analysis. We 
hypothesized that spontaneous induction of senescence could be an epigenetic re-
programming event.  We decided to investigate the expression levels of histone 
methyltransferases and demethylases, and examine the levels of histone residue modifications 
in immortal, pre-senescent and senescence programmed clones. We also hypothesized that the 
abberantly regulated histone residues in senescence and immortal clones may also regulated 
in cirrhosis and HCC. Therefore, we decided to screen normal, cirrhotic and tumor liver 
samples for spesific histone residues.     
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                                         CHAPTER 3. MATERIALS AND METHODS 
 
3.1 MATERIALS 
 
3.1.1 Reagents 
The general laboratory chemicals were supplied from Sigma Chemical Co. (St.Louis, USA), 
Merck (Darmstadt, Germany), Stratagene (Heidelberg, Germany) and AppliChem 
(Darmstadt, Germany). Ethanol was from Delta Kim Sanayi ve Ticaret A.S (Turkey). TGF-
beta and lithium chloride was supplied from (R&D Systems, Minneapolis, USA). Mayer’s 
heamatoxylene was supplied from Sigma (Missouri, USA). 
 
3.1.2 Nucleic acids and Proteins 
DNA molecular weight standard and ultrapure deoxyribonucleotides were purchased from 
MBI Fermentas GmbH (Germany). Protein size markers were from MBI Fermentas GmbH 
(Germany) and Euromedex (Soufferweyelsheim, France).  
 
3.1.3 Oligonucleotides 
The oligonucleotides used in polymerase chain reactions were synthesized and supplied from 
Iontek Inc. (Istanbul, Turkey) and Eurofins MWG (Ebersberg, Germany). 
 
3.1.4 Enzymes 
Taq DNA polymerases (EP0405) and SYBR Green Supermix (K0231, F-400, 600825) were 
supplied from MBI Fermentas, Finzymes (Finland) and Stratagene (La Jolla, USA). Reverse 
Transcriptase was supplied from MBI Fermentas (K1621) (Ontario, Canada).  
 
3.1.5 Electrophoresis 
Electrophoresis grade agarose was obtained from Sigma Biosciences Chemical Company Ltd. 
(St. Louis, MO, USA). Horizontal electrophoresis apparatuses were from Stratagene 
(Heidelberg, Germany) and E-C Apparatus Corporation (Florida, USA). Vertical 
electrophoresis apparatuses were from Invitrogen (California, USA) or BioRad (Hercules, 
USA). The power supply Power-PAC300 and Power-PAC200 was from Bio Rad Laboratories 
(CA, USA). The Molecular Analyst software used in agarose gel profile visualizing was from 
BioRad Laboratories (Hercules, CA, USA).   
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3.1.6 Protein transfer materials 
Immobilen P transfer (PVDF) membrane was from Roche (Germany) and nitrocellose 
membrane was supplied from Amersham& GE Healthcare (Buckinghamshire, UK). 3MM 
filter paper was from Whatman International Ltd. (Madison, USA).  
 
3.1.7 Tissue culture reagents and cell lines 
Dulbecco’s modified Eagle’s medium (DMEM), fetal calf serum and magnesium-free 
phosphate buffered saline (PBS) was obtained from GIBCO (BRL Company; Grand Island, 
USA) and Biochrom (Berlin, Germany). L-glutamine, calcium, and Penicillin/Streptomycin 
mixture was from Biochrom  (Berlin, Germany). Tissue culture flasks, petri dishes, 15 ml 
polycarbonate centrifuge tubes with lids and cryotubes were purchased from Costar Corp. 
(Cambridge, England). Geneticin-G418 sulfate was purchased from GibcoBRL, Life tech. 
(USA), Puromycin was purchased from Sigma (St. Louis, MO, USA).  
 
3.1.8 Antibodies and chemiluminescence 
The antibodies used in immunoblotting (western blotting) and immunostaining were obtained 
from different sources, and their working dilutions are given in Table 3.1. Anti-mouse (A-
4789) and anti-rabbit HRP (P0399) conjugated secondary antibodies were obtained from 
Sigma (Missouri, USA) and Dako (Glostrup, Denmark). Green fluoroscent secondary 
antibodies (A10680) (44-1100A1) (Alexa Flour 488) against mouse or rabbit were obtained 
from Invitrogen (California, USA). ECL Western Blotting detection kit (RPN2132) was 
purchased from Amersham Pharmacia Biotech Ltd. (Buckinghamshire, UK).  
 
Table 3.1  Antibodies 
 Company Antibody Cat No 
Dilution 
for 
Western 
1 in Xul 
Dilution for 
Immunperoxidase 1 
in Xul 
Abcam H3 K4 Me3 -  Rabbit- Pol ab8580 5000 1200 
Abcam H3 K9 Me1 - Rabbit - Pol ab9045 2000 600 
Upstate H3 K9 Me3 - Rabbit Antiserum Ups 07-523 5000 1200 
Upstate H3 K27 Me1 - Rabbit -Pol -IgG Ups 07-448 5000 1200 
Upstate H3 K27 Me3 - Rabbit - Pol- IgG Ups 07-449 5000 1200 
Abcam H3 K36 Me1 - Rabbit- Pol ab 9048 2000 600 
Abcam H3 K36 Me3 ab 9050 2000 1200 
Abcam H3 K79 Me3 - Rabbit- Pol ab2621 2000 300 
Upstate H4 K20 Me3 Ups 07-463 2000 600 
Upstate H3 Pab - Rabbit - Pol  IgG Ups 06-755 500 500 
Upstate H4 Pab  - Rabbit - Pol  IgG  Ups 07-108 1000 500 
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Abcam H3 Monoclonal - Mouse ab 31827 2000 500 
Abcam H4 Monoclonal - Mouse ab 24834 2000 500 
Abcam 5-Methyl Cytidine - Mouse  ab 10805 2000 - 
Upstate H3 R2 Me2 - Rabbit Antiserum Ups 07-585 2000 600 
Abcam H3 R17 Me2 - Rabbit -Pol Ab8284 5000 900 
Upstate H4 R3 Me2 - Rabbit IgG Purif. Ups 07-213 2000 600 
Upstate H4 K Ac Pab Ups 06-598 1000 250 
Abcam TFDP2 Ab26260 1000 250 
 
3.1.9 Kits 
Trireagent was from AppliChem (Darmstadt, Germany) and the RNA isolation kit was from 
Macharel Nagel, (Duren, Germany). RevertAid first strand cDNA synthesis kit was from MBI 
Fermentas. DAB+ substrate kit was supplied from Dako (Glostrup, Denmark). One cycle 
cDNA synthesis kit for affymetrix experiments were supplied from Affymetrix (U.S.A). 
 
3.2 SOLUTIONS AND MEDIA 
3.2.1 General Solutions 
50X Tris-acetic acid-EDTA (TAE):    2 M Tris-acetate, 50 mM EDTA pH 8.5 
Diluted to 1X for working solution. 
Ethidium bromide:      10 mg/ml in water (stock solution), 
30 ng/ml (working solution) 
1X Gel loading buffer:     0.25% bromophenol blue, 0.25% xylene 
cyanol, 50% glycerol, 1mM EDTA 
 
3.2.2 Tissue culture solutions 
DMEM/RPMI working medium 10% FBS, 1% penicillin/streptomycin,      
1% Non-Essential Amino Acid were 
added and stored at 4oC. 
10X Phosphate-buffered saline (PBS)   Per liter: 80 g NaCl, 2 g KCl, 14.4 g 
Na2HPO4, 2.4 g KH2PO4, pH 7.4 or      
1XPBS was obtained commercially from 
GIBCO 
Freezing solution  10% DMSO and 90% FCS were mixed 
freshly. 
Antibiotics 
Geneticin (G418 Sulfate)   500 mg/ml solution in double-distilled 
water. Sterilized by filtration and stored at 
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-20°C (stock solution). 500 µg/ml 
(working solution for stable cell line 
selection), and 250 µg/ml(working 
solution for maintenance of stable cell 
lines). 
Puromycin       2 mg/ml solution in double-distilled water, 
sterilized by filtration (0.2 um pores) and  
stored at -20°C (stock solution). 2 µg/ml 
(working solution for stable cell line 
selection), and 1 µg/ml (working solution 
for maintenance of stable cell lines). 20°C 
(stock solution). 2 µg/ml (working 
solution). 
3.2.3 RNA solutions 
DEPC-Treated Water   1ml DEPC was added to 1lt ddH2O and 
stirred under hood overnight. DEPC was 
inactivated by autoclaving. 
FA Gel Buffer  Stock solution (10XFA Gel Buffer) was 
prepared by dissolving 20.927g MOPS, 
3.40g NaAc and 1.86g EDTA in 500ml 
ddH2O. pH of the stock solution was 
adjusted to 7.0. Working solution was 
prepared by diluting the stock solution to 
1X with ddH2O. 
5x RNA Loading Buffer Bromophenol blue solution 16 µl, 500 
mM EDTA, pH 8.0. 80 µl, 37% 
formaldehyde 720 µl, 100% glcerol 2 ml, 
Formamide 3084 µl, 10x FA gel buffer 4 
ml, RNase free (DEP-C treated) water to 
10 ml. 
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3.2.4 Protein extraction and western blotting solutions 
RIPA Buffer   50 mM Tris pH: 8.0, 150 mM NaCl, 1% 
NP-40, 1% NP-40, 0.5% 
SodiumDeoxycalate, 0.1% SDS and  
1X protease inhibitor mix were mixed in 
ddH2O. 
Bradford Stock Solution   17.5 mg Coomassie brilliant blue was 
dissolved in 4.75 ml ethanol and 10 ml 
phosphoric acid and completed to 25 ml 
final volume with ddH2O. 
Bradford Working Solution   1.5 ml Bradford stock solution was mixed 
with 0.75 ml 95% Ethanol and 1.5 ml 
phosphoric acid and completed to final 
volume up to 25 ml with ddH2O. 
Or commercial Bradford Solution was obtained from Sigma. 
 
30% Acrylamide mix (1:29)  Per 100 ml: 29 g acrylamide, 1 g 
bisacrylamide in double-distilled water, 
filtered, degassed, and stored at 4°C (stock 
solution).  
5X SDS gel-loading buffer  3.8 ml double-distilled water, 1 ml of 0.5 
M Tris-HCl, 0.8 ml glycerol, 1.6 ml of 
10% SDS, o.4 ml of 0.05% bromophenol-
blue. Before use, β-mercaptoethanol was 
added to 5% to reach 1% when mixed 
with samples. 
5X SDS-electrophoresis buffer   Per liter: 15.1 g Tris base, 95 g Glycine, 5 
g SDS. Diluted to 1 X for working 
solution. Stored up to 1 month at 4°C. 
10% Ammonium persulfate (APS)    0.1 g/ml solution in double distilled water 
(Prepared freshly). 
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1.5 M Tris-HCl, pH 8.8  54.45 g Tris base (18.15 g/100 ml) ~150 
ml distilled water Adjust to pH 8.8 with 1 
N HCl. Completed to 300 ml with distilled 
water and stored at 4° C. 1 M Tris-HCl, 
pH 6.8 12.14 g Tris base ~ 60 ml distilled 
water, adjust to pH 6.8 with 1 N HCl. 
Completed to 100 ml with distilled water 
and store at 4° C. 
Wet Transfer Buffer   6 g tris and 28.8g glycine was mixed with 
1ml 10% SDS and 20% methanol and 
completed to final volume of 1 liter. 
10XTBS   Per liter: 100 mM Tris-base, 1.5 M NaCl, 
pH 7.6 in double distilled water. 
TBS-T   0.3% Tween 20 was added into 1X TBS 
solution. 
Blocking Solution   3% milk powder in 0.3% TBS-Tween 20 
solution 
 
3.2.5 Immunofluorescence and immuoperoxidase solutions 
DAPI (4', 6-diamidino-2-phenylindole)   0.1-1 µg/ml (working solution in PBS). 
4% paraformaldehyde  4 g paraformaldehyde in 100 ml. PBS, pH 
7.4. Stable at 4°C for a week. 
PBS-TritonX-100 (PBS-T)  0.1 TritonX-100 in PBS 
DAB + substrate 1 drop solution A in 1 ml solution B. 
Blocking Solution  10%FBS, 0.3% Triton-X in 1xPBS 
Dilution Solution 2%FBS, 0.3% Triton-X in 1xPBS. 
                                                                                                                                        
3.2.6 SABG solutions 
SABG solution pH 6.0 200 µl 200nM citric acid, 50 µl 100mM 
potasium ferrocyanide, 50 µl 100mM 
potasium ferricyanide, 75 µl 2 M NaCl, 20 
µl 100 mMMgCl2, 200 µl sodium buffer, 
380 µl distilled H2O for 1ml SABG 
solution. 
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Na buffer pH 6.0  420 µl 1M Na2HPO4, 180 µl NaH2PO4 
 
 
3.2.7 Immunohistochemistry solutions 
Citrate buffer 10 mM pH 6  Citric acid solution 0.1 M (anhydrous) 
(solution A), Sodium Citrate solution 0.1 
M (solution B), 9 ml solution A+41 ml 
solution B+450 ml H2O (adjust pH with 
NaOH) 
Blocking Solution     5% milk in 1XPBS 
Dilution Solution     1% BSA 1xPBS 
Washing Solution     0.5% milk in 1xPBS 
 
3.3 METHODS 
 
3.3.1 Tissue culture techniques 
 
3.3.1.1 Cell Lines  
14 HCC derived cell lines (Huh7, FOCUS, Mahlavu, Hep40, Hep3B, HepG2, PLC/PRF/5, 
SK-Hep1, Snu182, Snu387, Snu398, Snu423, Snu449 and Snu475) used in this study were 
cultured as described in previously (38). Briefly, cell lines were maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM, Biochrom, UK) supplemented with 10% fetal calf serum, 
50 mg/ml penicillin/streptomycin, and 1% non-essential aminoacid.  
Huh7- derived isogenic clones were obtained by  either G-418 (200 µg/ml) selection 
after transfection with neomycin- resistance pcDNA3.1 (Invitrogen) or pEGFP-N2 (Clontech) 
plasmids, or by low-density cloning. Huh7-derived isogenic clones C1 and C3 were obtained 
with pCDNA3.1 and G11 and G12 with pEGFP-N2 (61). For low-density cloning, cells were 
plated at 30 cells per cm2 and single-cell derived colonies were expanded in 24-well plates. 
Culture medium was refreshed in every three days. The cells were incubated at a 37oC 
incubator with an atmosphere of 5% CO2 in air. The cells were passaged before reaching 
confluence. The growth medium was aspirated and the cells were washed with 1X PBS. 
Trypsin solution (Biochrom, UK) was added to the flasks to detach the monolayer cells from 
the surface. Cells were dispersed by pipetting the cells with fresh medium. The cells were 
transferred to new flasks using different dilutions depending on requirements. 
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 Primary human liver cells (NHEP) were supplied from Lonza (Basel, Switzerland) as 
a cryopreserved vial (CC-2591), with its special medium HCM (hepatocyte culture medium, 
phenol red free) (CC-3198). Before culturing  supplement kit (CC-4192) obtained from Lonza 
was added into medium. Instructions for culturing the NHEP were sitrictly followed that were 
obtained from manufacturer. While thawing cells, the tube containing the cell suspension was 
centrifuged at 50 x g in a refrigerated centrifuge (2-8ºC) for three minutes. The recommended 
seeding density for attachment is approximately 150,000 cells/cm
2
. on plates or flasks coated 
with 60 µg/cm
2 
Type 1 Collagen.  
DMEM and PBS were kept at 4oC, trypsin was kept at -20oC. All the solutions were 
warmed to 37oC before use. 
 
3.3.1.2 Cell lines for microarray study  
In vitro microarray experiments were performed with senescenceprogrammed (C3, G12), and 
immortal (C1I, G11I) clones. Senescence-programmed clones were tested at proliferating 
presenescent (C3P, G12P) and senescent (C3S, G12S) states. Immortal clones were tested 
after PD 150. Proliferating pre-senescent cells were tested at PD 20-30 before senescence-
arrest. Presenescent cels were >85% BrdU-positive upon labeling for 24h. Senescent cells 
were <5% BrdU-positive and displayed >50% senescence-associated β-galactosidase (SABG) 
activity. 
 
3.3.1.3 Thawing cell lines 
One vial of the frozen cell line from the liquid nitrogen tank was taken and immediately put 
into ice. The vial was then placed into 37oC water bath until the external part of the cell 
solution was thawed (takes approximately 1-2 minutes). The cells were resuspended gently 
using a pipette and transferred immediately into a 15 ml. sterile tube containing 10 ml cold 
fresh medium. The cells were centrifuged at 1500 rpm at 4oC for 5 minutes. Supernatant was 
discarded and the pellet was resuspended in 10 ml 37oC culture medium to be plated into 100 
mm dish. After overnight incubation in a humidified incubator at 37°C supplied with 5% 
CO2, culture mediums were replenished. 
 
3.3.1.4 Cryopreservation of cell lines 
Exponentially growing cells were harvested by trypsinization and neutralized with growth 
medium. The cells were counted and precipitated at 1500 rpm for 5 min. The pellet was 
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suspended in a freezing solution (10% DMSO, 90% FCS) at a concentration of 4x106cells/ml. 
1 ml of this solution was placed into 1 ml screw capped-cryotubes. The tubes were left at -
70°C overnight. The next day, the tubes were transferred into the liquid nitrogen storage tank. 
 
3.3.1.5 TGF-β and LiCl  treatment 
Cells were seeded into 6 cm plates 24 before the treatment. At the time of treatment cells were 
at 30% confluency. 5 µg TGF-β was added into fresh medium which was then applied onto 
plates. DMEM without TGF-β was added to some other plates that will be used as negative 
control. After four days of treatment cells were washed with 1xPBS and pelletted. Fresh 
medium containing 20 nM LiCl was used for LiCl treatment. As the negative control of LiCl, 
20 nM NaCl containing medium was used. After three days, NaCl treated and one LiCl 
treated plate was washed and pelletted to be used as time zero. Other plates were cultured 
with fresh DMEM, and stopped and pelletted at hours of 6, 12, 24, 30, 36 and 48.  
 
3.3.2 RNA extraction 
3.3.2.1 Extraction of total RNA from tissue culture cells 
Exponentially growing monolayer cultures were washed twice with ice-cold PBS, 
tyripsinized, pelleted and snap frozen in liquid nitrogen and stored at -70oC until needed for 
RNA preparation. The total RNA isolation from cell line pellets was performed directly by 
use of NucleoSpin RNA II kit (740955) (MN Macherey-Nagel, Duren, Germany) according 
to the manufacturer’s instructions. The RNAs were eluted in a total volume of 30-50 µl. 
DNAse digestion was performed according to the kit protocol.The concentration of the 
isolated RNA and the ratio of absorbance at 260 nm to 280 nm were measured with the 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Montchanin, DE, USA) in 
triplicate. Isolated RNAs were stored at -80oC. 
For in-vitro microarray study, immortal, presenescent and senescent cells (described 
above) were plated in triplicate and subjected to RNA extraction. RNA quality was evaluated 
by the ratio of 18S to 28S RNAs by Agilent 2100 Bioanalyzer (Agilent Technologies, USA); 
all samples passed this quality control test.  
 
3.3.2.2 Extraction of total RNA from tissue samples 
The isolation of RNA requires pure reagents and care in preparation due to the sensitivity of 
RNA to chemical breakdown and cleavage by nucleases. Therefore all the solutions and 
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materials were treated with DEPC (AppliChem, Darmstadt, Germany) in order to avoid 
RNase contamination and hence degradation of RNA. 
Total RNA of tumor tissues was isolated with TRI reagent (AppliChem, Darmstadt, 
Germany). The frozen tumor and cirrhosis tissue samples were cut into 5-µm-thick sections 
and used for RNA isolation (4-5 slices for each sample). Tissue samples were lysed in 1ml 
TRI reagent with a homogenizer and passed through a 21-gauge needle several times. After 5 
min incubation at room temperature, 0.2 ml chloroform was added per ml of TRI reagent. 
Tubes were shaken vigorously by hand for 15 seconds and incubated at room temperature for 
2-3 min. After incubation the mixture was centrifuged at 12000xg for 15 min at 4oC and then 
aqueous phase was collected into a new tube. 0.5 ml isopropanol was added onto aqueous 
phase per 1ml of TRI reagent used. The mixture was incubated at room temperature for 10 
min and then centrifuged at 12000xg for 15 min at 4oC to recover RNA. The supernatant was 
removed and the pellet was washed with 75% ethanol twice, centrifuged at 7500xg for 5 min 
at 4oC. The pellet was air-dried and dissolved in ddH2O. The isolated RNA solution was 
subjected to a second round of isolation by using NucleoSpin RNA II kit (Macharel Nagel, 
Duren, Germany) to remove any remaining contaminants of DNA. 
 
3.3.3 Expression Microarray Analysis 
 
3.3.3.1 Microarray experiments 
In-vitro microarray experiments were performed at Ankara University Biothecnology Institute 
by Dr. Hilal Ozdağ. GeneChip Human Genome U133 Plus 2 arrays were used on Affymetrix 
platform. Protocols supplied by the manufacturer were strictly followed (One-Cycle cDNA 
Synthesis Kit, Affymetrix). Briefly, 2 µg of RNA from cell line samples was converted to 
double-stranded cDNA (One-Cycle cDNA Synthesis Kit, Affymetrix). The cDNA samples 
then served as a template in an invitro transcription (IVT) reaction to obtain biotinylated and 
amplified cRNA (GeneChip IVT Labeling Kit, Affymetrix). 20 µg of labeled cRNA was 
fragmented, and 15 µg of fragmented RNA was hybridized to GeneChips for 16 hours. 
Immediately following hybridization, the GeneChip arrays were washed and stained with 
streptavidin phycoerythrin conjugate using an automated protocol on a GeneChip Fluidics 
Station 450, followed by scanning on a GeneArray Scanner. 
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3.3.3.2 Data processing and quality control  
GeneChip Operating Software (GCOS, Affymetrix) was used to collect and store the data. 
CEL files were uploaded to RMAExpress program to assess the quality of the arrays at the 
image level (2009, http://rmaexpress.bmbolstad.com/). Quality assessment of the Affymetrix 
datasets was performed using affyPLM (affyPLM; 
http://www.bioconductor.org/packages/2.4/bioc/html/affyPLM.html) on R suite of 
programme (R 2.4.0 or later). AffyPLM was used to detect artifacts on arrays that could pose 
potential quality problems and also for assessment of homogeneity of expression signal across 
arrays (Appendix A).  
 
3.3.3.3 Determination of differentially expressed gene sets  
The raw Affymetrix intensity measurements of all probe sets were background corrected, 
normalized and summarized into gene expression level measurements by applying the RMA 
(Robust Multichip Average) algorithm of the ‘affy’ package and log transformed (log 2 base) 
in Bioconductor suite of array analysis tools running in R version 2.4.0 (140). Please see 
required R packages for this analysis in Table 3.2. 
Table 3.2    Required R packages 
Package URL 
affy http://www.bioconductor.org/repository/release1.4/package/html/affy.html 
Biobase http://www.bioconductor.org/repository/release1.4/package/html/Biobase.html 
hgu95av2c
df 
http://www.bioconductor.org/data/metaData.html 
affyPLM http://www.bioconductor.org/repository/release1.4/package/html/affyPLM.html 
affydata http://www.bioconductor.org/repository/release1.4/package/html/affydata.html 
gcrma http://www.bioconductor.org/repository/release1.4/package/html/gcrma.html 
matchprobes http://www.bioconductor.org/repository/release1.4/package/html/matchprobes.
html 
hgu95av2pr
obes 
http://www.bioconductor.org/data/metaData.html 
siggenes http://www.bioconductor.org/packages/2.3/bioc/html/siggenes.html 
multtest http://www.bioconductor.org/packages/2.3/bioc/html/multtest.html 
genefilter http://www.bioconductor.org/packages/2.5/bioc/html/genefilter.html 
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The code used for loading the affy package, reading the targets file and the CEL files into R 
and image plots is given in Appendix B1. 
Differentially expressed probesets in the in vitro dataset derived from immortal, presenescent, 
and senescent Huh7 clones were identified between any two classes (i.e., immortal vs. 
senescent, immortal vs. presenescent, and presenescent vs. senescent) using a two-tailed, 
unpaired, unequal variance Welch’s t-test using R statistical package 
(www.bioconductor.com). The significance test code is given in Appendix  B2. 
 
Probesets were considered significantly differentially expressed if the raw p value was less 
than 0.05 for a given probeset in both sets of clones (e.g., for determining probesets 
modulated between immortality and senescence conditions, C11I versus C3S clones, as well 
as G11I versus G12S clones were compared). Moreover, only those probesets showing 
expression modulation in the same direction in both the C and G clones were used for future 
analysis. The resulting probeset list containing differentially altered genes as described above 
was further filtered by discarding probesets with annotations stated as unknown or those with 
ambiguous annotations based on HGU133 plus2 version release 21, November 2006.  
 
Confirmatory and further analyses with in vitro dataset were performed using BRB-
ArrayTools developed by Dr. Richard Simon and BRB-ArrayTools Development Team 
(2009, BRB Array Tools; http://linus.nci.nih.gov/BRB-ArrayTools.html). Annotations for the 
differentially expressed probesets were done using release 28, version 2.2.5, also. Experiment 
set used is in Table 3.3.  
Table 3.3  Experiment file of in-vitro data 
EXP 
Patient 
Id Group 
05-09-2006_g12_X3-1.CEL G12P P 
29-08-2006_g12_X3-2.CEL G12P P 
29-08-2006_g12_X3-3.CEL G12P P 
g11_X6-1_07-12-2005.CEL G11 I 
g11_X6-2_07-12-2005.CEL G11 I 
g11_X6-3_07-12-2005.CEL G11 I 
g12-L1_16-12-2005.CEL G12L S 
g12-L2_16-12-2005.CEL G12L S 
g12-L3_16-12-2005.CEL G12L S 
L1_ 15-12-2005.CEL C3L S 
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L2_ 15-12-2005.CEL C3L S 
L3_ 15-12-2005.CEL C3L S 
pC1_X29-2_06-01-2006.CEL C1 I 
pC1-X29-1_21-12-2005.CEL C1 I 
pC1-X29-3_21-12-2005.CEL C1 I 
X4-1_14-12-2005.CEL C3P P 
X4-2_14-12-2005.CEL C3P P 
X4-3_14-12-2005.CEL C3P P 
 
3.3.3.4 Visualization of datasets  
For all cluster analyses, Cluster 3.0 program 
(http://bonsai.ims.utokyo.ac.jp/~mdehoon/software/cluster/) was used to perform hierarchical 
clustering (141), (142). First data was adjusted by centering genes and arrays separately based 
on mean values, then average linkage was applied to genes and arrays using correlation 
(uncentered) similarity metric. Cluster files were visualized by Java Treeview (143) 
(http://jtreeview.sourceforge.net/). 
 
3.3.3.5 Data integration  
Common probesets between the any two gene lists obtained from in vitro and in vivo datasets, 
CROPPER (http://katiska.uku.fi/jmpaanan/cgi-bin/cropper/multi.pl) and custom perl-codes 
(CIF, by Ahmet Rasit Ozturk) developed in Bilkent University were used. 
 
3.3.3.6 Functional gene annotation cluster analysis  
DAVID (144), GSEA (Gene Set Enrichment Analysis, (145), OntoTools 
(http://vortex.cs.wayne.edu/projects.htm, (146) and Ingenuity pathway analysis (Ingenuity® 
Systems, www.ingenuity.com) were used to annotate the functions of gene lists.  
 
3.3.3.6.1 DAVID 
DAVID was used from the link: http://david.abcc.ncifcrf.gov/tools.jsp. Probe set lists were 
downloaded to Functional Annotation tool of DAVID. As the cutoff for significance; we 
selected biological groups with >1.3 enrichment score, <0.001 p-value, and <5% FDR 
multiple test corrected values. 
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3.3.3.6.2 GSEA (Gene Set Enrichment Analysis) 
Version 2 of GSEA was downloaded from http://www.broad.mit.edu/gsea/. Gene sets were 
downloaded from MsigDB database. The file extentions used in the analysis were *.gct for 
expression data, *.cls for phenotype file, *.gmt for gene sets, and *.chip for chip annotations. 
Phenotypes were permutted 1000 times. Gene sets which had <20% FDR were selected for 
evaluation. Data was collapsed with the collapse parametre of the software. “Weighted” was 
used as enrichment statistic. Signal2noise was selected for metric for ranking genes. Gene sets 
which were >500 and <15 genes were excluded from the analysis. “Meandiv” was used as 
normalization mode. “149” option was selected as seed for permutation.  
 
3.3.3.6.3 Onto Express 
A data set containing gene identifiers and corresponding expression values was uploaded into 
in the application. Binomial distribution was used as the statistic method in onto-express 
analysis. <0.05 was used as the cut-off value.  
 
3.3.3.6.4 Ingenuity Pathway Analysis 
The trial version of ingenuity pathway analysis software was used. A data set containing gene 
identifiers and corresponding expression values was uploaded into in the application. Each 
gene identifier was mapped to its corresponding gene object in the Ingenuity Pathways 
Knowledge Base. Fischer’s exact test (p<0.05) was used to calculate a p-value determining 
the probability that each biological function and/or disease assigned to that data set. 
 
3.3.3.7 Meta data 
3.3.3.7.1 HPEC replicative senescence data 
Gene expression dataset (two –channel array) reported by Schwarze et al (147) from 
proliferating (HPEC-P), replicative early senescent (growth arrest, but SABG-negative; 
HPEC-ES), replicative senescent (SABGpositive; HPEC-S), and human papillomavirus E7 
oncogene-immortalized (HPEC-I) HPEC was downloaded from SMD (release 1.11, 2006, 
July), Stranford Microarray Database (http://smd.stanford.edu). Log(2) base of R/G 
normalized median ratio, with >0.6 regression correlation, was retrieved. More than 50% 
good data according to SMD criteria was filtered and quantile normalized in R (9597 probe 
sets (6927 genes) and 9 samples). SMD uses the external sources of biological 
annotation:NCBI, SwissProt, dbEST, Locuslink, RHdb, Unigene, GeneCards, Genemap99. 
The merge of HPEC data and our data was made using gene symbols by CIF. CIF took the 
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mean value for redundant gene symbols. Resulting data was “median center”-normalized and 
subjected to cluster analysis, as described previously. 
 
3.3.3.7.2 IMR90 Oncogene-induced senescence data 
.CEL files of 10 affy chips (Affymetrix HGU-133A; 22283 probes) generated by Collado et. 
al. (148)  was downloaded from GEO (Gene Expression Omnibus, 
http://www.ncbi.nlm.nih.gov/geo/) with the GEO accession number of GSE2487. Data was 
normalized using RMA method and then median centered, as described previously.  Merge of 
IMR90 data and our data was made using gene symbols by CIF. CIF took the mean value for 
redundant gene symbols. Resulting data was “quantile” and “median center”-normalized and 
subjected to cluster analysis, as described previously.  
 
3.3.3.7.3  HCC molecular classification data 
HCC molecular classification dataset reported by Boyault et al (57 HCC, three hepatocellular 
adenoma, five non-tumor liver pool), obtained through special permission (149), was using 
BRB-ArrayTools.  
 
3.3.3.8   BRB array tools 
Further analyses with combined in vitro dataset were performed using BRB-ArrayTools 
developed by Dr. Richard Simon and BRB-ArrayTools Development Team (2009, BRB 
Array Tools; http://linus.nci.nih.gov/BRB-ArrayTools.html). We performed binary tree 
classification to predict the class of samples provided by the Boyault datasets using BRB 
array tools. The individual binary classifiers were based on the “Compound Covariate 
Predictor” incorporating genes that were differentially expressed among genes at the 0.001 
significance level as assessed by the random variance t-test. 
 
3.3.4   Quantification of nucleic acids 
 
3.3.4.1 Horizontal agarose gels of DNA samples 
DNA fragments were fractionated by horizontal electrophoresis by using standard buffers and 
solutions. DNA fragments less than 1 kb were generally separated on 1.0% or 2.0 % agarose 
gel, those greater than 1 kb (up to 11 kb) were separated on 0.8 % agarose gels. Agarose gels 
were completely dissolved in 1x TAE electrophoresis buffer to required percentage in 
microwave and ethidium bromide was added to final concentration of 30 µg/ml. The DNA 
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samples were mixed with one volume loading buffer and loaded onto gels. The gel was run in 
1x TAE at different voltage and time depending on the size of the fragments at room 
temperature. 
 
3.3.4.2 Gel electrophoresis of total RNA 
RNA was fractionated through 1% (w/v) agarose gels containing formaldehyde which 
disrupts hydrogen bonds. 0.5 g agarose was melted in 1X formaldehyde gel running buffer, 
allowed to cool, and 10 ml of 37% formaldehyde was added. The gel was immediately poured 
in a laminar hood. 5µl of RNA sample was mixed with 15 µl of RNA loading buffer and 
heated at 70 °C for 5 minutes. Samples were quenched on ice and loaded onto gel. 
Electrophoresis was performed at a constant voltage (85 V) for 4 hr at 4 °C in 1X 
formaldehyde gel running buffer. Following electrophoresis, gel was soaked for 5 min in 5 
volumes water to remove formaldehyde. This step was repeated for 3 times. The gel was 
stained in 30ug/ml ethidium bromide solution for 5 min, and destained overnight in double-
distilled water. 
Nucleic acids were visualized under ultraviolet light (long wave, 340 nm) and GeneRuler 
(MBI Fermentas) DNA size markers was used to estimate the fragment sizes.1 kb DNA 
ladder for horizontal agarose gels and 100 bp ladder for vertical agarose gels. 
 
3.3.5 First strand cDNA synthesis 
First strand cDNA synthesis from total RNA was performed using RevertAid First Strand 
cDNA synthesis kit (MBI Fermantas, Germany). The RevertAid kit relies on genetically 
engineered version of Moloney Murine Leukemia Virus reverse transcriptase (RevertAid M-
MuLV RT) with low RNase H activity. This allows the synthesis of full length cDNA from 
long templates. The first strand reactions were primed with oligo(dT)18 primer to specifically 
amplified mRNA population with 3’-poly(A) tails. As the reaction conditions and components 
of this kit and those of conventional PCR are compatible, first strand synthesized with this 
system can be used as a template for PCR. 
1 to 5 µg total RNA was used to synthesize the first stand cDNA following the manufacturer’s 
instruction. After 1:1 dilution of total reaction products in DEPC-treated water, 2 µl of diluted 
first strand cDNA was used for PCR. The rest is stored in -20 °C. 
 
3.3.6 Polymerase chain reaction (PCR) 
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3.3.6.1 Primer design for expression analysis by semi-quantitative and quantitative PCR 
The primer pairs that have been used in expression profile analyses were designed carefully 
using “Primer exe” or “Primer 3.0” 
(http://frodo.wi.mit.edu/cgibin/primer3/primer3_www.cgi) programmes. Forward and reverse 
primer were positioned on different exons of the gene of interest, so that the primer pair was 
either be able to produce a longer amplicon from genomic DNA or not be able to amplify 
from the covered genomic DNA region in a given PCR condition (critical parameter was 
extension time). Therefore the amplicon, which was amplified from cDNA, was not be longer 
than 1500 bp for semi-quantitative PCR and 200 bp for quantitative PCR. The sequences of 
the gene-specific primers were put into the blast search to determine their specificities. None 
of the primer pairs showed significant homology to other sequences in the genome but their 
own.Primers used for expression analysis have been designed strictly considering these 
criteria, and listed in Table 3.4. For real-time PCR analysis, all primers were subjected to the 
“primer efficiency” analysis with serialy diluting (2 fold-dilutions) the parental Huh7 cDNA. 
The Ct values were obtained in 1, 1:2, 1:4, 1:8, 1:16, 1:32 and 1:64 fold dilutions and primer 
efficiencies were calculated by using the formula; E=2[-1/slope]. The primer efficiency values of 
the primers which were used in Q-PCR analysis were listed in Table 3.4, also. 
    
Table 3.4 Primers, and their sequences. Primer efficiencies were given only for primers 
used in Q-PCR. 
Name Sequence 
Primer efficiency 
(if used in Q-PCR) 
E2F1-F 5'-CATCAGTACCTGGCCGAGAG-3'  
E2F1-R  5'-CCAGTTCAGGTCGACGACAC-3' 2.06 
E2F2-F 5'-GCCAAGAACAACATCCAGTG-3'  
E2F2-R 5'-TCAGGTGCTTGAAGCTCAGA-3' 1.7 
E2F3-F  5'-CAAGACTTGAAGTGCCTGAC-3'  
E2F3-R  5'-GCTATGTCCTGAGTTGGTTG-3' 1.8 
E2F4-F 5'-CAGCAGCAGCAGCAACAGTA-3'  
E2F4-R 5'-ACATCAACTCCTCCAGCAGC-3' 2.1 
E2F5-F 5'-AGGCACCTTCTGGTACACAA-3'  
E2F5-R 5'-AAGCAGCACATGGATAGGTC-3' 2 
E2F6-F 5'-CAGGCCTTCCATGAACAGAT-3'  
E2F6-R 5'-ACATCGATAGGTCCGTTGGT-3' 2.1 
E2F7-F 5'-CAAGGATCAGGTGGCTACTC-3'  
E2F7-R  5'-GGAGGCACCACTCTCTTACT-3' 2.1 
E2F8-F 5'-GCATGCTCGAGGACAGTGGT-3'  
E2F8-R 5'-GATGAGCACTGCGTGAGAGG-3' 1.7 
DP1-F 5'-AGAAGTCTGGTCCCCAAGG-3'  
DP1-R 5'-AAGTCATCGTCCTCCTCGTC-3' 1.9 
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DP2-F 5'-GGAGTCAGGCAAATGCTCTC-3'  
DP2-R 5'-GCTAAGGCCACTTCTGCATC-3' 2 
ACTB-F 5'-CCAACCGCGAGAAGATGACC-3'  
ACTB-R 5'-GGAGTCCATCACGATGCCAG-3' 2 
ACE2-F  5'-AGGATGTGCGAGTGGCTAAT-3'  
ACE2-R 5'-AGGCTGTTGTCATTCAGACG-3' - 
EHF-F 5'-GATCTCCATGACAACCACCA-3'  
EHF-R 5'-AGAGGATGTCGCGGATGAAT-3' - 
HEPH-F 5'-CCTCTCACCGTCATCACCAA-3'  
HEPH-R 5'-CAGAGGCCAGCATCTCAACA-3' - 
KRT19-F 5'-GATGAGCAGGTCCGAGGTTA-3'  
KRT19-R 5'-GTGTGTCTTCCAAGGCAGCT-3' - 
MAGEB2-F 5'-TGAATTCTCAGGACTGGTCG-3'  
MAGEB2-R 5'-GCTTCAGTGACCTGAGGAAC-3' - 
PRDM1-F 5'-TCCACCTGAGAGTGCACAGT-3'  
PRDM1-R 5'-ATCTCTTGTGGCAGACCTGG-3' - 
NOX1-F 5'-TCCTTGCACCGGTCATTCTT-3'  
NOX1-R 5'-CCACGCTTGTTCATCTGCAA-3' - 
TIMP2-F 5'-GTCAGTGAGAAGGAAGTGGA-3'  
TIMP2-R 5'-CTCTATATCCTTCTCAGGCC-3' - 
GIPC2-F 5'-CCACAATGTTTGAAGCTGGA-3'  
GIPC2-F 5'-ATCACCAATGACTCCCCAAA-3' - 
CAPN2-F 5'-CAAGTCAGATGGCTTCAGCA-3'  
CAPN2-R 5'-AACTCCTTCAGCCCCAGCTT-3' - 
CCNG2-F 5'-GCCTTGTGCCTTCTCAATTT-3'  
CCNG2-R 5'-AGCTGTTGTGGAGGTTCTGG-3' - 
NGFRAP1L1-F 5'-CAGCCGATTTCAAGGCTAAG-3'  
NGFRAP1L1-R 5'-TCCAGGCTCCTGGTATTCAC-3' - 
REEP1-F 5'-GCACTTTTCACCACAGCAGA-3'  
REEP1-R 5'-TTTTGAAGATAGCGTGGGATG-3' - 
MAF-F 5'-TGGAGTCGGAGAAGAACCAG-3'  
MAF-R 5'-GCTTCCAAAATGTGGCGTAT-3' - 
MAP3K5-F 5'-CGTGAGCACGCTCAGTTCTA-3'  
MAP3K5-R 5'-TTCCGAACCAATTCTTCCAG-3' - 
SSTR1-F 5'-TAACAGACCGCACATGCACT-3'  
SSTR1-R 5'-CGGCTCTGGACTGGTAAATG-3' - 
PPARGC1A-F 5'-GATACACTTTGCGCAGGTCA-3'  
PPARGC1A-R 5'-GTGGAAGCAGGGTCAAAGTC-3' - 
IL17D-F 5'-TCAGTGCCTTCCACCACAC-3'  
IL17D-R 5'-CACAGGCAGTAGGCTTCAGG-3' - 
KLF4-F 5'-GTTCCCATCTCAAGGCACAC-3'  
KLF4-R 5'-CCCCGTGTGTTTACGGTAGT-3' - 
MAPK13-F 5'-GGAGCTAGACGTGGACAAGC-3'  
MAPK13-R 5'-AATGGGGCTGAAGTTCACAA-3' - 
RASGEF1B-F 5'-CTGGCCAAACAAGTGAGTGA-3'  
RASGEF1B-R 5'-TGAAGACTGGTACTGTGAGCAGA-3' - 
TFEC-F 5'-AACAACAGAGAGCCCGAGAA-3'  
TFEC-R 5'-TGGCAGACCATGAGTACGAG-3' - 
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TMEFF1-F 5'-CTGCATCCATGGAAAATGTG-3'  
TMEFF1-R 5'-GCTTTTGCCTACTTGGCACT-3' - 
TP53INP1-F 5'-GGGGCAGCATATTCATTGTT-3'  
TP53INP1-R 5'-TAAGATTTTGGCGACGAAGG-3' - 
ZNF177-F 5'-CAATTGCTATGCAGAACATTCC-3'  
ZNF177-R 5'-GAAGGCTTTCCCACAGTCAC-3' - 
ZNF304-F 5'-ACTCCTTGAGGAGGCACAGA-3'  
ZNF304-R 5'-TGCCTCATGTTCTGCTTCAC-3' - 
ZNF419-F 5'-TTGTGACTTCAGCCATACCG-3'  
ZNF419-R 5'-CACAGTGCTGCTTCTGGTGT-3' - 
ZNF585A-F 5'-CCTGAAGCAGAGGTGGTCAT-3'  
ZNF585A-R 5'-TCAAATTTGGCGCATTCATA-3' - 
C18ORF22-F 5'-GCGGCCGCATGTGGGCTGCGGCGGGC-3'  
C18ORF22-R 5'-GGATCCCTCCCTGCTTGCTCCGCA-3' - 
TGIF-F 5'-GCGGCCGCATGAAAGGCAAGAAAGGT-3'  
TGIF-R 5'-GGATCCAGCTGTAAGTTTTGCCTG-3' - 
THOC4-F 5'-AGATCTATGGCCGACAAAATGGAC-3'  
THOC4-R 5'-GGATCCACTGGTGTCCATTCTCGC-3' - 
ZNF232-F 5'-GCGGCCGCATGGAACCTCCTGGTCCT-3'  
ZNF232-R 5'-GGATCCATGGGAAGGCTCTTTTCT-3' - 
FBXL11-F 5'-ACTGCATAACCAACCGTTCC-3'  
FBXL11-R 5'-TTCTCGATCCACTGCTTCCT-3' 2.2 
CARM1-F 5'-GGCTCCATAATGACCGTGTG-3'  
CARM1-R 5'-GCGAACAGTGGTGACTGGAA-3' 1.9 
PRMT1-F  5'-CACCAACGCCTGCCTCATAA-3'  
PRMT1-R  5'-TGGCAGCGTGTGAACTCGAT-3' 2.2 
ASH1L-F 5'-GTCTCATGATCCAGTGTGAC-3'  
ASH1L-R 5'-GATGAAGTAGACACAGCCAG-3' 2.2 
MLL3-F 5'-CATCCTACAGCTGCTGAGAA-3'  
MLL3-R 5'-GACATCTGGAGCACTGCTAA-3' 2.1 
EZH2-F 5'-AGCCTTGTGACAGTTCGTGC-3'  
EZH2-R 5'-CAGCGGCTCCACAAGTAAGA-3' 2 
SUV420H1-F 5'-CCGCCAAGGAACTCTGTGAA-3'  
SUV420H1-R 5'-AATGCCTTGAGCTCCTCGAA-3' 2.2 
PCAF-F 5'-GAATTAGAGAGACAGGCTGG-3'  
PCAF-R 5'-GGAGCTTCTGTTCTCTTCAC-3' - 
JARID1B-F 5'-AAGAACCGTGAACTGGCAGC-3'  
JARID1B-R 5'-TGTTGTGCCAGGAGGTTGAG-3' 2.1 
UTX-F 5'-GGAAGTTGCAGCTACATGAG-3'  
UTX-R 5'-TCCTGATGACCTGGTGTTCT-3' 1.9 
JMJD2B-F 5'-TTCCTGCGGCATAAGATGAC-3'  
JMJD2B-R 5'-GGTGGCGAAGTTGGTAGATT-3' 2.3 
JMJD3-F 5'-TCTGCAGGAGGAGAAGGAGA-3'  
JMJD3-R 5'-TCCACCGCTTAGCATCAGAC-3' 2.1 
SMYD2-F 5'-GACATGGTCAGATATGCACG-3'  
SMYD2-R 5'-CCTGGTACATCATGTGCAAC-3' 2.2 
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SETD2-F  5'-TGATCACAAGGCAGACTCAG-3'  
SETD2-R   5'-CAGGTCCATCTCAGCTTCAT-3' 2 
 
3.3.6.2 Expression analysis of a gene by semi-quantitative PCR 
 
3.3.6.2.1 Determination of optimal cycle of a gene for semi-quantitative PCR 
Using equal amount of templates for PCR amplifications of a gene of interest give 
comparable results at a certain number of PCR cycles. The number of optimal PCR cycle was 
determined by an initial study for each gene by performing 35-cycle PCR during which PCR 
amplicon samples were collected by 3-cycle intervals. Agarose gel analysis of samples from 
20th, 23rd, 26th, 29th, 32nd, 35th, cycles of PCR with an equal load defined the minimum 
number of cycle to visualize the product on agarose gel and the saturation cycle. Agarose gels 
were analyzed by Densitometric Fluorescence-Chemiluminescence image analyzer and The 
Molecular Analyst software (BioRad). The determined cycle number was used for 
amplification of the gene of interest. 
 
3.3.6.2.2 GAPDH normalization 
Equal volume (2µl) of all first strand cDNA samples was used for cold-PCR amplification of 
GAPDH transcript using the pre-determined optimal cycle number for GAPDH (18 cycles). 
Then an equal volume of each sample was loaded onto agarose gel and intensity of each band 
was analyzed by Densitometric Fluorescence-Chemiluminescence image analyzer and The 
Molecular Analyst software. After intensities were determined, intensity of sample with the 
highest densitometric reading and 2 µl loading volume were used as reference points for 
normalization of input loading volume of other samples for expression analysis of both 
GAPDH and gene of interest by cold PCR amplification. Amplification products were 
analyzed in computer.  
 
3.3.6.2.3 PCR amplification of target region  
A reaction mixture of 2.5µl 10X reaction buffer, 1.5µl MgCl2 (25mM), 0.5 µl dNTP (10µM), 
1µl of each primer (10 pmol), and 0.2 µl Taq DNA polymerase (5u/µL) was prepared per 2µl 
cDNA and total volume was adjusted to 25µl with ddH2O. The optimized PCR condition for 
all primer pairs used in this study was as follows: 
 
Initial denaturation 95.0oC  5 min 
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Denaturation   95.0oC  30 sec 
Annealing   60.0oC  30 sec   30 cycles 
Extension   72.0oC  30 sec 
Final extension  72.0oC  10 min 
 
3.3.6.3 Quantitative real time RT-PCR 
Real-time qRT-PCR was performed on BioRad iCycler (Bio-Rad, California, USA) using the 
BioRad iQTM SYBR Green Supermix or Stratagene MX3005P (Stratagene, U.S.A.) using 
Stratagene SYBR green supermix. The amplification mixtures contained 2.0 µl of 1:1-diluted 
cDNA template, 12.5 µl SYBR Green PCR Master Mix Buffer (2X), and 10 pmol of forward 
and reverse primers in a total volume of 25 µl. The cycling conditions were as follows: an 
initial incubation of 95°C for 5 min and then 45 cycles of 95°C for 30 s, 60°C for 30 s and 
72°C for 30 s  during which the fluorescence data were collected. To verify that the used 
primer pair produced only a single product, a dissociation protocol was added after 
thermocycling, determining dissociation of the PCR products from 55°C to 95°C in 80 cycles. 
The amplification reactions were performed in 96 well-PCR plates and the plates were sealed 
with optical sealing tapes (Bio-Rad, California, USA). All PCR reactions were studied in 
duplicate or triplicate. Tumor and matched normal samples were always analyzed in the same 
run to exclude between-run variations and each sample was studied in duplicate. A no-
template control of nuclease-free water was included in each run. Following amplification, a 
reaction product melt curve was obtained to provide evidence for a single reaction product. 
The iCycler iQ Optical System Software (version 3, BioRad Laboratories) or Stratagene 
MxPro Software (Strategene laboratories) were used to determine the melting temperatures of 
the products. The threshold cycle (Ct) value was calculated as the cycle where the 
fluorescence of the sample exceeded a threshold level.  
 
3.3.6.3.1 Amplification efficiency calculations 
The PCR amplification efficiencies (E) were evaluated by 2-fold dilution series of cDNAs (1-
1:256 dilution) for each pair of primers used in this study by using Huh7 cDNA. A graph of 
threshold cycle (Ct) was produced and the reaction efficiency was determined for each primer 
set by using the slope of this graph (E=2(-1/slope)) and presented at Table (La Jolla, USA). For 
the evaluation of the real-time RT-PCR results 2-∆∆Ct method was corrected according to 
efficiency method (150) as: [(Etarget) ∆CtTarget (control-sample)/ (Eref) ∆CtReference 
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(control-sample)] using normal pair samples as control. In this formula, in the place of 
“reference” the Ct values of three reference genes, ACTB was used.  
 
3.3.7 Total Protein isolation 
 
3.3.7.1 Protein isolation from tissue culture cells 
Adherent monolayer cells (both stable and parental cells) were grown to 70% confluency in 
growth medium lacking selective antibiotic. After removal of growth medium, cells were 
washed twice with ice-cold PBS to remove any serum residue. 400 µl of RIPA lysis-buffer 
(150 mM NaCl, 50 mM Tris-HCl pH 8.0, 0.5% sodium deoxycholate, 1 % NP-40, 0.1% SDS 
and 1X Complete Protein Inhibitor mix (Roche)) was added into tissue culture petri dish (6 
cm or 10 cm), and cells were scraped with rubber scrapper. Complete lysis was achieved by 
pipetting of crude cell lysates several times and by incubating the lysates on ice for 30 min 
with vortexing every 6 minutes, and then centrifuged at 13.000 XG for 30 minutes. Total cell 
protein was collected as supernatant. 
 
3.3.7.2 Protein isolation from tissue samples 
The 5 µm thick tissue sections were cut with cryostat and collected in an eppendorf tubes. 
Tissues were freezed in liquid nitrogen after excision. Some nitrogen was added onto tissues 
in a mortar, and they were powdered with a mortar and pestle. 500 ul RIPA buffer was added 
onto powdered tissue. The collected samples were vortexed for 60 s and incubated on ice for 1 
hour. After they were homogenized with a polytron during 15 secods 2 times. They were 
centrifuged a 14.000 XG for 30 minutes at 4 °C. The supernatant were stored at -80 °C.  
 
3.3.7.3 Histone extraction 
Cells were harvested and washed twice with ice-cold PBS. PBS and subsequent buffers were 
supplemented with 5 mM sodium butyrate to retain levels of histone acetylation. Cells were 
resuspended in Triton Extraction Buffer (TEB: PBS containing 0.5% Triton X 100 (v/v), 2 
mM phenylmethylsulfonyl fluoride (PMSF), 0.02% (w/v) NaN3) at a cell density of 107 cells 
per ml. Cells were lysed on ice for 10 minutes with gentle stirring, and centrifuged at 6,500 x 
g for 10 minutes at 4°C to spin down the nuclei. Supernatant were removed and discarded. 
The nuclei was washed in half the volume of TEB and centrifuged as before. The pellet was 
re-suspended in 0.2 N HCl at a density of 4x107 nuclei per ml. The histones were acid 
extracted over night at 4°C. Then, samples were centrifuged at 6,500 x g for 10 minutes at 
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4°C to pellet debris. the supernatant, which contains the histone protein, was saved and 
protein content was determined using the Bradford assay. Aliquots were store at -20°C. 
 
3.3.8 Quantification of proteins 
After the cell lysates were prepared, their concentrations were detected by Bradford assay. As 
described in Table 3.5. 2 µl of the samples were diluted with 98 µl deionised water and then 
900 µl of Bradford working solution was added to the samples and mixed well. After 5 
minutes of incubation, the protein amounts of the samples were measured at OD595 nm 
versus blank reagent. Known concentrations of BSA were prepared according to Table 3.6 as 
a standard. After reading at OD595, samples and standard values were plotted; unknown 
concentrations were calculated from the standard curve.  
Table 3.5 A standard curve preparation with BSA dilution. 
Tubes 1 2 3 4 5 6 7 8 
BSA (µl) 0 2.5 5 7.5 10 12.5 15 20 
ddH2O (µl) 100 97.5 95 92.5 90 87.5 85 80 
Bradford (µl) 900 900 900 900 900 900 900 900 
Total (ml) 1 1 1 1 1 1 1 1 
 
Table 3.6 Protein sample preparation for Bradford assay 
Tubes 1 2 3 4 5 
Sample (µl) 0 2 2 2 2 
ddH2O (µl) 100 98 98 98 98 
Bradford (µl) 900 900 900 900 900 
Lysis buffer (µl) 2 0 0 0 0 
 
3.3.9 Western Blotting 
10% Bis-tris gel (invitrogen) was used for western blot assays. Invitrogen vertical gel system 
was set up according to manufacturer’s instructions. For 10% Bis-tris gel (invitrogen), 
MOPS-SDS running buffer and Nu-PAGE Transfere buffer (Invitrogen) were used. Equal 
amounts of cell lysates were solubilized in 1X LDS sample buffer with 1X sample reducing 
agent (Invitrogen), denatured at 70°C for 10 min and incubated on ice for 2 min. After a quick 
spin, samples were loaded onto polyacrylamide gel. After electrophoresis at 120 V for 1-2 
hours, proteins were transferred onto PVDF western blotting membrane (Roche) by using 
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wet-tramsfere technique in Invitrogen electroblotting apparatus according to the 
manufacturer’s instructions at 25V for 2 or 4 hours (depending on the size of the target 
ptorein). Membrane was immediately treated for an hour in blocking solution at room 
temperature and probed with primary antibody either for an hour at room temperature or 
overnight at 4°C. After washing 3 times for 10 min. in TBS-T solution at room temperature, 
the membrane was incubated with appropriate HRP conjugated secondary antibody for 1 hr. 
The membrane was washed 3 times for 10 min in TBS-T solution at room temperature. After 
final wash, the blot was exposed to ECL western blot detection kit (Amersham) according to 
manufacturer’s instructions. The chemiluminescence emitted was captured on X-ray film 
within 30 sec. to 25 min. exposure times.  
 
3.3.10 Immunofluorescence 
Autoclaved-sterilized coverslips were placed into the well of 24-multiwell plates. 5x104 cells 
were seeded onto each coverslip and grown overnight in 0.5 ml growth medium. Cells were 
washed with PBS and fixed in 0.5 ml of 4% formaldehyde for 5 min. 
After fixation cells were permeabilized with 0.5% TritonX-100/0.5% Saponin in PBS for 5 
min 3 times and blocked in 0.5 ml blocking solution for 1 hour at room temperature. 
Coverslips were probed with primary antibody in appropriate dilution for 1 hr at room 
temperature or overnight at 4°C. After 3 times washing for 5 min each with dilution solution, 
appropriate FITC-conjugated secondary antibody was applied for 45 min at room 
temperature. Cells were washed 3 times for 5 min with dilution solution and DNA counter 
staining was performed by with Hoechst 33258 or DAPI for 3 min. Hoechst 33258 or DAPI 
was aspirated and destaining was done in double-distilled water for 15 min. immediately after 
coverslips were taken out from the well and excess water removed by tissue paper, coverslips 
were mounted onto slides containing 10 µl 80% glycerol, or mounting medium. All steps after 
the addition of FITC-conjugated secondary antibody were performed in the dark. 
Stained cells were examined under fluorescence microscope (ZEISS or Olympus) and pictures 
were captured in a digital Kodak Camera (DC290, Eastman Kodak Co., Rochester, NY), 
using Adobe Photo Deluxe (Adobe Systems Inc.) software. The pictures were edited using 
Adobe Photoshop 5.0 (Adobe Systems Inc.) software. Digital images were magnified when 
needed during picture editing. 
 
3.3.11 Immunoperoxidase 
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Autoclaved-sterilized coverslips were placed into the well of 24-multiwell plates. 5x104 cells 
were seeded onto each coverslip and grown overnight in 0.5 ml growth medium. Cells were 
washed with PBS and fixed in 0.5 ml of 4% formaldehyde for 5 min. After fixation cells were 
permeabilized with 0.5% TritonX-100/0.5% Saponin in PBS for 5 min 3 times and blocked in 
0.5 ml blocking solution for 1 hour at room temperature. Coverslips were probed with 
primary antibody in appropriate dilution for 1 hr at room temperature or overnight at 4°C. 
After 3 times washing for 5 min each with dilution solution, appropriate HRP-conjugated 
secondary antibody was applied for 45 min at room temperature. Cells were washed 3 times 
for 5 min with dilution solution. As the substrate of HRP, DAB plus was prepared freshly. 
Cells were incubated with DAB+ within 30 seconds to 3 minutes, and washed with tab water 
for 3 minutes. DNA counter staining was performed by with Mayer’s Heamatoxylene (Sigma) 
for 3 min. Deastaining was done with distilled water during 5 minutes. Coverslips were taken 
out from the well and excess water removed by tissue paper, coverslips were mounted onto 
slides containing 10 µl 80% glycerol, or mounting medium. Stained cells were examined and 
counted under light microscope (ZEISS or Olympus) and pictures were captured in a digital 
Kodak Camera (DC290, Eastman Kodak Co., Rochester, NY).  
 
3.3.12 Immunohistochemistry on paraffin-embedded tissue sections 
Slides were washed with dH2O in the glass container briefly. Parrafin removal was successed 
by incubationg the slides in an owen at 70°C for 60 min.s, and then incubated with toluene 
3X10 min.s. Endogenous peroxidase was inhibitted by incubating slides in 100% ethanol for 2 
min.s and 3% H2O2, prepared in methanol, for30 min.s. Samples were treated with 100% 
ethanol, 90% ethanol and than 70% ethanol for 2 min.s interval for rehydradion step, and 
washed with dH2O for 5 min.s. Antigen retrievel was successed by boiling the slides in citrate 
buffer for 20 min.s and washed two times with dH20. The slides were blocked in blocking 
solution for 30 min.s. Slides were incubated with primary antibody solution in appropriate 
dilutions overnight at 4°C. After washing with wash solution three times for five min.s, 
Envision Dual Link (Dako) was applied on slides during 1 hour. Secondary antibody was 
washed and the slides were treated with DAB+ substrate for 30 sec.s to 10 min.s. Counter 
staining was performed with Mayer’s heamatoxylene for 2:30 min.s. The tissue slides were 
mounted with mounting medium and coverslipts and examined under light microscope 
(Olympus). The cells were counted under the light microscope by an experienced pathologist.  
 
 
 55 
3.3.13 SABG assay 
SABG activity was detected by using a described protocol (151). SABG positive and negative 
cells were identified and counted under the light microscope.        
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CHAPTER 4. RESULTS 
 
4.1  Identification of senescence and immortality gene network and its role in 
hepatocellular carcinoma 
 
4.1.1 Expression analysis of immortal and reprogrammed senescent cells of 
hepatocellular carcinoma 
Recently, our group has observed that some single cell clones of cancer cell lines changed 
morphology and ceased proliferation at late passages with features reminiscent of cellular 
senescence. Different Huh7-derived clones were expanded in long-term culture and their 
potential was examined to undergo replicative senescence by a recent group member, Nuri 
Ozturk. It has been observed that some clones performed more than 100 PD in culture with 
stable proliferation rates and heterogeneous SABG staining, while others sustained a limited 
number of PD, then entered a growth arrest phase with full SABG staining patterns. For 
example, Huh7 derived C3 clone performed only 80 PD, whereas Huh7  derived C1 clone 
replicated over 150 PD. Permanently arrested C3 cells (PD 80) displayed enlarged size, 
flattened shape, and fully positive SABG staining, whereas early passage C3 (PD 57) and C1 
(PD 179) cells displayed normal morphology with heterogeneous SABG staining (Figure 
4.1.1). 
 
Figure 4.1.1  Senescence associated B-galactosidase (SABG) staining of immortal and 
senescent cells. 
 
To generate the expression data, we generated the genome wide expression profiling in 
immortal, pre-senescent and senescent clones. Two immortal clones, namely C1 and G11, 
were tested after 150 PD following clone isolation. Two senescenceprogrammed clones, 
namely C3 and G12, were analyzed at both presenescent (20-30 PD before senescence arrest) 
and senescent (~80 PD) states. Three biological replicates were used for RNA extraction from 
each clonal cell with a total of 18 cell line samples. Preparation of labelled nucleic acids from 
Senescent-C3 Immortal-C1 
 57 
mRNAs, the Affymetrix HG-U133 plus2 hybridization and raw data retrievel were performed 
in Ankara University Biotechnology Institute with the colloboration of Dr. Hilal Ozdag. RNA 
quality was evaluated by the ratio of 18S to 28S RNAs by Agilent Bioanalyzer; all samples 
passed this quality control test (integrity number >4) (data not shown). The quality of every 
single Affymetrix data was assessed using AffyPLM software in R. Chip pseudo-images (not 
shown) and NUSE and RLE plots retrieved from the AffyPLM  revealed that all 18 Affy data 
were with high quality (Figure 4.1.2). 
 
Figure 4.1.2 Quality assessment of microarray data. NUSE and RLE plots of 18 Affy-
chips retrieved from affyPLM software showed that all chips were with high quality.  
 
4.1.2 Differentially expressed gene set between immortal, pre- and senescent clones  
Then, the raw data were background corrected, normalized (Figure 4.1.3) and summarized 
into gene expression level measurements by applying the RMA (Robust Multichip Average) 
algorithm of the ‘affy’ package and log transformed (log 2 base) in Bioconductor in R 
(Appendix A and B1). Differentially expressed probesets derived from immortal, 
presenescent, and senescent Huh7 clones were identified between any two classes (immortal 
vs. senescent, immortal vs. presenescent, and presenescent vs. senescent) using a two-tailed, 
unpaired, unequal variance Welch’s t-test using R statistical package (Appendix B2). 
Probesets were considered significantly differentially expressed if the raw p value was less 
than 0.05 for a given probeset in both sets of clones (e.g., for determining probesets 
modulated between immortality and senescence conditions, C11I versus C3S clones, as well 
as G11I versus G12S clones were compared). We identified 6390 probesets showing 
expression modulation in the same direction in both the C and G clones. This gene set 
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discriminated the groups from each other with high accuracy (Figure 4.1.4). Gene and probe 
numbers differentially expressing between any two groups were given in Table 4.1.   
      
Figure 4.1.3 Plots of microarray data before (left) and after (right) normalization. The 
plots were generated in R, using AMDA package. We observe that any bias coming from 
technology is eliminated after normalization. 
 
Figure 4.1.4 Huh7 isogenic clones significant gene list (6390 probe sets) unsupervised 
hierarchical cluster analysis (p<0.05) (I: immortal, P: pre-senescent, S: senescent) Red: up-
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regulation, green: down-regulation and black: no change. The grouping of different 
phenotypes with high accuracy was observed.  
Table 4.1.1 The numerical report of significant probes and genes 
  I->PS PS->S I->S 
Gene        
up 1054 1029 1665 
down 1095 994 1408 
total 2149 2023 3073 
Probe       
up 1202 1224 2086 
down 1350 1164 1786 
total 2552 2388 3872 
 
4.1.3 Confirmation of the microarray data 
After obtaining significant gene set, we wanted to test the accuracy of our microarray data by 
RT-PCR. Sixteen senescence upregulated genes and nine immortal upregulated genes were 
selected randomly, and primers were designed. We applied semi-quantitative RT-PCR using 
the mRNA material prepared from an independent (from the mRNA samples used in 
microarray study) set of immortal, pre-senescent and senescent clones. GADPH gene was 
used as the internal control. All of the amplifications gave the same results as the microarray 
data, most of them changing more dramatically in RT-PCR than microarray value (Figure 
4.1.5 A and B). From the set of senescence up-regulated genes; the genes tested were ACE2 
(angiotensin I converting enzyme 2), NOX1 (NADPH oxidase 1), TIMP2 (Tissue inhibitor of 
metalloproteinases 2 ), HEPH (Hephestine), PRDM1 (B-lymphocyte-induced maturation 
protein 1), EHF (ETS domain-containing transcription factor ), MAGEB2 (cancer/testis 
antigen family 3, member 2), CAPN2 (Calcium-activated neutral proteinase 2), TM7SF1 
(Transmembrane 7 superfamily member 1 protein ), NGFRAP1L1 (Nerve growth factor 
receptor-associated protein 2 ), GPR74 (G protein-coupled receptor 74 ), REEP1 (receptor 
expression enhancing protein 1), MAP3K5 (MAP/ERK kinase kinase 5 ), PPARGC 
(peroxisome proliferator activated receptor gamma, coactivator 1 alpha ), and MAP7 
(microtubule-associated protein 7). Tested immortality related genes were; RAD50 (RAD50 
(S. cerevisiae) homolog), NBN (Cell cycle regulatory protein p95), MND1 (meiotic nuclear 
divisions 1 homolog (S. cerevisiae)), MRE11A (DNA recombination and repair protein), 
SLC7A5 (Solute carrier family 7 member 5), TMCO6 (transmembrane and coiled-coil 
domains 6), DKK1 (dickkopf (Xenopus laevis) homolog 1), GLUD1 (glutamate 
dehydrogenase (NAD(P)+)), and ROBO2 (roundabout (axon guidance receptor, Drosophila) 
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homolog 2). The correlation of microarray data and RT-PCR data was 1 (100% correlation) 
for  both senescence and immortality related genes.  
 
C1 C3E C3L G11 G12E G12L 
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Figure 4.1.5 Confirmation of the microarray data. A) RT-PCR analysis of senescence and, 
B) immortal up-regulated genes. C1 and G11 cells are two immortal clones, C3E and G12E 
cells are pre-senescent clones and C3L and G12L are senescent cell clones. The mRNA 
samples used for the analysis were from the different cell vials from the mRNA samples used 
in microarray study. The correlation efficient between microarray data and RT-PCR data were 
found to be 1 (http://www.easycalculation.com/statistics/correlation.php). 
 
4.1.4 Analysis of significant gene set on other senescence microarray data 
As our senescence model was a unique model; we, then, wanted to see whether the gene 
expression profile of our senescence model resembles to other senescence models. We 
screened the literature for the publicly available microarray data performed with different 
senescence and immortalized cell models.  We selected 2 studies and analyzed them, as 
summarized in material-methods.  Schwarze and his colleagues profiled the global gene 
expression of replicative senescence in HPECs (Human prostate epithelial cells) (147). They 
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have analyzed expression analysis of proliferating HPECs, serially passaged early-senescent 
and late-senescent HPECs and hTERT-immortalized HPEC cells. Collado and his friends 
studied with Mek:Erk induced OIS (oncogene-induced senescence) using IMR90 (human 
fetal lung) cells (148). They have compared the expression profiles of Mek:Erk transfected 
senescent, both Mek:Erk and small t-antigen induced senescent, and Mek:Erk, E6 and E7, and 
small t-antigen induced immortal IMR90 cells. We merged 6390-gene set with downloaded 
and normalized data, and performed non-supervised hierarchical cluster analysis. We 
observed that our significant gene signature could succesfuly discriminate both replicative 
senescent cells and oncogene-induced senescent cells from their immortalized counterparts 
(Figure 4.1.6 A and B). For the Schwarze data-set, we observed that early- and late-senescent 
HPEC cells were grouped together with C3S and G12S senescent clones; proliferating HPEC 
cells clustered in the same branch with C3P and G12P pre-senescent clones, and hTERT 
immortalized HPECs grouped together with C1 and G11 immortal cells. Mek:Erk and 
Mek:Erk-Small t-antigen   induced senescent IMR90 cells were clustered together with C3S, 
G12S and C3P, G12P clones, respectively. On the other hand, Mek:Erk-E67-Small t-antigen 
transfected immortal IMR90 cells were grouped together with C1 and G11 immortal clones.    
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HPEC-ES 
HPEC-S 
A 
 63 
 
Figure 4.1.6 Meta-analysis with previously published senescence data. A) Unsupervised 
cluster analysis with Schwarze et. al. data, 2682 genes were common between 9597 probes 
and 6390 probes (HPEC E7I: E7 immortalized HPECs, HPEC-P: proliferating HPEC cells, 
HPEC-ES: early senescent HPECs, HPEC-S: late senescent HPECs). B) Unsupervised cluster 
analysis with Collado et. al. data, 3654 genes were common between 22283 probes and 6390 
probes (MEK-OIS: Mek:Erk induced senescent IMR90 cells, MEK-OIS-t: Mek:Erk and 
Small t-antigen induced senescent IMR90 cells, MEK-E67I-t: Mek:Erk, E6 and E7 and small 
t-antigen transfected immortal IMR90 cells).  
 
4.1.5 Functional classification of senescence and immortality genes 
To identify significant biological processes and pathways regulated differentially between 
immortal, pre- and senescent clones, we have used some bioinformatic tools, such as GSEA 
(Gene Set Enrichment Analysis), and Onto-tools as summarized in Materials and Methods. 
The most significant gene sets upregulated in groups that was obtained from GSEA software 
were listed in Table 4.1.2. “Enrichment plots” and “Blue-pink dendograms” of the most 
significant gene-sets enriched in groups were given in Figure 4.1.7 (complete lists were given 
in Appendix C). The genes that are upregulated in immortal group enriched in E2F1 targets, 
stem-cell related genes, DNA repair and cell cycle related gene sets. Stress response, HOX 
and TNF-α induced gene sets were clustered in pre-senescent up-regulated genes. Senescence 
G12S C3S 
MEK-OIS 
G12P C3P 
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G11I C1I 
MEK-E67I-t 
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up-regulated gene sets were immune function related, stress response, electron transporter 
activity, protein modification, HDAC inhibitor responsive and HOX gene groups.   
Table 4.1.2 Examples of significantly upregulated GSEA gene sets 
IMM vs SEN: IMMORTAL ENRICHED GENE SETS n=13* 
NAME SIZE ES** 
FDR*** q-
val 
RANK AT 
MAX 
E2F1_TARGETS_CHIP 38 0.580218 0.051051 2847 
CANCER_UNDIFFERENTIATED_META_UP 65 0.487906 0.113817 2000 
BRENTANI_REPAIR 36 0.621496 0.117194 1989 
MANALO_HYPOXIA_DOWN 80 0.563608 0.127927 1777 
NF90_DN 29 0.61834 0.132696 1179 
CMV_IE86_UP 37 0.720344 0.139809 1827 
SERUM_FIBROBLAST_CELLCYCLE 114 0.581189 0.140873 2000 
PEART_HISTONE_DOWN 73 0.408196 0.144511 1732 
DOX_RESIST_GASTRIC_UP 47 0.614502 0.147354 2000 
SERUM_FIBROBLAST_CORE_UP 173 0.376459 0.154137 2678 
P21_ALL_DN 30 0.634628 0.160947 2646 
BRCA_PROGNOSIS_NEG 88 0.439633 0.16169 1681 
CROONQUIST_IL6_STARVE_UP 29 0.762213 0.176304 2131 
 
PRE-SEN vs IMM: PRE-SENESCENCE  ENRICHED GENE SETS n=127* 
NAME SIZE ES** 
FDR*** q-
val 
RANK AT 
MAX 
IFNG_5ENDOTHELIAL_DOWN 68 0.44511 0.106698 4692 
HYPOXIA_REVIEW 80 0.527992 0.107922 3379 
TESTIS_EXPRESSED_GENES 61 0.402888 0.108234 375 
H2O2_CSBDIFF_C2 26 0.546498 0.109624 3482 
HDACI_COLON_BUT12HRS_UP 34 0.476826 0.111217 4478 
TNFALPHA_30MIN_UP 38 0.388466 0.111307 2836 
TNFALPHA_4HRS_UP 39 0.507071 0.111435 4462 
CHIARETTI_T_ALL 238 0.469172 0.1137 2905 
OXSTRESS_BREASTCA_UP 27 0.519261 0.114023 411 
UV_UNIQUE_FIBRO_DN 28 0.613834 0.114061 4349 
CMV_24HRS_UP 58 0.521695 0.116577 3018 
CROONQUIST_IL6_STROMA_UP 36 0.591776 0.11798 2096 
TNFA_5ENDOTHELIAL_DOWN 71 0.539296 0.118261 1445 
UVB_NHEK1_UP 140 0.488482 0.118437 5081 
TNFA_5ENDOTHELIAL_UP 70 0.636198 0.119345 2220 
HOX_GENES 52 0.626138 0.11986 3451 
TSA_HEPATOMA_CANCER_UP 30 0.667311 0.122257 2067 
SMITH_HTERT_DOWN 61 0.45944 0.160955 2179 
 
SEN vs IMM: SENESCENCE  ENRICHED GENE SETS n=247* 
NAME SIZE ES** 
FDR*** 
q-val 
RANK 
AT MAX 
JECHLINGER_EMT_DOWN 40 0.567248 0.066461 4702 
ANDROGEN_GENES 52 0.674071 0.066919 1840 
WERNERONLY_FIBRO_UP 30 0.609646 0.069974 2586 
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BRENTANI_IMMUNE_FUNCTION 50 0.527649 0.070526 4456 
ROSS_MLL_FUSION 77 0.548274 0.07101 2989 
SMITH_HTERT_DOWN 61 0.530096 0.071046 1680 
VEGF_MMMEC_12HRS_UP 25 0.675701 0.071742 3150 
IFN_BETA_GLIOMA_UP 50 0.418442 0.072413 5049 
TESTIS_EXPRESSED_GENES 61 0.420126 0.073636 279 
STRESS_TPA_SPECIFIC_UP 49 0.38809 0.075366 3829 
HDACI_COLON_BUT12HRS_UP 34 0.581869 0.075561 3484 
H2O2_CSBDIFF_C2 26 0.520755 0.075762 2201 
BRCA1_OVEREXP_UP 128 0.535055 0.076798 2340 
ELECTRON_TRANSPORTER_ACTIVITY 113 0.555891 0.080027 1595 
PENG_RAPAMYCIN_UP 155 0.415837 0.080085 3642 
BRENTANI_PROTEIN_MODIFICATION 144 0.482071 0.083533 4586 
BRENTANI_DEATH 70 0.499667 0.086309 2388 
JISON_STRESS 30 0.519862 0.087565 4518 
HOX_GENES 52 0.524791 0.088914 2947 
HYPOXIA_REVIEW 80 0.550173 0.090366 3959 
*FDR<0.2 
**ES:Enrichment score 
***FDR: False discovery rate 
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Gene Ontology (GO) annotation of differentiating genes were performed using Onto-
Express software (Figure 4.1.8 A, B and C). Immortal upregulated genes (>1 fold, compared 
to senescence) grouped in protein biosynthesis, DNA replication and repair, nucleic acid 
I enriched P enriched S enriched 
Figure 4.1.7 Enrichement plots and cluster dendograms 
of 3 enriched gene sets. Enrichment plots are the profiles of 
the Running ES Score and Positions of GeneSet  Members 
on the Rank Ordered List. 
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metabolism, and RNA splicing processes. Senescence and pre-senescence enriched groups 
were chromosome organization and biogenesis, epidermis development, mesodermal cell fate 
determination, metabolism and immune response (corrected p<0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
A 
C 
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Figure 4.1.8 Biological functions of A) immortal clone upregulated (>1 fold), B) senescence 
clone upregulating (>1 fold) C) pre-senescence clone upregulated (>1 fold) gene lists. 
Biological processes with a corrected p<0.05 were considered as significant.  
 
4.1.6 Identification of the role of senescence and immortality genes in HCC  
In order to understand the role of senescence and immortality related genes in HCC 
development and molecular heterogeneity; we integrated the senescence/immortal Huh7 
microarray data and liver tissue microarray data. A member of our group, Ayca Arslan-Ergul, 
has generated in vivo microarray data using 37 freshly frozen cirrhosis and HCC samples (20 
cirrhosis, 17 HCC). Affymetrix GeneChip HG-U133 plus2 chip was used for global 
expression analysis. The raw data was analyzed using BRB Array Tools, and significant gene 
list were obtained using t-test (p<0.05). We identified 10185 probesets that displayed 
differential expression between cirrhosis and tumor samples. Next, we integrated significant 
probesets generated from in vitro cell line and in vivo clinical samples (Figure 4.1.9). 1909 
probesets were found to be common (senescence and immortality gene network:SIGN). 
 
Figure 4.1.9   Venn diagram of probesets selected by two-tailed unpaired Welch’s t test and 
class comparison test in BRB array tools from in vitro cell line and in vivo tissue analysis 
data, respectively. Red circle represents number of probesets differentially expressed between 
pre-senescent, senescent and immortal cells (P < 0.05). Blue circle represents number of 
probesets differentially expressed between cirrhosis and HCC tissue samples (P < 0.05). A 
total of 1909 probesets that display differential expression in both cell lines and tissues was 
selected as SIGN probesets.  
To test whether our cancer cell-derived probeset can discriminate between normal cell 
replicative senescence and immortality, we compared our Huh7 clone data with data reported 
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for human prostate epithelial cells (HPEC; Schwarze et al. 2002). Two major clusters were 
formed. Senescent Huh7 clones (C3S, G12S) clustered together with senescent and early 
senescent (growth-arrested, but not yet positive for SABG activity) HPEC (HPEC-ES/S). 
Immortal Huh7 clones (C1I and G11I) clustered together with HPEC immortalized by Human 
Papilloma Virus E7 oncoprotein (HPEC-I). Proliferating presenescent Huh7 clones (C3P, 
G12P) were clustered next to senescent cells, whereas proliferating HPEC (HPEC-P) were 
positioned next to immortal cells (Figure 4.1.10 A). The SIGN signature could successfully 
discriminate our immortal, pre- and senescent Huh7 clones, as well as senescent, early 
senescent and immortalized HPECs. The SIGN signature also separated cirrhosis and HCC 
samples into two major clusters. One cluster included 85% (17/20) of cirrhosis, and the other 
71% (14/17) of HCC samples (data generated by Ayca Arslan-Ergul) (Figure 4.1.10 B). 
Cirrhosis and HCC have been considered as in vivo states of hepatocellular senescence and 
immortality, respectively. Hence, our in vitro and in vivo combined data identified a signature 
that could serve for classification of different hepatic lesions with respect to the states of 
senescence and immortality. 
 
4.1.6.1 Molecular classification of HCC by the SIGN signature  
Genomics and gene expression studies revealed that HCC is a heterogeneous disease that can 
be classified into different molecular subtypes (152). Recently, Boyault et al., (149) integrated 
genomic and gene expression data and classified HCCs into six distinct groups (G1 to G6). 
TP53 and CDKN2A inactivation and chromosomal instability (immortality-associated events) 
were observed in G1-G3, but not in G4-G6 groups, strongly suggesting that senescence and 
immortality events may contribute to HCC heterogeneity. Therefore, we subjected this 
independent cohort of tumors to the SIGN signature analysis (65 samples, 1292 probe set). 
Unsupervised clustering with the SIGN signature generated two major clusters, each divided 
into two smaller clusters that we named as 1A, 1B, and 2A, 2B (Figure 4.1.11). Each SIGN 
signature cluster was highly enriched in a specific group of tumors. Cluster 1A (n=11 HCCs, 
three adenomas, and five non-tumor samples) was composed of G4 (78.9%), and G5 group 
(21.1%) of tumors. Non-tumor sample pools and adenoma samples of the G4 group formed 
two close sub-clusters under 1A. Cluster 1B (n=15 tumors) was composed of mainly G6 
(53.3%) and G5 (40.0%) tumors. Cluster 2A (n=23) was composed of mainly G3 (30.4%), G1 
(26.5%) and G2 (21.7%) tumors. Cluster 2B (n=8), similar to cluster 1A, was composed 
mostly (87.5%) of G4 tumors. Based on the major component tumor group(s) of each cluster, 
we concluded that clusters 1A and 2B were enriched G4 tumors. Class 1B in G6 and a G5, 
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and cluster 2A in G1-G3 tumors, respectively. The latter three groups were sub-clustered as 
G1, G2 and G3 tumors in sub-clusters 2A1, 2A2, and 2A3, respectively. 
 
 
Figure 4.1.10   Hierarchical clustering of senescence-programmed and immortal cell 
lines, and cirrhosis and hepatocellular carcinoma (HCC) tissues, using the Senescence 
and Immortality Gene Network (SIGN) probeset. (A) Experimental dendrogram showing the 
clustering of Huh7-derived clones and human prostate epithelial cells (HPEC) into immortal, 
presenescent and senescent clusters (top). (B) Experimental dendrogram showing the 
clustering of tissue samples into cirrhosis and HCC subgroups (top). 
Proliferating normal 
 
HPEC-p 
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Figure 4.1.11 The SIGN signature separates hepatocellular carcinomas (HCCs) into 
distinct sub-clusters with differential expression of senescence- and immortality-
associated genes. (A) Hierarchical clustering of gene expression data from Boyault et al. 
(2007). Experimental dendrogram showing the clustering of hepatocellular carcinoma (HCC) 
tissues into four major clusters, identified as 1A, 1B, 2A and 2B, respectively, and three 
A 
B 
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minor clusters, identified as 2A1, 2A2 and 2A3, respectively. The correlation with SIGN 
clusters and previously identified HCC groups (G1 to G6) was also shown. *non-tumor liver 
tissue pools; **adenoma samples (top). (1292 gene probesets and 65 tissue samples). 
The reclassification of molecular groups of HCC according to the SIGN signature 
provided us with preliminary evidence that senescence- and immortality-associated genes 
may play an important role in HCC heterogeneity. To test this hypothesis, we first compared 
the newly described HCC SIGN classes according to relative contributions of senescence- and 
immortality associated genes. We used the classifier probesets generated by the binary tree 
analysis (Figure 4.1.12 A and Appendix D) to select genes that displayed a >1.5-fold change 
between senescent and immortal cells (p value cut-off for binary tree analysis was 0.001). The 
ratios of the number of senescence- and immortality-associated genes between HCC classes 
were compared (Figure 4.1.12 B). A comparison of “normal-like” class 1A tumors with class 
2B tumors did not show any significant difference (P = 1), indicating that these two classes of 
tumors share the same or a similar SIGN signature. In contrast, class 1B tumors displayed a 
significant enrichment of immortality-associated genes in comparison with class 1A and 2B 
tumors (P <0.0004). The class 2A tumors, containing the most advanced HCC samples, which 
formed a distant class from the other three groups, were also highly enriched in immortality-
associated genes (P < 2X10-7). Taken together, these findings strongly suggest that 
hepatocellular immortality plays a major role in HCC heterogeneity. Tumors of class 1A and 
2B were the least enriched, and class 2A tumors the most enriched in immortality associated 
gene expression, with class 1B tumors in an intermediate position. 
 
  
A 
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Figure 4.1.12 Binary analysis and senescence-immortality associated gene rate of 
Boyault groups A) Classification of 65 HCC, 3 adenoma, and 5 non-tumor samples obtained 
from Boyault et. al, by binary tree analysis using SIGN probe sets. 513 probe sets 
discriminated the 2a from 1a, 2b, and 1b with 94% accuracy, 164 probe sets discriminated the 
1b from 1a, 2b with 95% accuracy, and 70 probe sets discriminated the 1a from  2b with 
100% accuracy (Appendix D) B) Differential expression of senescence- and immortality-
associated genes between different SIGN classes of HCC. Genes with more than 1.5-fold 
expression change between senescence arrested and immortal cells were identified by binary 
tree comparison of different tumors, and data were presented as % ratios of senescence-up-
regulated (blue) and immortality-up-regulated (red) genes. 
 The integration of senescence- and immortality-associated gene expression data with 
in vivo tissue data provided us a unique opportunity to address the contribution of senescence- 
and immortality-related biological processes to HCC. First of all, the SIGN signature was 
overlaid onto a global molecular network developed from information contained in the 
Ingenuity Pathways Knowledge Base. Networks of these focus genes were then 
algorithmically generated based on their connectivity. The most significant network was a 
protein network which is called “DNA Replication, Recombination, Repair, Gene Expression, 
Cancer that includes 33 proteins. The second network was “Cancer, Gastrointestinal Disease, 
Cell Cycle” network again containing 33 proteins (Figure 4.1.13 A and B).  
 For identifying the biological processes characterizing different SIGN classes of HCC, 
we first performed a pair-wise class comparison analysis at two different significance levels 
(P < 0.001 and P < 0.01). Next we used these datasets to perform a DAVID Functional Gene 
Cluster Analysis. Normal-like class 1A tumors were used as a reference. As summarized in 
Table 4.1.3, class 2B tumors down-regulated monocarboxylic acid metabolism genes. 
Compared to class 2B, class 1B tumors up-regulated chromosome organization, DNA 
B 
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metabolism and cell cycle genes. These tumors showed also down-regulation of genes 
involved in wounding response and carboxylic acid metabolism. Compared to class 1B, class 
2A tumors displayed a generalized down-regulation of intermediary metabolism genes (genes 
involved in beta-oxydation, fatty acid, sulfure amino acid, amino acid derivative 
metabolism/catabolism, amine metabolism/catabolism, and xenobiotic metabolism). Major 
up-regulated processes in these tumors were cell proliferation (cell cycle, checkpoint, mitosis, 
DNA replication), RNA metabolism (splicing and transcription), chromosome organization, 
and DNA damage response. 
 
   
 
Network 1 Network 2 
A 
B 
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Figure 4.1.13 The protein networks generated through the use of Ingenuity Pathway 
Analysis. A) This is the list of networks. The SIGN data set containing gene identifiers was 
uploaded into in the application. Each gene identifier was mapped to its corresponding gene 
object in the Ingenuity Pathways Knowledge Base. B) First 4 networks generated by SIGN 
signature. Networks of these focus genes were algorithmically generated based on their 
connectivity.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Network 3 Network 4 
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Table 4.1.3 Biological pathways affected in hepatocellular carcinoma classes according 
to SIGN  
 
 
4.1.6.2 DNA damage response genes as potential therapeutic targets 
We repeatedly observed the upregulation of DNA damage response genes in different steps 
and classes of HCC. Although some genes such as TOP2A have been already associated to 
HCC (153), the role of these genes in HCC remains elusive. Therefore, we further analyzed 
the expression changes of DNA damage response genes (154). We compared two major 
classes of SIGN classes of HCC; normal-like 1A tumors versus chromosome instable 2A 
tumors. We identified 31 genes up-regulated in 2A class tumors, 14 of which were involved in 
DNA damage checkpoint. These tumors also over-expressed nine base-excision, seven 
nucleotide-excision, six double-strand break and five mismatch repair genes (Table 4.1.4).  
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Table 4.1.4 Up-regulation of DNA damage response genes  
 
DSBR: Double‐strand break repair; BER: base‐excision repair; NER: nucleotide‐excision 
repair; MMR: DNA mismatch repair. 
1Direct repair, 2Repair gene expression, 3Chromatin assembly, 4Acetyl 
transferase‐sistercohesion, 5Hydrolyzes oxidized purine nucleoside triphosphate, 6Translesion 
synthesis, 7SSB repair, 8DNA breakage & rejoining, 9AcHvates TOP2A expression, 10DNA 
and RNA helicase 
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4.2 Expression analysis of E2F/DP family in senescence and immortality, and 
senescence association of DP-2 
 
4.2.1 Differential expression of E2F/DP family genes in senescent and immortal 
hepatocellular carcinoma cells 
To understand the involvement of E2F/DP family members in senescence and immortality of 
liver; we, first, performed unsupervised hierarchical cluster analysis of E2F/DP family genes 
using our microarray data of immortal, pre- and senescent Huh7 clones. As shown in figure 
4.2.1 A, pair-wise complete-linking hierarchical raw-cluster classified family members in two 
groups. The first group of genes composed of E2F1, E2F2, E2F7, E2F6, E2F5, E2F8, and 
DP1 displayed increased expression in immortal clones. The second group of genes composed 
of E2F3a, E2F4 and DP2 displayed increased expression in pre-senescent and/or senescent 
cells.  
In order to confirm differential expression of E2F/DP family genes in immortal and 
senescent cells, we quantified their relative expression levels by real-time PCR assay. 
Triplicate samples from immortal C1 and G11 clones, and senescence-arrested C3 and G12 
clones were tested in parallel experiments. These studies confirmed the up-regulation of 
E2F1, E2F5, E2F7, E2F8 and DP1 in immortal clones and the up-regulation of E2F3a and 
DP2 in senescent clones (>2 fold changes; Figure 4.2.1 B). The correlation efficiency of Q-
PCR data with microarray data was 80%.  
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Figure 4.2.1 Differential expression of E2F and DP family members in immortal, 
presenescent and senescent cells derived from Huh7 cell line. A) Treeview image of 
hierarchical cluster analysis of E2F1-8 and DP1,2 probe sets extracted from the Affymetrix 
HG-U133 plus expression microarray experiment of immortal (G11-I and PC1-I), pre-
senescent (G12-P and PC3-P) and senescent (G12-S and PC3-S) clones. Red: up-regulation, 
green: down-regulation and black: no change B) Quantitative RT-PCR analysis of E2F1-8 
and DP1/DP2 transcripts in immortal (G11-I and PC1-I) and senescent (G12-S and PC3-S) 
clones. Immortal/senescent ratio refers to fold changes, expressed as log (2) transformed. The 
G and C clones were analyzed separately. Error bars represent the standard deviations of 3 
independent experiments with 2 groups of immortal (G11-I and PC1-I) and senescent (G12-S 
and PC3-S) clones. The mRNA samples used for the Q-PCR analysis were from the different 
cell vials from the mRNA samples used in microarray study. Primer efficiencies were given in 
Table 3.4. 
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4.2.2 Expression analysis of differentially regulated E2F/DP genes in HCC cell lines 
Next, we quantified the expression of differentially regulated E2F/DP genes in a set of 13 
HCC cell lines. Relative expression levels were represented as fold changes from the 
expression levels observed in senescent C3 cells, and immortal C1 cells were used as positive 
control (Figure 4.2.2). As shown in figure 4.2.2, E2F1, E2F5, E2F7, E2F8 and DP1 genes 
that displayed increased expression in immortal cells showed highly variable expression in 
HCC cell lines.  E2F1, E2F7 and DP1 genes were up-regulated in the majority (>8/13) of cell 
lines. But the expressions of E2F5 and E2F8 showed a decrease rather than an increase in the 
same set of cell lines. E2F3a and DP2 genes that displayed a loss of expression in immortal 
cells were also studied in HCC cell lines. The expression of E2F3a showed an increase rather 
than a decrease in almost all cell lines tested. The observations with DP2 were the most 
striking, as they indicated a consistent deficit in expression in all 13 HCC cell lines tested. 
This suggested that loss of DP2 expression was strongly associated with immortal phenotype 
of HCC cells. 
  
Figure 4.2.2 mRNA expression levels of differentially regulated E2F/DP genes in HCC 
cell lines compared to senescent cells, as tested by quantitative RT-PCR. Fold change refers 
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to log (2) transformed values of each cell line, as normalized to expression level of C3 
senescent cells. Error bars represent the standard deviations of 3 independent experiments. 
 
4.2.3 DP2 protein is abundant in senescent clone but lost in immortal clone  
Based on transcript expression data, we decided to further explore the expression status of 
DP-2 gene in HCC. We first performed DP2 analysis by immuocytochemistry. Strong nuclear 
staining was observed in C3 cells at both pre-senescent (C3-P) and senescent (C3-S) states, 
whereas immortal C1 cells (C1-I) displayed only weak nuclear staining with the exception of 
mitotic cells (Figure 4.2.3 A). In order to confirm the association of DP-2 positivity with 
senescence, we also performed double staining. Immortal C1 (C1-I) and senescent C3 (C3-S) 
cells were first subjected to senescence-associated β-galactosidase (SABG) staining, followed 
by immunostaining with anti-DP-2 antibody. Immortal cells were negative for both SABG 
and nuclear DP-2 staining, but senescent cells were positive for both staining (Figure 4.2.3 B). 
We also performed DP-2 immunostaining on NHEPs (primary human hepatocytes) at culture 
days 1 and 5, and observed very strong nuclear positivity (Figure 4.2.3 C). Immunoperoxidase 
staining results of the HCC cell lines were compatible with Q-PCR results. For example, 
Hep3B and SNU387 cells did not display significant staining, but Hep40 and SNU398 cells 
displayed weakly positive heterogeneous staining (Figure 4.2.3 D). 
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Figure 4.2.3 DP-2 immunostaining; shows increased expression in pre-senescent (C3-P) and 
senescent (C3-S) cells, as compared to immortal (C1-I) cells. A) Immunoperoxidase staining 
with anti-DP2 antibody (brown); counter-staining with hematoxylene. B) Senescence-
associated β-galactosidase (blue) and anti-DP-2 antibody (brown) co-staining assay indicates 
that nuclear DP-2 staining is associated with senescence. C) Nuclear DP-2 staining using four 
different HCC cell lines.  
Next, we performed western blot analysis to identify DP2 isoforms expressed in 
immortal, senescent and NHEPs (normal human hepatocyte cells). Human cells express at 
least three DP2 isoforms (55, 49 and 43 kDa, respectively), as reported previously (83). 
A 
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Senescent C3 cells (C3-S) expressed 49 kDa and 43 kDa isoforms, but dominantly 43 kDa 
isoform. Immortal C1 cells (C1-I) showed decreased expression in total protein level. They 
decreased the expression of 43 kDa isoform dramatically and displayed a rather increased 
expression of 49 kDa isoform (Figure 4.2.4 A). NHEPs expressed the 49 kDa isoform and 43 
kDa isoform very weakly, however we observed unidentified bands around 60-65 kDa in 
NHEPs. Moreover, we saw the same bands in some cirrhosis and HCC samples (Figure 4.2.4 
B). We concluded that the 49 and 43 kDa isoforms of DP-2 protein may be associated with 
immortality and senescence respectively. This isoforms may be regulated differentially in 
different phases of cell cycle also.  
  
 
Figure 4.2.4 Expression analysis of DP-2 protein A) western blot analysis with whole cell 
extracts identified 49 kDa and 43 kDa DP-2 isoforms in C1, C3 and NHEPs cells. Previously 
un-identified bands were detected in NHEPs (normal human hepatocyte cells). Calnexin 
(Clnx) was used as a loading control. B) western blot analysis of DP-2 in 4 pairs of cirrhosis-
HCC tissue samples. Extra bands were detected in tissue samples also. 
 
4.2.4 Examination of the DP-2 isoforms in different cell cycle conditions and upon 
TGF-β treatment 
Based on western blot data indicating that 43 kDa isoform is the major form expressed in 
senescence cells, and 49 kDa protein become dominant in immortal cells, we hypothesized 
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that different DP-2 isoforms may be regulated differentially during cell cycle. In order to test 
this hypothesis, we used LiCl (lithium chloride) which is known to stop cell cycle in G1 
phase. When LiCl containing medium is replaced with fresh medium, cells continue to 
progress through the cell cycle (155). We treated the C1-I (immortal) cells with LiCl-
containing medium for 4 days, as well as with NaCl as a control. At the end of 4th day, we 
stopped the NaCl treated plate and one LiCl-treated plate, which we called time 0. We have 
supplied the other plates with fresh medium and stopped one vial at 6th, 12th, 24th, and 30th 
hours. We observed that the levels of 49- and 43 kDa protein changes in different hours of 
cell cycle (Figure 4.2.5 A). We, then, wanted to examine the levels of the two isoforms in a 
different type of senescence model. In our group, it has been, recently, identified that most of 
the liver cancer cell lines enter into senescence upon TGF-β treatment (Serif Senturk, 
unpublished data). TGF-β treated and non-treated C1-I and parental Huh7 cell lysates were 
subjected to DP-2 immunoblot analysis. As shown in 4.2.5 B, the small isoform was 
expressed very strongly in TGF- β treated Huh7 cells, whereas long isoform couldn’t be 
detected. On the other hand, non-treated control cells were observed to express long isoform, 
and very weakly small isoform. In C1-I cells, again, short isoform became strongly dominant 
when the cells were treated with TGF- β, just like C3-S (senescent) clone. We concluded that 
upon senescence arrest, the 43 kda DP-2 protein is dominantly expressed and may have 
potential role in senescence arrest.    
 
Figure 4.2.5 Western blot analysis of DP-2 in LiCl and TGF- β treated cells. A) Cell cycle 
synchronization of C1I cells with LiCl identified that the 43- and 49 kDa proteins are 
A B 
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regulated differentially in different time-points. LiCl: lithium chloride, NaCl: sodium 
chloride. Equal loading was indicated as ponceau staining of the same membrane before 
blotting. B) TGF-β treatment differentiates the dominantly expressed DP-2 protein in Huh7 
and C1I cells. 
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4.3 Epigenetic changes in immortality and senescence of liver in vitro and in vivo  
 
4.3.1 Differential expression of histone modifying enzyme genes in senescent and 
immortal hepatocellular carcinoma cells 
Based on our observation indicating that expression of epigenetic related gene groups 
are changing between senescent and immortal Huh7 clones, we hypothesized that epigenetic 
changes may play an important role in this cell fate determination. We, first, searched for 
significant histone methylating and de-methylating enzymes in our in-vitro microarray data. 
We, then, grouped these genes according to their expression values (Figure 4.3.1 A). Raw 
cluster analysis revealed two distinct groups; up-regulated enzymes in immortal and pre- and 
late senescence. JMJD4-3- and 2B, MLL3, JARID1B, FBXL11, ASH1L, SUV420H1, SMYD2, 
HSPBAP1, SETD5, PRDM1 and SETD2 were grouped together as senescence associated 
genes. On the other hand, immortality associated enzymes were JMJD1C, KIAA1718, MINA, 
EZH2, CARM1, PRMT1, PRDM16, UTX, and WHSC1. For Q-PCR validation was performed 
for the enzymes that have known histone residue targets. Microarray results were confirmed 
for all tested enzymes, except UTX (Figure 4.3.1.B). The correlation efficiency of Q-PCR data 
with microarray data was 92%.  
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Figure 4.3.1   Expression analysis of histone methyltransferases and de-methylases in 
immortal and senescence Huh7 clones. A) gene-based clustering of enzymes generated two 
groups. Image has been performed using GenePattern software. Red: up-regulation, blue: 
down-regulation. Scaled-bar was shown below. B) Selected histone methyltransferases and 
de-methylases in senescent cells compared to immortal cells, as tested by quantitative RT-
PCR. Fold change refers to log (2) transformed values. Error bars represent the standard 
deviations of 3 independent experiments. The mRNA samples used for the Q-PCR analysis 
were from the different cell vials from the mRNA samples used in microarray study. Primer 
efficiencies were given in Table 3.4. 
 
4.3.2 Histone methylation changes between immortal and senescent Huh7 clones 
We, then, compared histone modification patterns of N-terminal tails of histone 3 and 4 in 
immortal, pre- and late-senescent Huh7 clones. We used antibodies against specific 
methylation residues of lysine (K) and arginine (R) aminoacids of H3 and H4. We, first, used 
immunocytochemistry to asses methylation levels of H3K4me3, H3K9me1- and 3, 
H3K27me1- and 3, H3K36me1- and 3, H3K79me3, H4K20me3, H3R2me2a (asymmetric), 
H3R17me2a, H4R3me2a in clones. We obtained positive signal for all the residues tested, 
except H3K79me3. In pre- and late-senescent Huh7 clones, H3K27me1, H3K36me3, and 
H4K20me3 were observed to be increased compared to immortal clone (Figure 4.3.2 A). 
Late-senescent clones had substantially more methylated status of H3K27me3, H3R4me2a, 
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and H4R3me2a compared to other clones (Figure 4.3.2 B). Moreover, H3K27me3 and 
H3R2me2a residues increased gradually from immortal to late-senescent cells. The staining 
intensity of H4R3me2a was very weak. We could observe no marked differences in the 
methylation levels of H3K4me3, H3K9me1- and 3, H3K36me1, H3R17me2a (Figure 4.3.2 
C). 
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Figure 4.3.2 Histone methylation status of H3 and H4 tail modifications in immortal, 
pre- and senescent cells. A) Immonoperoxidase images of histone methyl residues over-
representing in senescent clone (brown) B) in both pre- and senescent clones (brown). C) The 
histone methylation statuses that do not show any marked change. Counter staining was 
performed with Mayer’s heamotoxylene (blue). H: histone, K: lysine, R: arginine, me: methyl.    
 
C 
 91 
 We, also, carried out the same analysis in an other senescence model. We tested the 
same histone residues on hTERT immortalized, proliferating (PDL 45), and replicative 
senescent (PDL 65) MRC5, a human fibroblast cell line. We observed marked increase of 
H3K27me1- and 3, H4K20me3, H3R2me2a and H4R3me2a in replicative-senescent arrested 
fibroblasts compared to hTERT immortalized and proliferating normal fibroblasts (Figure 
4.3.3). On the other hand, senescent MRC5 cells showed enhanced H3K9me1- and 3 levels 
when we compared the staining intensity just with proliferating MRC5. We concluded that 
H3K27me1- and 3, H4K20me3, H3R2me2a and H4R3me2a residue changes may 
discriminate immortal cells from senescence-arrested cells. Histone 3 lysine 9 methylation 
changes were only observed between replicative senescent and its normal proliferating 
counterpart, indicating that this residue may be regulated specifically in replicative 
senescence.  
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Figure 4.3.3 Immunoperoxidase analysis of histone methylation residues in replicative 
senescence model of MRC5. A) Immunoperoxidase images of residues which show clear 
over-representation in late replicative senescence compared to both proliferating normal and 
hTERT immortalized MRC5s. B) Images of residues which show change between 
proliferating normal and late senescent cells. (brown: positive signal). Young: MRC5 PDL 
(population doubling) 45, old: MRC5 PDL65.   
  
4.3.3 Does histone methylation levels differ in-vivo? 
As we indicated before, immortal and senescent cells may represent tumor and cirrhosis 
stages of liver cancer. We hypothesized that histone methylation may be amended in the 
tumorigenesis process of liver. To test this hypothesis, we performed immunohistochemistry 
analysis with the antibodies of residues which were observed to change in-vitro. We have 
collaborated with Dr. Funda Yılmaz in Ege University Department of Pathology for the 
staining of selected histone residues on formalin fixed paraffin-embedded normal liver, 
cirrhosis, and HCC tissue samples. All five histone methylation residues tested (H3K27me3, 
H4K20me3, H3K36me3, H3R17me2a, H4R3me2a) showed homogenous and ubiquitous 
nuclear positivity in all normal livers (n=10). This kind of staining was called as pattern 1 
(Figure 4.3.4 A). Whereas, more heterogeneous pattern with local or dispersed loss of nuclear 
positivity (pattern 2) has been obtained HCC for all residues tested, and in cirrhosis for 
B 
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H4K20me3 and H3R17me2 (Figure 4.3.4 B). H3K36me3 and H3R17me2, also, showed 
apparent decrease in macro-regenerative nodules compared to micro-regenerative nodules. 
10% of cirrhosis samples (n=13) lost the homogenous H3K27me3 positivity, whereas 33% of  
HCC (n=10) is observed to have decreased H3K27me3. Ubiquitous H4K20me3 nuclear 
staining was lost in 33% of cirrhosis samples, and 75% of HCC. H3K36me3 stained 
homogenously and ubiquitously in all cirrhosis samples, but this pattern was lost in 33% of 
HCC samples. Partial loss was observed in 25% and 66% of cirrhosis and HCC samples, 
respectively. 12% of cirrhosis samples lost their H4R3me2a, and 66% of HCC samples had 
decreased staining of this residue. The partial loss of H3K27me3, H4K20me3, H3K36me3 
and H4R3me2a in HCC perfectly correlated with in-vitro findings performed with immortal 
and senescent Huh7 clones. These residues may be involved in aberrant regulation of 
oncogenes and tumor suppressors in HCC.  
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     Figure 4.3.4 Histone mehtylation in in-vivo A) Example images of Pattern 1 and 2 
staining. While analyzing the histone residue staining of tissue samples, we have used a 
nomenclature. Homogenously and strongly stained areas were named as “Pattern 1”, on the 
other hand heterogeneous and weak staining, partial or local loss of nuclear positivity was 
called “Pattern 2”. Top, and middle panel images were examples of H3K36me3 staining, 
bottom panel from H3R17me2a straining. B) Bar-chart representations of the results of 
immunohistochemistry counts of indicated histone residues. Y-axis values were calculated by 
dividing the number of pattern 1tissue samples to number of all tissue samples for a given 
histone residue and tissue type. A partial loss of the 5 residues tested in HCC samples was 
observed. Bottom chart represents the same counts comparing macro- and micro-regenerative 
nodules. H3K36me3 and H3R17me2a residues were observed to loss ubiquitous staining 
pattern in macro-regenerative nodules compared to micro-regenerative nodules.  
 
4.3.4 Histone variant differences in immortal and senescent Huh7 cells   
In order to test, whether the levels histone 2 variants differ between senescence and 
immortality; we carried out immunoperoxidase analysis of H2AX, H2AZ, macroH2A, and 
H2B variants in immortal, pre- and late-senescent Huh7 cells. The monoclonal antibodies 
were obtained from Dr. Stephan Dimitrov Lab in Institute Albert Bonniot in Grenoble. 
B 
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Interestingly, H2AX and H2AZ were observed to increase dramatically in pre-senescence 
stage, and remain abundant in senescence (Figure 4.3.5A). mH2A variant, increased gradually 
from immortal to senescence cells. No marked difference was observed for H2B (Figure 
4.3.5A). The three H2 variants, H2AX, H2AZ and mH2A, may be characteristic variants for 
our senescence model, and they may have functional roles in senescence arrest.  
 
 
Figure 4.3.5 Histone variant levels of immortal, pre- and senescent cells. A) The histone 2 
variants, H2AX and H2AZ, increased in pre-senescence level. B) mH2A increased in pre- and 
senescent cells gradually. H2B did not change significantly. Positive signal:brown, counter 
staining: Mayer’s heamatoxylene.   
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CHAPTER 5. DISCUSSION 
 
5.1 Global expression analysis of immortality and senescence in liver cancer  
 
5.1.1 Identification of differentially expressed genes between immortal, pre- and 
senescent Huh7 clones 
Hepatocellular carcinoma development is a multi-step process which takes more than 20 
years. Hepatocellular senescence is a process gaining growing interest in the physiopathology 
field of chronic liver diseases (52), yet the observations are fragmented and somewhat 
contradictory. Telomere shortening and senescence have been observed in hepatocytes of 
cirrhotic liver, and replicative senescence was proposed as a key mechanism that contributes 
to cirrhosis development (136). Our previous observations provided experimental evidence 
for the generation of senescence-arrested clones from immortal HCC cell lines. Clonal C3 
cells have displayed telomerase repression, progressive telomere shortening, and permanent 
growth arrest after ~80 PD with senescence associated morphological changes and positive 
SABG staining. Similar changes have also been observed with G12, another independently 
derived clone. Thus, we have concluded that immortal cancer cells have the intrinsic ability to 
reprogram the replicative senescence. As expected, this shift in cell fate resulted in a complete 
loss of tumorigenicity (61).  
 A complete set of genes associated with hepatocyte senescence and immortality was 
lacking. To better understand the molecular mechanisms of senescence switch from immortal 
cells, we, first, determined differentially expressed genes in presenescent, senescent and 
immortal clones derived from a well-differentiated HCC cell line; Huh7. Our analysis 
revealed large number of differentially expressed genes between groups, especially between 
immortal and pre-senescence, and immortal and senescence. This was suprising for the clones 
derived from the same cell line. We concluded that a genetic and phenotypic switch may be 
taking place from immortal cells. We, then, determined senescence and immortality-related 
biological processes and pathways. We observed a gradual increase in immune function and 
cellular stress related gene groups in pre- and late-senescence. Also, metabolism, nucleosome 
assembly and chromatin biogenesis and electron transport related genes were specifically 
enriched in pre- and late senescent cells. One of the most interesting finding was very 
significant upregulation of DNA repair genes in immortality. We hypothesized that over-
expressed DNA repair genes may give a survival advantage to immortal clones that have high 
division rate.  As expected, cell cycle, mitosis related and cell division gene groups were most 
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significantly up-regulated groups in immortal cells. We, also, observed up-regulation of E2F1 
target genes. E2F1 is known to be a mediate proliferation and cell cycle progression. RNA 
splicing related genes was also up-regulated specifically in immortal cells. The implication 
and role of these gene groups in the immortal and senescence phases, as well as in cirrhosis 
and HCC remain to be elucidated. 
We, also, examined the resemblance of the established senescence and immortality expression 
profiles of liver with expression profiles of senescence models in different cellular systems. 
Meta-analysis was performed with replicative senescence model in HPECs and an oncogene 
induced senescence model in IMR90 cells. The significant probe set of immortality and 
senescence could discriminate both replicative and oncogene-induced senescent cells from 
their immortalized counterparts. Replication induced early and late senescent HPEC cells 
were grouped together with C3S and G12S senescent Huh7 isogenic clones. Proliferating 
HPECs were enriched with pre-senescent C3P and G12P cells. On the other hand, C1 and 
G11 immortal Huh7 clones were grouped together with hTERT-immortalized HPECs. 
Furthermore; C3S, G12S and C3P, G12P Huh7 isogenic clones were clustered together with 
Mek:Erk and Mek:Erk-Small t-antigen induced senescent IMR90 cells, respectively. 
Mek:Erk-Small t-antigen-E6/7 transfected immortal cells were enriched with C1 and G11 
immortal cells. These findings indicate that spontaneous induction of senescence in liver 
cancer cells share common genetic features with both replicative and oncogene induced 
senescence. These results may give us clue about existence of a common gene signature 
differentiating in all types and cellular models of senescent cells.      
 
5.1.2 Establishing a senescence and immortality gene network signature for cirrhosis 
and hepatocellular carcinoma  
To better understand the role of cellular senescence in hepatocellular carcinogenesis, we 
explored the expression of senescence- and immortality-associated genes in HCC and its 
preneoplastic lesions, including cirrhosis. Along with gene expression levels of pre-senescent, 
senescent and immortal clones, we also determined differentially expressed genes between 
liver cirrhosis and HCC (Ayca-Arslan Ergul). Then, we obtained a set of genes by integrating 
the cell line and tissue data to generate a “SIGN signature”. This signature was tested against 
independent clinical datasets to analyze the role of senescence and immortality genes in 
hepatocellular carcinogenesis and tumor heterogeneity. This novel approach allowed us to 
show that cellular senescence and immortality mechanisms are deeply involved in HCC.  
 100 
 The SIGN signature alone was able to classify a cirrhosis and HCC with high 
accuracy. The cirrhosis was significantly enriched in senescence genes in confirmation of 
previous observations describing cirrhosis as a state of cellular senescence (156). 
Hepatocellular carcinogenesis from cirrhotic lesions was associated with a significant increase 
in the ratio of upregulated immortality genes in HCC. This finding indicates that the transition 
from senescence to immortality is a progressive event in HCC. 
 The availability of large-scale genomic analysis and gene expression profiling 
methods contributed significantly to a better understanding of tumor heterogeneity and 
molecular classification of tumors (157). Here, we show that senescence and immortality 
genes play a major role in the molecular heterogeneity of HCC. We reclassified a recently 
described HCC cohort using SIGN signature. This cohort was initially classified into six 
groups (G1-G6) and is composed of tumors with well-characterized clinical and genetic 
characteristics (149). The SIGN signature identified four major (1A, 1B, 2A, 2B) and three 
minor (2B1, 2B2, 2B3) classes. The 1A class, which grouped nontumor and some HCC 
samples together, was a “normal-like” group. Class 2B did not differ significantly from 1A in 
terms of senescence and immortality gene balance, suggesting that class 2B tumors also may 
display normal-like, or minimally deviant phenotypes. These two classes were composed 
mostly from G4 tumors, which are characterized by chromosomal stability and lack of 
frequent gene mutations. In contrast, class 1B tumors, which differed from 1A and 2B by a 
significant increase of immortality-associated genes, included G5 and G6 tumors with 
chromosomal stability and high rates of CTNNB1 mutations. Class 2A tumors displayed the 
highest rate of immortality-associated genes. G1, G2 and G3 tumors formed three subclasses 
within this class. These three groups have in common chromosomal instability, and they 
display TP53 and AXIN1 mutation at different frequencies. In addition, G3 tumors display 
CDKN2A promoter methylation. These genetic aberrations correlate with senescence bypass 
by checkpoint gene inactivation (TP53 mutation, CDKN2A promoter methylation). 
Chromosome instability observed in these tumors strongly suggests that tumor cells have 
survived a “crisis” stage with telomere fusions giving rise to chromosomal aberrations. The 
upregulation of a large set of DDR genes in HCC, and the association of this process with 
tumor progression indicate that liver malignancy is associated with acquired ability to deal 
with DNA damage. This finding correlates with well-known resistance of HCCs to currently 
available therapies. Thus, although DNA repair deficiency increases tumor susceptibility in 
normal cells, increased repair capacity may be beneficial for tumor cells. It will be interesting 
to investigate whether DNA damage response genes that are upregulated in HCC may serve 
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as novel targets for combined therapies using DNA damaging agents together with DNA 
repair inhibitors. In summary, our findings demonstrate that senescence and its bypass (i.e. 
immortality) play a central role in human hepatocellular carcinogenesis as well as in the 
molecular classification of HCC. These findings may serve in designing new prognostic and 
therapeutic approaches. 
  
5.2 DP-2 is associated with senescence  
In this study, we first identified the member of E2F and DP families that are differentially 
expressed in senescent and immortal cells. Then, we showed that DP2 were consistently over-
expressed in senescent cells. The availability of Huh7-derived isogenic clones with different 
cell fates allowed us to characterize differential expression of E2F/DP members in senescent 
and immortal cells. Potential implications of E2F and DP family members in senescence and 
immortality were addressed by comparative analysis of immortal and senescence-arrested 
Huh7 clones. Other HCC cell lines, immortal by definition were also analyzed for 
confirmation. Among ‘activating’ E2Fs required for S-phase entry, E2F1 showed an almost 
consistent up-regulation in both immortal C1 cells and HCC cell lines. E2F3a also showed 
up-regulation in most HCC cell lines, although its expression was slightly higher in senescent 
clones compared to senescence-arrested cells. Over-expression of E2F1 in HCC has already 
been reported (82), but the status of E2F3a in these cells was not known. Among ‘repressive’ 
E2F members that function in G0/G1 phase, E2F5 was slightly up-regulated in immortal cells, 
but its expression was strongly inhibited in poorly differentiated SNU387, SNU423 and 
SNU475 cell lines with 3-8 fold decrease when compared to senescent cells. Thus, E2F5 
might be involved in growth repression in a subset of HCCs. A third group of E2F genes 
(E2F6-8) is believed to play also a ‘repressive’ effect, but their cellular functions are poorly 
known (69). E2F7 and E2F8 were slightly up-regulated in immortal cells, but only E2F7 
displayed increased expression in many, but not in all HCC cell lines, whereas the expression 
of E2F8 was decreased in most HCC cell lines. Thus, loss of E2F8 in HCC cells correlates 
with its known functions, but the over-expression of E2F7 remains to be further explored.  
DP family of DNA-binding genes encodes proteins interacting with both ‘activating’ 
E2F1-3a and ‘repressive’ E2F3b-6 proteins (69). In this study we observed opposite patterns 
of DP1 and DP2 expressions. DP1 was up-regulated in immortal cells, and in most HCC cell 
lines, whereas DP2 was consistently down-regulated in immortal and HCC cell lines. The 
respective roles of these proteins in E2F functions are poorly known. However, over-
expression of DP1 in HCC has been previously reported, and this correlates with its 
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hyperproliferative effects (158). Studies on the expression of DP2 in cancer or immortal cells 
are limited. Based on our observations showing consistent decrease of DP2 transcripts in 
immortal HCC cell lines, we decided to further explore this gene as a potential marker for 
liver malignancy. Our in vitro studies at the protein level showed strong nuclear expression in 
pre-senescent and senescent cells, as compared to weak expression in immortal cells. The Q-
PCR and immunoperoxidase results were confirmed by western blot; total protein level of 
DP-2 protein was always observed to be higher in senescent cells compared to immortal cells. 
Western blot analysis showed that senescent cells express dominantly 43 kDa isoforms, which 
displayed decreased levels in immortal cells. On the other hand, 49 kDa isoform was observed 
to be very weakly expressed in senescent cells, but more abundant in immortal cells. The 
same shift was observed in TGF-β induced senescence model. We concluded that these two 
isoforms of DP-2 may be regulated differentially in senescence and immortality and play 
important roles in progression and/or maintenance of these phases. We, also, observed change 
in the amount of isoforms during different time periods of cell cycle. Previously, Van Der 
Sman et. al. observed that in G0, the anti-DP2 monoclonal antibody recognized 3 isoforms of 
apparent molecular masses of  approximately 55, 48, and 43 kDa, and the faster migrating 
forms of each proteins  predominated as cells entered G1 in B lymphocyte cells which 
supports our findings (159).  In a study searching E2F and retinoblastoma protein in neuronal 
differentiation, total DP-2 protein was observed to increase dramatically in adult brain 
compared to embryos; the most interesting thing for our study was to see that small isoform 
was expressed in adult brain, and just big isoform was seen in embryonic neurons (87). It will 
be noteworthy to search whether small isoform is specific to terminally differentiated cells, 
whereas big isoform is expressed in stem cells. The pathways regulating different isoforms in 
immortal and senescence cells, and the molecuar functions of these proteins must be 
extensively studied. We have, also, observed slowly migrating bands in primary hepatocytes 
and tissue samples which we have not seen in cell line data. Whether these proteins are 
previously unidentified isoforms of DP-2 or not must be further elucidated.  
 
5.3 Histone methylation levels of some H3 and H4 residues change in immortality and 
senescence of liver in vitro and in vivo 
It has long been known that the way genes are packaged inside the nucleus of a cell can 
determine their expression (transcription). Molecular tags on histones have crucial roles in 
controlling the activity of associated genes; such tags include acetyl, methyl and phosphate 
groups. Of the various types of histone modification, methylation is the most stable (160).  It 
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is tightly regulated by specific enzymes that add or remove a methyl group. Although, great 
effort has been devoted to elucidate the implication of DNA methylation in cancer, including 
HCC; our knowledge of the involvement of histone methylation changes was rather poor. 
Especially, in liver cancer there was no study examining the histone methylation changes. 
There were some encouring reports showing that long-term administration of diets deficient in 
choline and methionine caused hepatocellular carcinoma in mice. Moreover, treatments with 
various methionine metabolites in experimental animal models of liver disease showed 
hepatoprotective properties (161). In this study, we, first, showed that a significant group of 
histone methyltransferases and demethylases were differentially regulated in immortal and 
senescent Huh7 clones. The two H3K4 methyltransferases, MLL3 and ASH1L, and the 
demethylase JARID1B were upregulated in senescent cells. We have observed the over-
expression of H3K27 methyltransferase, EZH2, and down regulation of the demethylases 
JMJD3, and UTX in immortal cells. JMJD2B, an H3K9 demethylase, was upregulated in 
senescence cells. Both of the two H3K36 methyltransferases, SETD2 and SMYD2, and two 
demethylase of the same residue, FBXL11 and JMJD2B, were upregulated in senescence 
cells. SUV420H1, the H4K20 methyltransferase, was upregulated in senescence cells. The 
histone arginine methyltransferases, CARM1 and PRMT1, did not show a specific change (<1 
fold change). Some of these enzymes have been releted to various cancer types (see 
introduction), the role of these enzymes in the liver cancer development must be intensively 
studied. 
We, than, wanted to compare the global levels of the H3 and H4 methylated residues in 
these cells. In order to observe and compare the nuclear positivity and cellular heterogeneity, 
we have choosen to perform immunocytochemistry experiment. Five of the residues did not 
show any change in the global levels. Interestingly, all of the other residues were observed to 
increase and become more homogenous in senescent cells. The decrease in the level of 
H4K20me3 was expected, because it has been previously shown that this residue was 
regulated by Rb protein and hypomethylated in cancer cells of various tumor models (162). 
We observed the decrease of this residue, along with, H3K27me3, H3K36me3, H3R2me2, 
H3R17me2, in HCC compared to non-tumor liver. The function, the up-stream regulators and 
targets of these residues in HCC must be studied extensively. Also, the factors mediating 
these changes must be elucidated. We couldn’t observe a perfect correlation of histone residue 
changes with enzyme expression levels, except the upregulation of SUV420H1 and 
H4K20me3 in senescent cells. The global histone hypomethylation may be caused from 
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altered methylation methabolism in liver cancer. It has been showed that S-adenosyl-L-
methionine/S-adenosylhomocysteine ratio and liver-specific methionine adenosyltransferase 
(MatI/III) progressively decreased in dysplastic and neoplastic liver lesions developed in c-
Myc transgenic mice and in human HCC with better (HCCB) and poorer (HCCP) prognosis 
(based on patient's survival length), which caused extended DNA hypomethylation and 
genomic instability (163). It shoud be searched whether the global lypomethylation of histone 
residues is a consequence of methionine metabolism aberations. 
We have also showed global increase in the levels of H2AZ, H2AX, and mH2A histone 
variants in senescence committed liver cancer cells. They may serve as markers of 
senescence, and may have important functions in immortality and senescence, as well as in 
HCC development. The mechanism and consequences of this histone variant replacement 
must be searched. 
Our results show that histone methylation regulators may be very important to serve as 
new diagnostic, prognostic and therapeutic approaches.   
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CHAPTER 6.  FUTURE PERSPECTIVES 
 
Immortal and senescence associated network and its implication in HCC  
We identified that many biological processes were differentially regulated in immortal and 
senescence arrested liver cancer cells. Among our significant gene set, the potential 
senescence and immortality markers should be identified. Today, there is no strong diagnostic 
marker for cirrhosis that will help to monitor patients before HCC development, without 
biopsy. As senescent cells may represent cirrhosis, and immortal cells HCC; any cirrhosis and 
HCC markers should be searched. For this purpose, candidate molecules should be selected 
from the most dramatically changing genes and a large cohort of cirrhosis and HCC tissue and 
serum samples must be screened for the levels of these genes and their proteins.  
We found that DNA damage response and repair genes were up-regulated in immortal 
cells. The possibility that DNA damage, which can not be repaired, may be one of the major 
causes of the senescence arrest should be tested. The role of DNA repair pathway in HCC 
should be investigated.  
It is widely believed that tumor cells include a population of cells responsible for the 
initiation of the tumor that is called “cancer stem cell”. They have self-renewal capacity and 
potential for multidirectional differentiation. It is possible that in parental Huh7 cells, the 
cancer stem cell population may produce both highly tumorigenic immortal clones which may 
have the stem cell properties, and terminally differentiated cells which do not divide and 
become senescent. This hypothesis should be tested using some cancer stem cell markers. 
It will be very useful to test some of the genes from SIGN signature on an independent 
cohort of liver samples. Especially, immunohistochemistry analysis with selected proteins on 
normal, dysplastic, cirrhotic and tumor liver samples and HCC samples with different 
subtypes should be performed.  
 
DP-2 and senescence 
We found that total DP-2 is over-expressed in senescence cells in mRNA and protein level. 
And, the expressed isoforms were changing between immortal and senescent cells. Over-
expression and knock-down analysis of the two isoforms in-vitro should be carried out to 
examine their function in cell proliferation and growth. Although it will be challenging to 
raise specific antibodies against each isoform, target genes of each isoform will be useful to 
identify.  
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DP proteins are bound to E2F proteins before binding to the target promoter. It will be 
important to identify E2F partner(s) of DP-2 isoforms. 
Surprisingly, we have observed extra bands in primary human liver cells. With mass 
spectrometry analysis, these bands should be tested whether they are DP-2 isoforms or not. 
DP proteins share high homology among each other and with E2F proteins also. The extra 
bands could be products of cross-reactivity or liver specific DP protein and its modified forms 
(ex. Phosphorylated forms).  
To observe oscillations of DP-2 isoforms in different stages of cell cycle, the cell cycle 
phases should be determined with flow cytometry analysis after cell cycle synchronization of 
different HCC cell lines. 
 
Epigenetic changes in immortality and senescence of liver in vitro and in vivo  
The functional roles of the identified histone modifying enzymes in senescence and cell 
proliferation should be studied intensively with over-expression and silencing experiments in-
vitro. Strong candidates obtained from in-vitro assays should be tested in-vivo using knock-
out mice strains. Candidate proteins should be subjected to chromatin immunoprecipitation 
analysis to identify their targets in senescent and immortal conditions.  
The histone methylation changes of senescent/immortal cells and non-tumor/tumor 
samples should be confirmed by mass spectrometry analysis. The expression targets of the 
changing residues should be determined by ChIP-Seq technology in these contexts. Also, 
methionine metabolism changes in these cells should be determined to test the possibility that 
global hypomethylation of histone residues could be result from aberrant methionine 
metabolism in HCC.    
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Appendix A: Quality control of arrays using AffyPLM package of Bioconductor suite 
using R programme 
%download AffyPLM 
source("http://bioconductor.org/biocLite.R") 
biocLite("affyPLM") 
%load the package 
library(affyPLM) 
options(width = 60) 
%load the dataset and fit probe-level models to all of the probesets 
require(affydata) 
data(DATA) 
Dilution = updateObject(DATA) 
Pset <- fitPLM(DATA) 
%produce a chip pseudo image of the weights for the second array in the dataset 
image(Pset, which = 2) 
%produce the residual images for the second chip in the DATA dataset 
image(Pset, which = 2, type = "resids") 
image(Pset, which = 2, type = "pos.resids") 
image(Pset, which = 2, type = "neg.resids") 
%draw Relative Log Expression (RLE) box-plots  
RLE(Pset, main = "RLE for DATA dataset") 
%draw Normalized Unscaled Standard Errors (NUSE) box-plots 
NUSE(Pset, main = "NUSE for Dilution dataset") 
 
Appendix B:  Normlization and significance analysis codes using R programme 
B1. Code for normalization with RMA 
library(affy) 
setwd(system.file("data",package="DATA")) 
dir() 
getwd() 
pd <-read.phenoData("PHENODATA.txt",header=TRUE,row.names=1,as.is=TRUE) 
rawAffyData <- ReadAffy(filenames=pData(pd)$FileName,phenoData=pd) 
rawAffyData 
image(rawAffyData[,1]) 
image(rawAffyData[,2]) 
hist(log2(pm(rawAffyData[,1])), breaks=100, col="blue") 
hist(log2(mm(rawAffyData[,1])), breaks=100, col="blue") 
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mva.pairs(pm(rawAffyData)[,c(1,3,5,7)]) 
eset <- rma(rawAffyData) 
eset 
%exame the effects of normalization using boxplots; 
# Before RMA normalization: 
boxplot(rawAffyData,col="red") 
 
# After RMA normalization: 
boxplot(data.frame(exprs(eset)),col="blue") 
 
B2. Code for two-tailed, unpaired, unequal variance Welch’s t-test 
library(siggenes) 
library(multtest) 
library(genefilter) 
 
 
callItSig<-function(normFile) { 
#indices in R starts from 1!!!!!!!!!!!!!!!!!!!!! 
 explimit <- 4 
 FDR <- 1.0  
 for (i in 1:2) { 
     for (j in (i+1):3) { 
  print(c(i,j)) 
  getsiglistTtest(normFile,explimit,i,j,FDR) 
     } 
 } 
 for (i in 4:5) { 
     for (j in (i+1):6) { 
  print(c(i,j)) 
  getsiglistTtest(normFile,explimit,i,j,FDR) 
     } 
 } 
} 
 
dene<-function(normFile) { 
 explimit <- 4 
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     for (i in 5:5) { 
     for (j in 6:6) { 
  print(c(i,j)) 
  getsiglistTtest(normFile, explimit,i,j,FDR) 
     } 
 } 
} 
 
 
getsiglistTtest<-function(normFile, explimit,grp1,grp2,FDR) { 
 getwd(); 
 Data <- read.csv(normFile) 
 
 de = Data[, 2:19] 
 de.gnames = Data[, 1:1] 
 de.cl = c(1,1,1,2,2,2,3,3,3,4,4,4,5,5,5,6,6,6) 
 dind1<-de.cl==grp1 
 dind2<-de.cl==grp2 
 dgr1<-de[,dind1] 
 dgr2<-de[,dind2] 
 de1<-cbind(dgr1,dgr2) 
 
 #filter genes below explimit 
 #At least 1 probe should be expressed above explimit 
 #f1 <- kOverA(6, explimit); 
 f1 <- kOverA(1, explimit); 
 ffun <- filterfun(f1); 
 which <- genefilter(de1, ffun); 
 print('number of remaining genes after expfilter:') 
 print(sum(which)) 
 def<-de1[which,] 
 def.gnames<-data.matrix(Data[which,1]) 
  
 #t-test class labels should be either 0 or 1 
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 def.cl<-c(0,0,0,1,1,1) 
 
 teststat <- mt.teststat(def, def.cl) 
 
 qqnorm(teststat) 
 qqline(teststat) 
 print("qq plot for teststat plotted") 
 
 #to get regulation information 
 tmp <- mt.teststat.num.denum(def, def.cl, test = "t") 
 num <- data.matrix(tmp$teststat.num) 
 print ("num") 
 print (dim(num)) 
 print (num[1:10,])  
 
 #find raw p values 
 rft <- rowFtests(data.matrix(def), factor(def.cl), 
var.equal= F) 
 rawp0 <- rft$p.value  
 
print (dim(data.matrix(rawp0))) 
 
 procs <- c("BH") 
 #adj_p is in its orijinal order -not in accending order 
 res <- mt.rawp2adjp(rawp0, procs) 
 adjp <- res$adjp[order(res$index), ] 
print(dim(adjp)) 
 
 print(FDR) 
 which <-  mt.reject(cbind(adjp), FDR )$which[,2] #there 
are only one proc 'BH' 
 result <-  mt.reject(cbind(adjp), seq(0,1.0,0.01) )$r  
   
 #print significance into file 
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 fileName = paste(grp1,grp2,"sig.csv", sep = "") 
 write.table(result, file = fileName, sep = "\t", col.names 
= TRUE, quote = FALSE)  
 
 print ("Number of significant genes") 
 print(sum(which)) 
 gsignificant<-def[which,] 
   
 probeLabels<-def.gnames[which] #first column of def.gnames 
data matrix 
 significantAdjPValues<-adjp[which,2] 
 regulation<-num[which] 
 #allSignificant = cbind(probeLabels, 
significantAdjPValues, regulation) 
 allSignificant = cbind(probeLabels, adjp, regulation) 
  
 #TAGGING 
 #grp1(3 digits-18 values,  
 #grp2(3 digits-18) values 
   
 reg = as.numeric(allSignificant[,3]) 
   
 #all significant genes   
 print("all")   
 print(dim(allSignificant))   
 print(allSignificant[1:2,]); 
 fileName = paste(grp1,grp2,"genes.csv", sep = "") 
   
#write.table(tagValue, file = fileName, sep = "", col.names = 
FALSE, row.names = FALSE) 
 write.table(allSignificant, file = fileName, sep = "\t", 
col.names = TRUE, row.names = FALSE, quote = FALSE) } 
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B3. For quantile and median center normalization, the below code was used in R; 
d=read.table("DATA.txt",header=T) 
dim(d) 
d[1:5,1:5] # see a subset of the values in d 
#Load the rfunctions using 
source('rfunctions.txt') 
#Make side-by-side boxplots of the log signals from each 
channel. 
#(The "[,-1]" removes column 1 which contains the geneID.) 
  
boxplot(log(d[,-1])) 
#Boxplot of unnormalized data after log transformation using 
log.0 #function in which zeros are replaced by 1; the data in 
logd is #indexed from column 2 to 17, instead of using d[,-1]. 
  
logd=log.0(d[,2:27]) 
boxplot(logd) 
  
#List the objects that have been created during the R session 
so far. 
  
ls() 
#Quantile normalize using quant.norm 
  
qs<-quant.norm(logd) 
dim(qs) 
slide.medians<-apply(qs,2,median, na.rm=T) 
qsm<-sweep(qs,2,slide.medians)  #1=row 2=column 
plot(d[,2],d[,3] 
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Appendix C: Enriched gene sets (FDR<0.15) to immortal, pre-senescent and senescent 
phenotypes from GSEA analysis 
Immortal Enriched Gene Sets  
NAME SIZE ES NES 
NOM p-
val 
FDR q-
val 
FWER p-
val 
E2F1_TARGETS_CHIP 38 0.580218 1.66831 0.04 0.051051 0.24 
CANCER_UNDIFFERENTIATED_META_UP 65 0.487906 1.4689 0.086957 0.113817 0.71 
BRENTANI_REPAIR 36 0.621496 1.547644 0.058824 0.117194 0.59 
MANALO_HYPOXIA_DOWN 80 0.563608 1.469109 0.106383 0.127927 0.71 
NF90_DN 29 0.61834 1.479598 0 0.132696 0.7 
CMV_IE86_UP 37 0.720344 1.519632 0.065217 0.139809 0.62 
SERUM_FIBROBLAST_CELLCYCLE 114 0.581189 1.504461 0.083333 0.140873 0.68 
PEART_HISTONE_DOWN 73 0.408196 1.433983 0.019231 0.144511 0.76 
DOX_RESIST_GASTRIC_UP 47 0.614502 1.485551 0.130435 0.147354 0.7 
SERUM_FIBROBLAST_CORE_UP 173 0.376459 1.401126 0.142857 0.154137 0.79 
 
Pre-senescent Enriched Gene Sets 
NAME SIZE ES NES 
NOM p-
val 
FDR q-
val 
FWER 
p-val 
UV-CMV_UNIQUE_HCMV_6HRS_DN 92 0.527606 1.771172 0 0.033122 0.02 
UVB_NHEK3_C8 68 0.442606 1.520431 0.033898 0.105614 0.62 
IFNG_5ENDOTHELIAL_DOWN 68 0.44511 1.526414 0 0.106698 0.61 
HYPOXIA_REVIEW 80 0.527992 1.522686 0 0.107922 0.61 
BHATTACHARYA_ESC_UP 66 0.488177 1.53307 0 0.107988 0.59 
ET743_HELA_UP 45 0.567194 1.681733 0 0.108232 0.2 
TESTIS_EXPRESSED_GENES 61 0.402888 1.529274 0 0.108234 0.61 
H2O2_CSBDIFF_C2 26 0.546498 1.612152 0.016949 0.109624 0.4 
HPV31_DN 40 0.560783 1.517472 0.04 0.109773 0.63 
HDACI_COLON_BUT12HRS_UP 34 0.476826 1.538593 0.016393 0.111217 0.59 
TNFALPHA_30MIN_UP 38 0.388466 1.604211 0 0.111307 0.43 
TNFALPHA_4HRS_UP 39 0.507071 1.542008 0.020408 0.111435 0.59 
CHIARETTI_T_ALL 238 0.469172 1.542335 0 0.1137 0.58 
OXSTRESS_BREASTCA_UP 27 0.519261 1.581281 0 0.114023 0.49 
UV_UNIQUE_FIBRO_DN 28 0.613834 1.51406 0.043478 0.114061 0.64 
UVB_NHEK3_C0 101 0.446388 1.665794 0.05 0.115345 0.25 
CMV_24HRS_UP 58 0.521695 1.592209 0 0.116577 0.45 
CROONQUIST_IL6_STROMA_UP 36 0.591776 1.615106 0.034483 0.11798 0.4 
TNFA_5ENDOTHELIAL_DOWN 71 0.539296 1.588474 0 0.118261 0.48 
UVB_NHEK1_UP 140 0.488482 1.542381 0.017857 0.118437 0.58 
TNFA_5ENDOTHELIAL_UP 70 0.636198 1.505029 0 0.119345 0.66 
HOX_GENES 52 0.626138 1.634224 0.033333 0.11986 0.36 
AGUIRRE_PANCREAS_CHR1 28 0.444518 1.505444 0 0.122102 0.66 
TSA_HEPATOMA_CANCER_UP 30 0.667311 1.543693 0 0.122257 0.57 
BRCA1_OVEREXP_PROSTATE_UP 153 0.429095 1.548771 0 0.123862 0.55 
UVB_NHEK3_C1 67 0.523373 1.50596 0.074074 0.123984 0.65 
HINATA_NFKB_UP 107 0.495775 1.553349 0 0.124247 0.55 
GNATENKO_PLATELET 42 0.497503 1.500949 0.019231 0.125204 0.67 
MAGRANGEAS_LK_DOWN 27 0.566354 1.544468 0.018519 0.126184 0.57 
CMV_HCMV_TIMECOURSE_14HRS_DN 47 0.545241 1.625472 0 0.127177 0.38 
WERNERONLY_FIBRO_UP 30 0.516038 1.616954 0.017544 0.127732 0.4 
DAVIES_MGUS_MM 35 0.582801 1.654868 0.017544 0.129001 0.29 
CMV_ALL_UP 77 0.494515 1.553785 0 0.130787 0.55 
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CMV-UV_HCMV_6HRS_DN 122 0.440989 1.684124 0 0.133263 0.18 
UVB_NHEK3_ALL 467 0.43419 1.635004 0 0.134843 0.36 
TPA_RESIST_EARLY_DN 71 0.471609 1.706333 0 0.13683 0.13 
VEGF_MMMEC_ALL_UP 81 0.470771 1.555033 0.070175 0.138053 0.55 
TNFALPHA_ALL_UP 73 0.423217 1.638607 0.021277 0.144975 0.35 
DSRNA_UP 37 0.615536 1.484818 0.050847 0.148374 0.72 
TSA_HEPATOMA_UP 37 0.479156 1.473993 0.076923 0.148794 0.76 
 
Senescence Enriched Gene Sets 
NAME SIZE ES NES NOM p-val FDR q-val FWER p-
val 
UVB_NHEK3_C0 101 0.529704 1.795019 0 0.014449 0.01 
JECHLINGER_EMT_DOWN 40 0.567248 1.632176 0 0.066461 0.31 
ANDROGEN_GENES 52 0.674071 1.539559 0 0.066919 0.53 
TPA_SENS_LATE_DN 215 0.438801 1.540199 0 0.06807 0.53 
CMV_ALL_UP 77 0.526481 1.625971 0.016949 0.069499 0.32 
CHAUHAN_2ME2 36 0.590136 1.540363 0 0.069772 0.53 
GAMMA-UV_FIBRO_DN 39 0.602555 1.573477 0 0.069874 0.47 
ET743_RESIST_DN 34 0.614287 1.536661 0 0.069904 0.53 
WERNERONLY_FIBRO_UP 30 0.609646 1.543582 0 0.069974 0.51 
HEARTFAILURE_ATRIA_DN 130 0.420789 1.516926 0 0.070258 0.57 
TPA_RESIST_LATE_DN 57 0.396058 1.517356 0.032787 0.070383 0.57 
BRENTANI_IMMUNE_FUNCTION 50 0.527649 1.51455 0 0.070526 0.58 
ROSS_MLL_FUSION 77 0.548274 1.63458 0 0.07101 0.31 
SMITH_HTERT_DOWN 61 0.530096 1.520991 0 0.071046 0.57 
GNATENKO_PLATELET 42 0.560999 1.544467 0.038462 0.071057 0.51 
CMV_HCMV_TIMECOURSE_6HRS_DN 55 0.499551 1.532718 0.087719 0.07112 0.54 
CMV_HCMV_TIMECOURSE_ALL_DN 485 0.426087 1.517736 0 0.071663 0.57 
VEGF_MMMEC_12HRS_UP 25 0.675701 1.515263 0 0.071742 0.58 
TARTE_PC 75 0.498486 1.52461 0 0.071975 0.57 
UV-CMV_UNIQUE_HCMV_6HRS_UP 132 0.507713 1.520013 0 0.072139 0.57 
VEGF_MMMEC_3HRS_UP 55 0.565027 1.528134 0 0.072378 0.56 
IFN_BETA_GLIOMA_UP 50 0.418442 1.521049 0 0.072413 0.57 
POMEROY_CLASSIC_MD_UP 35 0.482009 1.574063 0 0.072561 0.47 
UV_UNIQUE_FIBRO_DN 28 0.693883 1.509896 0.020408 0.072759 0.6 
BRG1_ALAB_DN 32 0.637603 1.545172 0 0.072978 0.51 
UVC_HIGH_D5_DN 30 0.509219 1.524963 0 0.073 0.57 
TPA_SENS_EARLY_UP 43 0.506857 1.51335 0 0.073067 0.59 
UVB_NHEK1_UP 140 0.531042 1.567796 0 0.073152 0.48 
OLD_FIBRO_DN 144 0.473393 1.507356 0.017544 0.073555 0.6 
CMV_HCMV_TIMECOURSE_24HRS_UP 78 0.409778 1.510753 0.032787 0.073605 0.6 
TESTIS_EXPRESSED_GENES 61 0.420126 1.546217 0 0.073636 0.51 
ZHAN_TONSIL_BONEMARROW 40 0.629071 1.587898 0 0.073705 0.43 
MAGRANGEAS_LK_DOWN 27 0.592666 1.528387 0.02 0.073727 0.56 
GAMMA-UV_FIBRO_UP 33 0.521609 1.50285 0 0.073809 0.64 
UVC_TTD_8HR_DN 174 0.573355 1.503505 0.037736 0.07445 0.64 
TPA_RESIST_MIDDLE_DN 95 0.526807 1.578068 0 0.074467 0.44 
DAC_PANC_UP 402 0.492984 1.525007 0 0.07449 0.57 
CMV_24HRS_UP 58 0.544419 1.525394 0.018519 0.0747 0.57 
SHIPP_FL_UP 34 0.597953 1.510862 0 0.074812 0.6 
UVB_NHEK3_ALL 467 0.482413 1.574972 0 0.075041 0.46 
TSA_HEPATOMA_UP 37 0.579155 1.505651 0 0.075199 0.64 
STRESS_TPA_SPECIFIC_UP 49 0.38809 1.528615 0 0.075366 0.56 
DIAB_NEPH_DN 395 0.547135 1.54657 0 0.075378 0.51 
HDACI_COLON_BUT12HRS_UP 34 0.581869 1.503598 0.036364 0.075561 0.64 
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H2O2_CSBDIFF_C2 26 0.520755 1.550485 0.032787 0.075762 0.51 
UVB_SCC_UP 75 0.551089 1.589838 0.037736 0.076217 0.43 
CMV_8HRS_UP 29 0.645522 1.504032 0.018182 0.076395 0.64 
BRCA1_OVEREXP_UP 128 0.535055 1.552876 0 0.076798 0.5 
BRCA1_OVEREXP_PROSTATE_UP 153 0.515546 1.581965 0 0.077091 0.43 
CIS_XPC_DN 165 0.451638 1.498707 0.035714 0.077552 0.67 
NELSON_ANDROGEN_UP 58 0.633904 1.564215 0.038462 0.078025 0.49 
TPA_RESIST_EARLY_DN 71 0.559828 1.594541 0 0.078197 0.43 
ESR_FIBROBLAST_UP 43 0.579866 1.635322 0 0.078899 0.31 
ALZHEIMERS_INCIPIENT_DN 149 0.366612 1.552998 0.042553 0.079198 0.5 
FRASOR_ER_DOWN 61 0.614683 1.497046 0.018868 0.079398 0.67 
ELECTRON_TRANSPORTER_ACTIVITY 113 0.555891 1.591149 0 0.080027 0.43 
PENG_RAPAMYCIN_UP 155 0.415837 1.495589 0 0.080085 0.67 
TPA_SENS_EARLY_DN 275 0.436528 1.611422 0 0.080102 0.39 
GAMMA_ESR_WS_UNREG 29 0.533182 1.557451 0.020833 0.080314 0.5 
UVC_XPCS_8HR_DN 419 0.484027 1.494189 0.072727 0.0807 0.67 
UV-CMV_UNIQUE_HCMV_6HRS_DN 92 0.560455 1.670083 0 0.08074 0.23 
TPA_SENS_MIDDLE_DN 283 0.461157 1.553707 0 0.081753 0.5 
TSADAC_HYPOMETH_OVCA_UP 46 0.568358 1.607481 0.04918 0.082456 0.39 
4NQO_ESR_WS_UNREG 35 0.501657 1.595218 0 0.082541 0.43 
OXSTRESS_RPE_HNETBH_DN 40 0.553098 1.489436 0 0.082673 0.67 
HADDAD_10VS7 258 0.555508 1.491031 0 0.083298 0.67 
BRENTANI_PROTEIN_MODIFICATION 144 0.482071 1.489966 0 0.083533 0.67 
GAMMA_ESR_OLD_UNREG 27 0.555303 1.595654 0 0.083609 0.43 
HADDAD_INTVSHI 78 0.591266 1.485886 0 0.083647 0.67 
BRENTANI_SIGNALLING 179 0.480414 1.614325 0 0.083871 0.38 
WELCSH_BRCA_UP 39 0.641943 1.640859 0 0.084011 0.3 
UVC_HIGH_D2_DN 27 0.652063 1.485886 0 0.084733 0.67 
CROONQUIST_IL6_STROMA_UP 36 0.668543 1.473661 0 0.084909 0.69 
BRCA_BRCA1_NEG 126 0.507751 1.47201 0.017241 0.085109 0.72 
AGEING_BRAIN_UP 235 0.499644 1.472514 0 0.085398 0.72 
POMEROY_DESMO_MD_UP 43 0.66044 1.472946 0.02 0.085454 0.72 
DIAB_NEPH_UP 79 0.518199 1.474644 0 0.085519 0.69 
CMV_HCMV_TIMECOURSE_48HRS_DN 137 0.461609 1.475632 0 0.086275 0.69 
BRENTANI_DEATH 70 0.499667 1.46901 0.019608 0.086309 0.74 
UVC_TTD-XPCS_COMMON_DN 151 0.555435 1.47099 0.076923 0.086345 0.74 
UVC_XPCS_ALL_DN 494 0.47413 1.47764 0.074074 0.086645 0.69 
CIS_XPC_UP 127 0.475199 1.468085 0 0.087012 0.75 
BAF57_BT549_DN 341 0.447133 1.4759 0 0.087017 0.69 
FRASOR_ER_UP 30 0.487513 1.469477 0.018519 0.087128 0.74 
BRCA_ER_POS 457 0.475909 1.478164 0.018182 0.087562 0.69 
JISON_STRESS 30 0.519862 1.464754 0.058824 0.087565 0.75 
CHIARETTI_T_ALL 238 0.482512 1.478452 0.019608 0.087858 0.69 
DAVIES_MGUS_MM 35 0.645964 1.596943 0 0.088175 0.43 
AGUIRRE_PANCREAS_CHR12 53 0.44193 1.465833 0.058824 0.088246 0.75 
UV-4NQO_FIBRO_UP 26 0.504281 1.46477 0.017544 0.088458 0.75 
HYPOXIA_RCC_NOVHL_UP 51 0.347478 1.480868 0 0.088775 0.69 
HOX_GENES 52 0.524791 1.462452 0.068966 0.088914 0.77 
ET743_SARCOMA_72HRS_UP 59 0.530077 1.478459 0.037736 0.088942 0.69 
BAF57_BT549_UP 246 0.575868 1.480017 0 0.088972 0.69 
WERNERONLY_FIBRO_DN 52 0.443119 1.464944 0.035714 0.089264 0.75 
UVB_NHEK1_DN 207 0.47546 1.461989 0.072727 0.089756 0.78 
JECHLINGER_EMT_UP 54 0.495615 1.456824 0 0.090063 0.78 
TNFA_5ENDOTHELIAL_DOWN 71 0.547424 1.455563 0 0.090275 0.78 
HYPOXIA_REVIEW 80 0.550173 1.460117 0.061224 0.090366 0.78 
IL1_CORNEA_UP 49 0.51516 1.453653 0 0.090396 0.78 
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UVB_NHEK2_DN 71 0.501198 1.458573 0.018519 0.090462 0.78 
PGC 345 0.358022 1.457049 0 0.090538 0.78 
LVAD_HEARTFAILURE_DN 41 0.620823 1.455997 0.033333 0.090806 0.78 
SMITH_HTERT_UP 102 0.364173 1.458991 0 0.090846 0.78 
CMV-UV_HCMV_6HRS_UP 153 0.458724 1.453967 0 0.091035 0.78 
LU_IL4BCELL 65 0.555422 1.449735 0.018868 0.092097 0.79 
TARTE_MATURE_PC 369 0.481632 1.451684 0.019231 0.092127 0.78 
ET743_HELA_UP 45 0.604097 1.450358 0.02 0.092689 0.79 
HDACI_COLON_CLUSTER10 38 0.553578 1.449934 0.06383 0.092723 0.79 
ALZHEIMERS_INCIPIENT_UP 363 0.474854 1.447433 0 0.093578 0.8 
ROSS_CBF_MYH 48 0.559289 1.438206 0 0.093814 0.8 
VEGF_MMMEC_ALL_UP 81 0.570704 1.439187 0 0.093995 0.8 
SERUM_FIBROBLAST_CORE_DN 169 0.631641 1.441109 0 0.094016 0.8 
WERNER_FIBRO_DN 145 0.430143 1.446245 0.019608 0.09412 0.8 
UVB_NHEK3_C1 67 0.588784 1.43673 0.039216 0.094126 0.8 
ELECTRON_TRANSPORT 74 0.525587 1.441727 0.018182 0.094717 0.8 
UVB_NHEK3_C2 53 0.60958 1.44629 0.019231 0.094931 0.8 
UVC_TTD_ALL_DN 372 0.489484 1.441936 0.076923 0.095513 0.8 
VENTRICLES_UP 242 0.464334 1.641511 0 0.096013 0.3 
CMV_HCMV_TIMECOURSE_24HRS_DN 46 0.578211 1.442004 0 0.096322 0.8 
CMV-UV_HCMV_6HRS_DN 122 0.501885 1.670732 0 0.096888 0.23 
AS3_FIBRO_DN 26 0.607452 1.432599 0.037037 0.097466 0.8 
ASTON_DEPRESSION_DOWN 144 0.427018 1.4296 0.036364 0.097511 0.8 
HDACI_COLON_CLUSTER9 46 0.638488 1.427057 0 0.097672 0.8 
OLDWERNER_FIBRO_DN 94 0.4352 1.431258 0.054545 0.097845 0.8 
UVC_HIGH_ALL_DN 228 0.404757 1.426302 0.055556 0.097872 0.8 
EGF_HDMEC_UP 30 0.435594 1.425755 0 0.097924 0.8 
PROLIF_GENES 364 0.41644 1.42977 0 0.098172 0.8 
MYC_HUVEC_SAGE_ARRAY_UP 31 0.572238 1.427195 0.076923 0.098246 0.8 
UVC_TTD_4HR_DN 311 0.474129 1.424411 0.074074 0.098356 0.8 
HPV31_DN 40 0.595899 1.423133 0.02 0.098879 0.81 
CMV_24HRS_DN 61 0.539501 1.420248 0 0.100492 0.81 
KLEIN_PEL_DOWN 55 0.467475 1.418732 0.056604 0.101331 0.81 
VANTVEER_POOR_OUTCOME_BREAST 26 0.515549 1.417785 0.032258 0.10204 0.81 
UVC_HIGH_D7_DN 26 0.472073 1.413002 0.096154 0.10262 0.81 
OLDONLY_FIBRO_DN 50 0.545787 1.415358 0.017544 0.102799 0.81 
OKUMURA_MC_LPS 161 0.462536 1.41367 0.035088 0.103134 0.81 
HDACI_COLON_SUL48HRS_UP 67 0.473486 1.415542 0.057692 0.103544 0.81 
KANNAN_P53_UP 35 0.475635 1.411863 0.055556 0.103732 0.81 
CMV_HCMV_TIMECOURSE_14HRS_DN 47 0.61967 1.727448 0 0.105336 0.07 
BRG1_SW13_UP 42 0.557791 1.4068 0.019608 0.106262 0.82 
CORDERO_KRAS_CONTROL_UP 55 0.43038 1.407318 0 0.106567 0.82 
ROME_INSULIN_2F_UP 184 0.496577 1.674115 0 0.106804 0.21 
BRG1_H1299_UP 27 0.677177 1.407374 0 0.107302 0.82 
MUNSHI_MM_UP 65 0.421145 1.407426 0.036364 0.107853 0.82 
HYPOXIA_NORMAL_UP 182 0.472328 1.407477 0.035714 0.108607 0.82 
HDACI_COLON_SUL_UP 94 0.474511 1.401304 0.058824 0.110995 0.84 
TSA_PANC50_UP 37 0.625755 1.400271 0.017857 0.111162 0.84 
BROCKE_IL6 138 0.46826 1.396611 0.035088 0.112811 0.84 
ROSS_AML1_ETO 71 0.429583 1.396838 0.034483 0.112897 0.84 
GAMMA_UNIQUE_FIBRO_DN 57 0.565697 1.397869 0.055556 0.113286 0.84 
CMV_HCMV_TIMECOURSE_16HRS_UP 61 0.434897 1.397183 0 0.11343 0.84 
BRCA1_IRRADIATED_UP 67 0.374335 1.393639 0.103448 0.113904 0.84 
SERUM_RESPONSE_QUIESCENT 124 0.616004 1.394092 0 0.114431 0.84 
RETT_UP 34 0.646021 1.39102 0.056604 0.115319 0.86 
BRENTANI_TRANSCRIPTION_FACTOR 64 0.477982 1.388916 0.037736 0.115321 0.86 
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IFNA_UV-
CMV_COMMON_HCMV_6HRS_UP 
37 0.591534 1.384813 0.038462 0.115437 0.87 
DSRNA_UP 37 0.658925 1.386003 0.036364 0.115575 0.87 
ADIP_HUMAN_DN 27 0.535716 1.385176 0.084746 0.115736 0.87 
PENG_GLUCOSE_DOWN 134 0.372096 1.389107 0.038462 0.115879 0.86 
UVC_XPCS_4HR_DN 256 0.456261 1.39117 0.075472 0.115992 0.86 
KUROKAWA_5FU_IFN_RESISTANT 33 0.443834 1.386347 0.037736 0.11623 0.87 
GOLDRATH_MEMORY 53 0.541729 1.387367 0 0.116415 0.87 
TPA_RESIST_LATE_UP 35 0.439828 1.380128 0.074074 0.117864 0.87 
ASTON_DEPRESSION_UP 42 0.548533 1.380537 0.105263 0.118125 0.87 
VEGF_MMMEC_6HRS_UP 44 0.629904 1.378659 0.037736 0.11837 0.87 
DER_IFNB_HT1080_UP 94 0.445926 1.379096 0.037736 0.118467 0.87 
BRENTANI_CELL_ADHESION 92 0.480694 1.380578 0.054545 0.118718 0.87 
NING_COPD_DOWN 118 0.451157 1.380803 0.074074 0.118991 0.87 
IL1_CORNEA_DN 62 0.493998 1.376663 0.018868 0.120617 0.87 
CMV_HCMV_TIMECOURSE_12HRS_UP 31 0.710426 1.37455 0.019608 0.121766 0.87 
WERNER_FIBRO_UP 49 0.544032 1.68183 0 0.122409 0.16 
TSA_HEPATOMA_CANCER_UP 30 0.674212 1.368497 0.019231 0.128198 0.88 
PENG_RAPAMYCIN_DOWN 187 0.279038 1.369061 0.02 0.128297 0.88 
BRCA_PROGNOSIS_POS 36 0.445108 1.366953 0.083333 0.128552 0.88 
HPV31_UP 53 0.439527 1.364754 0.089286 0.130236 0.88 
HEARTFAILURE_VENTRICLE_DN 91 0.40835 1.363438 0.078431 0.131722 0.88 
TPA_RESIST_MIDDLE_UP 47 0.377921 1.362285 0.053571 0.132443 0.88 
ZUCCHI_EPITHELIAL_DOWN 43 0.545408 1.359827 0.14 0.133983 0.89 
UVC_TTD_8HR_UP 28 0.511491 1.36029 0.078431 0.134463 0.89 
TNFALPHA_4HRS_UP 39 0.464211 1.357956 0.142857 0.134615 0.9 
BLEO_HUMAN_LYMPH_HIGH_24HRS_
UP 
110 0.49081 1.358357 0.037736 0.134715 0.89 
CMV_ALL_DN 85 0.481313 1.355426 0.018868 0.135342 0.9 
HCV_HCC_MARKER 33 0.51848 1.358488 0.06 0.135403 0.89 
PENG_GLUCOSE_UP 35 0.430133 1.356731 0.089286 0.135519 0.9 
RCC_NL_UP 419 0.356098 1.356 0.092593 0.135557 0.9 
HDACI_COLON_SUL16HRS_DN 60 0.412051 1.353572 0.050847 0.136727 0.9 
BHATTACHARYA_ESC_UP 66 0.466258 1.350216 0.115385 0.137103 0.92 
TARTE_BCELL 36 0.430114 1.349684 0.037736 0.137192 0.92 
HDACI_COLON_BUT24HRS_UP 52 0.522272 1.35107 0.061224 0.137212 0.91 
INSULIN_SIGNALLING 98 0.41471 1.350464 0.055556 0.137346 0.91 
UVC_TTD-XPCS_COMMON_UP 30 0.410105 1.343498 0.086207 0.13743 0.93 
ZUCCHI_EPITHELIAL_UP 42 0.414096 1.343823 0.056604 0.137729 0.93 
MANALO_HYPOXIA_UP 94 0.510003 1.351183 0.092593 0.137771 0.91 
UVB_NHEK3_C8 68 0.527932 1.342486 0.075472 0.137889 0.93 
TGFBETA_EARLY_UP 35 0.575428 1.341942 0.037037 0.138104 0.93 
TNFALPHA_ALL_UP 73 0.362589 1.35147 0.022222 0.138123 0.91 
HDACI_COLON_TSA_DN 45 0.466434 1.343934 0.127273 0.138364 0.93 
ET743PT650_COLONCA_DN 27 0.505724 1.340014 0.102041 0.138818 0.93 
ATRIA_UP 237 0.439658 1.347618 0.018182 0.138855 0.93 
DER_IFNA_HT1080_UP 68 0.46514 1.35149 0.056604 0.138857 0.91 
HDACI_COLON_SUL24HRS_DN 106 0.371333 1.344118 0.018182 0.138936 0.93 
HINATA_NFKB_UP 107 0.554817 1.344244 0 0.139634 0.93 
CORDERO_KRAS_KNOCK_DOWN 73 0.539363 1.344624 0.058824 0.139851 0.93 
UVB_NHEK1_C6 96 0.459619 1.337254 0.053571 0.140189 0.94 
IL6_SCAR_FIBRO_UP 29 0.536438 1.344935 0.017544 0.140511 0.93 
OXSTRESS_RPETWO_DN 90 0.40091 1.345197 0.018519 0.140513 0.93 
IFNA_HCMV_6HRS_UP 63 0.535717 1.33742 0.072727 0.140664 0.94 
CMV_HCMV_TIMECOURSE_8HRS_UP 25 0.53186 1.332702 0.06 0.144215 0.94 
TGFBETA_ALL_UP 61 0.539831 1.331196 0.070175 0.144926 0.94 
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HDACI_COLON_SUL_DN 167 0.375718 1.32864 0.056604 0.145179 0.94 
BRG1_ALAB_UP 38 0.598762 1.328125 0.111111 0.145449 0.94 
IFNG_5ENDOTHELIAL_DOWN 68 0.431825 1.328703 0.09434 0.145813 0.94 
OLD_FIBRO_UP 55 0.358771 1.329397 0.087719 0.146073 0.94 
LVAD_HEARTFAILURE_UP 96 0.422225 1.327204 0.107143 0.146218 0.94 
UVC_LOW_ALL_DN 39 0.590909 1.328879 0.078431 0.146395 0.94 
RESISTANCE_XENOGRAFTS_UP 26 0.711607 1.323993 0.1 0.14662 0.94 
OXSTRESS_BREASTCA_UP 27 0.477987 1.324023 0.125 0.14729 0.94 
TENEDINI_MK 54 0.416251 1.324526 0.1 0.147439 0.94 
TPA_RESIST_EARLY_UP 28 0.440015 1.324989 0.078431 0.147817 0.94 
 
Appendix D: The list of probe sets obtained from binary tree analysis using SIGN 
probe-sets for distinct Boyault-HCC subclasses 
Discriminative probe sets of 2a from 1a, 2b, and 1b (n=513) 
Probe set Gene symbol 1a,1b,2b/2a IMM/SEN 
200003_s_at RPL28 0.73 1.15 
200019_s_at FAU 0.85 1.00 
200043_at ERH 0.79 1.01 
200081_s_at RPS6 0.75 1.54 
200594_x_at HNRNPU 0.68 1.23 
200618_at LASP1 0.73 0.75 
200675_at CD81 1.63 0.36 
200708_at GOT2 1.73 1.27 
200770_s_at LAMC1 0.65 0.68 
200772_x_at PTMA 0.70 2.12 
200788_s_at PEA15 0.74 0.77 
200829_x_at ZNF207 0.74 1.22 
200843_s_at EPRS 0.69 1.09 
200847_s_at TMEM66 1.38 0.93 
200916_at TAGLN2 0.71 1.06 
200996_at ACTR3 0.76 1.17 
200998_s_at CKAP4 0.49 0.95 
201001_s_at UBE2V1 0.77 1.57 
201090_x_at TUBA1B 0.67 1.11 
201093_x_at SDHA 1.43 1.66 
201111_at CSE1L 0.67 1.50 
201128_s_at ACLY 0.60 1.20 
201135_at ECHS1 1.66 1.28 
201202_at PCNA 0.69 1.92 
201241_at DDX1 0.82 1.27 
201252_at PSMC4 0.75 1.59 
201254_x_at RPS6 0.80 1.38 
201291_s_at TOP2A 0.52 2.26 
201292_at TOP2A 0.41 2.00 
201353_s_at BAZ2A 0.80 0.62 
201414_s_at NAP1L4 0.84 1.35 
201425_at ALDH2 1.94 1.15 
201432_at CAT 1.79 0.98 
201458_s_at BUB3 0.65 1.91 
201477_s_at RRM1 0.63 1.79 
201485_s_at RCN2 0.65 0.89 
201488_x_at KHDRBS1 0.70 1.36 
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201510_at ELF3 0.62 0.41 
201548_s_at JARID1B 0.56 0.17 
201555_at MCM3 0.65 1.60 
201584_s_at DDX39 0.57 1.40 
201594_s_at PPP4R1 0.66 1.86 
201608_s_at PWP1 0.77 1.20 
201697_s_at DNMT1 0.61 1.88 
201729_s_at KIAA0100 0.67 1.33 
201755_at MCM5 0.69 2.23 
201839_s_at TACSTD1 0.28 0.26 
201841_s_at HSPB1 0.55 0.84 
201853_s_at CDC25B 0.70 1.71 
201890_at RRM2 0.40 1.83 
201892_s_at IMPDH2 0.67 1.51 
201901_s_at YY1 0.74 1.12 
201968_s_at PGM1 1.89 1.36 
202003_s_at ACAA2 2.40 1.48 
202025_x_at ACAA1 1.91 0.90 
202029_x_at RPL38 0.76 0.96 
202041_s_at FIBP 0.83 1.53 
202094_at BIRC5 0.83 1.44 
202095_s_at BIRC5 0.49 1.90 
202153_s_at NUP62 0.78 1.35 
202187_s_at PPP2R5A 0.67 0.61 
202217_at C21orf33 1.46 1.27 
202220_at KIAA0907 0.69 0.64 
202240_at PLK1 0.79 2.04 
202246_s_at CDK4 0.61 1.30 
202261_at VPS72 0.72 1.18 
202309_at MTHFD1 2.66 1.59 
202324_s_at ACBD3 0.61 0.60 
202347_s_at UBE2K 0.77 0.82 
202372_at RAB3GAP2 0.81 0.66 
202396_at TCERG1 0.65 1.54 
202451_at GTF2H1 0.73 1.29 
202487_s_at H2AFV 0.74 1.32 
202503_s_at KIAA0101 0.44 1.54 
202556_s_at MCRS1 0.77 1.28 
202603_at NA 0.61 0.77 
202604_x_at ADAM10 0.71 0.86 
202651_at LPGAT1 0.45 0.90 
202656_s_at SERTAD2 0.75 0.75 
202679_at NPC1 0.56 0.66 
202691_at SNRPD1 0.65 1.59 
202705_at CCNB2 0.57 1.46 
202715_at CAD 0.80 1.55 
202726_at LIG1 0.72 2.31 
202758_s_at RFXANK 0.78 1.16 
202769_at CCNG2 0.66 0.31 
202779_s_at UBE2S 0.54 2.09 
202813_at TARBP1 0.63 0.62 
202846_s_at PIGC 0.64 0.74 
202852_s_at FLJ11506 0.78 1.21 
202862_at FAH 1.69 1.24 
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202870_s_at CDC20 0.51 1.69 
202935_s_at SOX9 0.33 0.87 
202954_at UBE2C 0.59 1.89 
202971_s_at DYRK2 0.76 0.49 
202984_s_at BAG5 0.83 1.08 
203046_s_at TIMELESS 0.76 1.85 
203075_at SMAD2 0.70 0.64 
203103_s_at PRPF19 0.81 1.34 
203145_at SPAG5 0.77 1.49 
203213_at CDC2 0.47 2.10 
203214_x_at CDC2 0.58 2.10 
203228_at PAFAH1B3 0.59 1.60 
203276_at LMNB1 0.76 2.86 
203318_s_at ZNF148 0.76 0.64 
203319_s_at ZNF148 0.68 0.69 
203358_s_at EZH2 0.67 3.52 
203362_s_at MAD2L1 0.65 1.86 
203429_s_at C1orf9 0.57 0.42 
203436_at RPP30 0.79 1.48 
203564_at FANCG 0.70 1.96 
203630_s_at COG5 0.72 0.86 
203639_s_at FGFR2 0.43 1.40 
203682_s_at IVD 1.46 1.55 
203692_s_at E2F3 0.79 0.86 
203696_s_at RFC2 0.74 1.47 
203711_s_at HIBCH 1.70 2.17 
203725_at GADD45A 2.12 0.54 
203732_at TRIP4 0.73 0.90 
203755_at BUB1B 0.54 1.62 
203758_at CTSO 1.86 0.35 
203764_at DLGAP5 0.55 2.12 
203790_s_at HRSP12 2.27 1.43 
203832_at SNRPF 0.68 1.29 
203856_at VRK1 0.68 1.81 
203924_at GSTA2 2.99 0.44 
203963_at CA12 0.48 0.57 
203967_at CDC6 0.58 1.86 
203968_s_at CDC6 0.59 2.24 
204023_at RFC4 0.50 2.42 
204026_s_at ZWINT 0.40 1.75 
204107_at NFYA 0.79 1.87 
204108_at NFYA 0.73 1.64 
204167_at BTD 1.44 0.45 
204170_s_at CKS2 0.51 1.20 
204252_at CDK2 0.77 2.27 
204263_s_at CPT2 1.65 1.42 
204291_at ZNF518A 0.73 1.47 
204444_at KIF11 0.70 1.94 
204510_at CDC7 0.69 2.10 
204649_at TROAP 0.82 1.26 
204705_x_at ALDOB 3.57 0.23 
204744_s_at IARS 0.69 1.25 
204753_s_at HLF 4.12 1.94 
204755_x_at HLF 3.50 2.33 
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204767_s_at FEN1 0.60 1.45 
204825_at MELK 0.66 1.99 
204867_at GCHFR 1.64 1.32 
204920_at CPS1 5.36 0.64 
204962_s_at CENPA 0.57 1.85 
205034_at CCNE2 0.64 2.03 
205042_at GNE 2.31 1.97 
205053_at PRIM1 0.63 2.11 
205141_at ANG 1.92 0.57 
205158_at RNASE4 1.71 0.66 
205167_s_at CDC25C 0.74 2.41 
205221_at HGD 3.07 0.67 
205235_s_at KIF20B 0.90 1.75 
205264_at CD3EAP 0.82 1.45 
205303_at KCNJ8 1.85 0.27 
205304_s_at KCNJ8 2.34 0.27 
205342_s_at SULT1C2 0.38 0.81 
205345_at BARD1 0.61 1.93 
205363_at BBOX1 3.53 0.08 
205364_at ACOX2 2.29 1.45 
205393_s_at CHEK1 0.74 2.48 
205394_at CHEK1 0.75 2.34 
205395_s_at MRE11A 0.78 1.74 
205436_s_at H2AFX 0.53 1.53 
205442_at MFAP3L 3.04 0.46 
205449_at SAC3D1 0.54 1.55 
205480_s_at UGP2 1.61 0.91 
205498_at GHR 2.96 0.79 
205530_at ETFDH 2.43 0.68 
205565_s_at FXN 1.35 1.37 
205614_x_at MST1 1.98 1.73 
205633_s_at ALAS1 2.13 0.56 
205650_s_at FGA 1.64 0.69 
205664_at KIN 0.74 1.51 
205690_s_at BUD31 0.73 1.40 
205768_s_at SLC27A2 2.21 0.46 
205769_at SLC27A2 2.23 0.50 
205807_s_at TUFT1 0.59 0.51 
205830_at CLGN 0.32 1.08 
205860_x_at FOLH1 2.15 0.32 
205865_at ARID3A 0.64 1.16 
205909_at POLE2 0.65 2.51 
205975_s_at HOXD1 0.70 0.48 
205999_x_at CYP3A4 4.35 0.62 
206036_s_at REL 0.76 0.63 
206052_s_at SLBP 0.72 1.40 
206074_s_at HMGA1 0.59 1.76 
206085_s_at CTH 3.18 2.15 
206102_at GINS1 0.47 1.80 
206208_at CA4 1.28 0.21 
206239_s_at SPINK1 0.13 0.41 
206262_at ADH1C 6.15 0.16 
206305_s_at C8A 3.91 1.60 
206316_s_at KNTC1 0.71 1.60 
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206363_at MAF 1.47 0.54 
206424_at CYP26A1 1.78 0.56 
206445_s_at PRMT1 0.74 2.61 
206535_at SLC2A2 2.39 1.99 
206539_s_at CYP4F12 1.72 1.78 
206571_s_at MAP4K4 0.65 1.34 
206697_s_at HP 2.52 0.83 
206734_at JRKL 0.83 0.58 
206797_at NAT2 3.39 0.31 
207081_s_at PI4KA 0.71 0.77 
207098_s_at MFN1 0.75 1.52 
207168_s_at H2AFY 0.62 0.71 
207392_x_at UGT2B15 2.91 0.08 
207414_s_at PCSK6 1.73 0.69 
207426_s_at TNFSF4 0.76 0.58 
207544_s_at ADH6 2.98 1.55 
207808_s_at PROS1 1.75 0.80 
207819_s_at ABCB4 4.97 1.98 
207842_s_at CASC3 0.77 1.16 
208079_s_at AURKA 0.54 1.98 
208113_x_at PABPC3 0.72 1.22 
208228_s_at FGFR2 0.31 1.44 
208369_s_at GCDH 1.88 1.47 
208641_s_at RAC1 0.75 0.97 
208644_at PARP1 0.71 1.34 
208660_at CS 0.75 1.14 
208678_at ATP6V1E1 0.81 0.62 
208684_at COPA 0.75 0.64 
208693_s_at GARS 0.69 1.53 
208694_at PRKDC 0.56 1.39 
208753_s_at NAP1L1 0.69 1.36 
208754_s_at NAP1L1 0.57 1.52 
208777_s_at PSMD11 0.76 1.22 
208783_s_at CD46 0.67 0.67 
208795_s_at MCM7 0.61 1.95 
208821_at SNRPB 0.57 1.46 
208855_s_at STK24 0.67 1.19 
208869_s_at GABARAPL1 1.88 0.47 
208877_at PAK2 0.71 1.71 
208882_s_at UBR5 0.61 1.54 
208926_at NEU1 0.62 0.35 
208931_s_at ILF3 0.70 3.04 
209019_s_at PINK1 1.51 0.44 
209053_s_at WHSC1 0.59 1.63 
209054_s_at WHSC1 0.76 1.40 
209171_at ITPA 0.83 1.62 
209219_at RDBP 0.64 0.86 
209220_at GPC3 0.13 0.62 
209259_s_at SMC3 0.55 1.50 
209301_at CA2 1.89 1.89 
209302_at POLR2H 0.78 1.40 
209326_at SLC35A2 0.79 0.48 
209366_x_at CYB5A 1.80 1.32 
209368_at EPHX2 2.64 1.33 
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209408_at KIF2C 0.69 2.33 
209421_at MSH2 0.62 1.90 
209460_at ABAT 2.76 0.58 
209464_at AURKB 0.70 2.48 
209484_s_at NSL1 0.75 1.08 
209642_at BUB1 0.62 2.22 
209646_x_at ALDH1B1 1.41 1.62 
209660_at TTR 2.45 0.34 
209678_s_at PRKCI 0.56 1.19 
209680_s_at KIFC1 0.76 1.50 
209699_x_at AKR1C2 1.94 0.09 
209713_s_at SLC35D1 1.43 1.19 
209735_at ABCG2 3.59 0.57 
209748_at SPAST 0.75 1.25 
209760_at KIAA0922 1.58 1.02 
209773_s_at RRM2 0.50 2.33 
209852_x_at PSME3 0.71 1.34 
209891_at SPC25 0.81 2.96 
209894_at LEPR 3.94 1.26 
209977_at PLG 2.66 2.33 
210049_at SERPINC1 2.70 2.57 
210052_s_at TPX2 0.55 1.78 
210053_at TAF5 0.78 1.42 
210059_s_at MAPK13 0.55 0.22 
210125_s_at BANF1 0.78 1.17 
210168_at C6 5.53 0.25 
210250_x_at ADSL 0.74 1.59 
210334_x_at BIRC5 0.74 2.18 
210473_s_at GPR125 1.78 1.09 
210652_s_at TTC39A 0.58 0.47 
210739_x_at SLC4A4 1.26 1.65 
210766_s_at CSE1L 0.73 1.63 
210891_s_at GTF2I 0.73 0.94 
210959_s_at SRD5A1 2.26 2.03 
211036_x_at ANAPC5 0.81 1.15 
211056_s_at SRD5A1 1.76 1.37 
211058_x_at TUBA1B 0.65 1.08 
211072_x_at TUBA1B 0.66 1.10 
211270_x_at PTBP1 0.76 1.62 
211303_x_at PSMAL 2.06 0.36 
211354_s_at LEPR 4.60 1.06 
211356_x_at LEPR 4.63 1.17 
211357_s_at ALDOB 3.52 0.33 
211401_s_at FGFR2 0.60 1.51 
211623_s_at FBL 0.64 1.98 
211682_x_at UGT2B28 2.21 0.07 
211761_s_at CACYBP 0.62 1.21 
211780_x_at DCTN1 0.83 1.20 
211814_s_at CCNE2 0.70 2.45 
211921_x_at PTMA 0.72 1.91 
211925_s_at PLCB1 0.84 2.16 
211928_at DYNC1H1 0.73 0.74 
211944_at BAT2D1 0.73 0.80 
211971_s_at LRPPRC 0.76 1.25 
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211972_x_at RPLP0 0.75 1.04 
211977_at GPR107 0.74 0.49 
212020_s_at MKI67 0.68 1.37 
212021_s_at MKI67 0.66 1.80 
212022_s_at MKI67 0.62 2.10 
212073_at CSNK2A1 0.78 1.38 
212098_at LOC151162 0.70 0.64 
212110_at SLC39A14 2.34 1.25 
212141_at MCM4 0.70 2.08 
212160_at XPOT 0.65 1.55 
212185_x_at MT2A 2.27 0.71 
212247_at NUP205 0.63 1.52 
212365_at MYO1B 1.79 0.75 
212368_at ZNF292 0.49 0.67 
212371_at FAM152A 0.66 1.48 
212375_at EP400 0.76 1.66 
212403_at UBE3B 0.82 0.71 
212432_at GRPEL1 1.34 1.27 
212459_x_at SUCLG2 1.63 1.33 
212467_at DNAJC13 0.80 0.59 
212542_s_at PHIP 0.68 0.89 
212680_x_at PPP1R14B 0.76 1.59 
212688_at PIK3CB 0.81 0.79 
212742_at RNF115 0.70 0.86 
212836_at POLD3 0.80 2.44 
212840_at UBXN7 0.72 0.85 
212899_at CDC2L6 0.54 0.73 
212964_at HIC2 0.63 0.77 
212973_at RPIA 0.70 1.29 
212983_at HRAS 0.75 1.34 
213008_at FANCI 0.64 2.00 
213043_s_at MED24 0.72 1.18 
213054_at KIAA0841 0.90 1.99 
213073_at ZFYVE26 0.76 0.50 
213088_s_at DNAJC9 0.62 2.24 
213092_x_at DNAJC9 0.63 2.75 
213101_s_at ACTR3 0.75 1.22 
213119_at SLC36A1 0.87 0.62 
213165_at CEP350 0.65 0.54 
213179_at RQCD1 0.78 1.30 
213222_at PLCB1 0.37 1.62 
213226_at CCNA2 0.67 2.73 
213241_at PLXNC1 0.60 0.46 
213279_at DHRS1 2.00 1.40 
213374_x_at HIBCH 1.70 1.93 
213380_x_at MSTP9 2.05 2.08 
213390_at ZC3H4 0.80 0.90 
213397_x_at ANG 1.58 0.61 
213405_at RAB22A 0.82 1.14 
213485_s_at ABCC10 0.64 0.59 
213523_at CCNE1 0.79 1.65 
213599_at OIP5 0.60 1.40 
213626_at CBR4 1.79 1.81 
213632_at DHODH 1.72 1.47 
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213646_x_at TUBA1B 0.68 1.10 
213671_s_at MARS 0.64 1.44 
213762_x_at RBMX 0.76 1.54 
213911_s_at H2AFZ 0.64 1.32 
213947_s_at NUP210 0.71 1.89 
213977_s_at CIZ1 0.82 1.02 
214004_s_at VGLL4 0.75 0.66 
214086_s_at PARP2 0.81 1.38 
214142_at ZG16 2.16 1.86 
214164_x_at CA12 0.45 0.75 
214198_s_at DGCR2 0.75 0.69 
214261_s_at ADH6 2.87 2.58 
214274_s_at ACAA1 2.52 0.79 
214306_at OPA1 0.79 2.37 
214308_s_at HGD 2.56 0.71 
214420_s_at CYP2C9 1.58 0.51 
214421_x_at CYP2C9 3.27 0.24 
214440_at NAT1 1.63 0.50 
214681_at GK 1.34 0.99 
214710_s_at CCNB1 0.56 1.48 
214719_at SLC46A3 2.90 0.24 
214734_at EXPH5 2.09 0.21 
214743_at CUX1 0.65 0.89 
214764_at RRP15 0.78 2.59 
214835_s_at SUCLG2 1.57 1.25 
214943_s_at RBM34 0.79 1.14 
215017_s_at FNBP1L 0.64 0.70 
215363_x_at FOLH1 2.27 0.33 
215380_s_at GGCT 0.74 1.82 
215772_x_at SUCLG2 1.56 1.33 
215773_x_at PARP2 0.84 1.42 
215867_x_at CA12 0.47 0.70 
216194_s_at TBCB 0.74 1.52 
216228_s_at WDHD1 0.92 1.94 
216237_s_at MCM5 0.59 2.18 
216271_x_at SYDE1 1.13 1.32 
216320_x_at MST1 2.05 1.76 
216381_x_at AKR7A3 2.88 1.36 
216559_x_at LOC100128836 0.82 1.67 
216661_x_at CYP2C9 3.14 0.38 
216687_x_at UGT2B15 2.70 0.24 
216952_s_at LMNB2 0.79 1.42 
217127_at CTH 3.82 1.93 
217238_s_at ALDOB 4.45 0.28 
217487_x_at FOLH1 1.73 0.35 
217564_s_at CPS1 6.53 0.67 
217640_x_at C18orf24 0.88 1.76 
217774_s_at HSPC152 0.78 0.98 
217815_at SUPT16H 0.73 1.41 
217829_s_at USP39 0.77 1.34 
217946_s_at SAE1 0.66 1.77 
217950_at NOSIP 0.84 1.40 
217973_at DCXR 3.56 1.24 
218021_at DHRS4 1.44 1.32 
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218039_at NUSAP1 0.47 1.65 
218045_x_at PTMS 1.39 1.77 
218107_at WDR26 0.63 0.55 
218115_at ASF1B 0.80 2.91 
218125_s_at CCDC25 1.42 1.92 
218227_at NUBP2 1.18 1.23 
218308_at TACC3 0.66 1.43 
218329_at PRDM4 0.83 0.92 
218336_at PFDN2 0.73 1.05 
218349_s_at ZWILCH 0.59 1.87 
218355_at KIF4A 0.61 1.84 
218367_x_at USP21 0.77 1.19 
218399_s_at CDCA4 0.72 2.49 
218510_x_at FAM134B 2.27 0.20 
218532_s_at FAM134B 2.16 0.15 
218542_at CEP55 0.67 2.02 
218544_s_at RCL1 1.65 1.53 
218586_at C20orf20 0.71 1.71 
218593_at RBM28 0.72 1.50 
218594_at HEATR1 0.66 1.32 
218618_s_at FNDC3B 0.55 0.75 
218624_s_at MGC2752 0.86 2.30 
218662_s_at NCAPG 0.62 2.49 
218663_at NCAPG 0.71 2.95 
218670_at PUS1 0.77 1.68 
218699_at RAB7L1 0.61 0.42 
218700_s_at RAB7L1 0.59 0.39 
218726_at HJURP 0.72 1.81 
218728_s_at DOCK5 0.45 0.59 
218734_at NAT11 0.76 1.51 
218741_at CENPM 0.69 1.83 
218750_at JOSD3 0.70 1.47 
218755_at KIF20A 0.66 2.46 
218782_s_at ATAD2 0.47 2.26 
218788_s_at SMYD3 0.53 1.68 
218789_s_at C11orf71 1.40 0.36 
218853_s_at MOSPD1 0.62 0.56 
218869_at MLYCD 1.82 1.00 
218883_s_at MLF1IP 0.55 2.53 
218924_s_at CTBS 1.47 0.59 
218973_at EFTUD1 0.83 1.06 
218984_at PUS7 0.67 1.91 
219004_s_at C21orf45 0.74 1.62 
219060_at C8orf32 0.66 2.06 
219076_s_at PXMP2 1.76 1.82 
219238_at PIGV 1.37 0.83 
219281_at MSRA 2.23 1.45 
219306_at KIF15 0.76 2.45 
219481_at TTC13 0.64 0.74 
219512_at DSN1 0.85 2.13 
219526_at C14orf169 0.84 1.10 
219588_s_at NCAPG2 0.75 2.82 
219787_s_at ECT2 0.54 1.99 
219803_at ANGPTL3 2.41 0.94 
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219848_s_at ZNF432 0.69 0.48 
219862_s_at NARF 0.72 1.42 
219874_at SLC12A8 0.69 0.38 
219954_s_at GBA3 4.10 1.00 
219997_s_at COPS7B 0.85 1.80 
220017_x_at CYP2C9 3.55 0.22 
220060_s_at C12orf48 0.86 2.14 
220085_at HELLS 0.56 3.10 
220108_at GNA14 1.33 0.60 
220239_at KLHL7 0.63 2.00 
220432_s_at CYP39A1 2.94 0.42 
220651_s_at MCM10 0.74 3.41 
220668_s_at DNMT3B 0.78 1.52 
220751_s_at C5orf4 1.67 0.56 
220964_s_at RAB1B 0.86 0.86 
221039_s_at DDEF1 0.74 1.79 
221142_s_at PECR 1.52 2.39 
221486_at ENSA 0.70 0.72 
221505_at ANP32E 0.62 1.60 
221520_s_at CDCA8 0.76 2.03 
221522_at ANKRD27 0.57 0.90 
221538_s_at PLXNA1 0.65 0.63 
221580_s_at JOSD3 0.59 1.36 
221637_s_at C11orf48 0.78 1.06 
221677_s_at DONSON 0.70 1.86 
221685_s_at CCDC99 0.79 2.16 
221708_s_at UNC45A 0.87 0.78 
221780_s_at DDX27 0.78 1.16 
221858_at TBC1D12 0.81 1.93 
221893_s_at ADCK2 0.81 0.92 
222036_s_at MCM4 0.55 1.90 
222037_at MCM4 0.58 2.94 
222039_at KIF18B 0.72 1.51 
222148_s_at RHOT1 0.76 0.98 
222155_s_at GPR172A 0.67 1.29 
222244_s_at TUG1 0.71 0.54 
33322_i_at SFN 0.39 0.76 
33323_r_at SFN 0.37 0.68 
33494_at ETFDH 2.34 0.64 
37943_at ZFYVE26 0.86 0.61 
41220_at SEPT9 0.74 1.30 
48031_r_at C5orf4 1.35 0.69 
49077_at PPME1 0.85 0.87 
57539_at LIME1 2.14 1.29 
 
Discriminative probe sets of 1b from 1a and 2b (n=164) 
1a,2b/1b Probe set Gene symbol IMM/SEN 
1.31 177_at PLD1 0.67 
0.65 200770_s_at LAMC1 0.68 
0.64 200783_s_at STMN1 1.62 
0.70 201291_s_at TOP2A 2.26 
0.58 201292_at TOP2A 2.00 
0.73 201637_s_at FXR1 1.64 
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1.59 201945_at FURIN 1.25 
0.59 201956_s_at GNPAT 1.04 
2.26 201983_s_at EGFR 0.73 
0.83 202240_at PLK1 2.04 
0.71 202338_at TK1 1.58 
1.70 202464_s_at PFKFB3 1.81 
0.54 202503_s_at KIAA0101 1.54 
0.66 202705_at CCNB2 1.46 
0.77 202715_at CAD 1.55 
0.63 202926_at NAG 0.92 
0.72 202954_at UBE2C 1.89 
0.62 203213_at CDC2 2.10 
0.67 203214_x_at CDC2 2.10 
0.80 203276_at LMNB1 2.86 
0.71 203362_s_at MAD2L1 1.86 
0.65 203418_at CCNA2 2.68 
1.32 203455_s_at SAT1 0.61 
0.77 203564_at FANCG 1.96 
2.32 203615_x_at SULT1A1 1.41 
0.61 203636_at MID1 0.45 
0.50 203637_s_at MID1 0.41 
0.69 203714_s_at TBCE 1.02 
0.27 203726_s_at LAMA3 0.10 
0.68 203755_at BUB1B 1.62 
0.69 203764_at DLGAP5 2.12 
1.96 203790_s_at HRSP12 1.43 
9.86 203914_x_at HPGD 0.62 
0.54 204026_s_at ZWINT 1.75 
0.77 204126_s_at CDC45L 2.74 
0.71 204127_at RFC3 1.88 
0.81 204444_at KIF11 1.94 
0.28 204602_at DKK1 4.15 
0.84 204603_at EXO1 2.54 
2.61 204646_at DPYD 2.00 
2.52 204705_x_at ALDOB 0.23 
0.45 204753_s_at HLF 1.94 
0.49 204755_x_at HLF 2.33 
0.83 204795_at PRR3 1.45 
0.72 204825_at MELK 1.99 
2.72 204836_at GLDC 1.65 
2.34 204846_at CP 0.99 
1.47 204934_s_at HPN 0.32 
3.83 204998_s_at ATF5 1.53 
3.61 204999_s_at ATF5 1.96 
2.20 205040_at ORM1 2.03 
0.80 205046_at CENPE 2.54 
0.66 205053_at PRIM1 2.11 
0.75 205167_s_at CDC25C 2.41 
1.34 205203_at PLD1 0.73 
1.34 205227_at IL1RAP 2.09 
4.43 205363_at BBOX1 0.08 
0.62 205436_s_at H2AFX 1.53 
1.68 205480_s_at UGP2 0.91 
3.60 205498_at GHR 0.79 
 138 
1.40 205614_x_at MST1 1.73 
2.47 205768_s_at SLC27A2 0.46 
2.52 205769_at SLC27A2 0.50 
0.55 205780_at BIK 0.31 
0.04 205815_at REG3A 0.39 
0.43 205862_at GREB1 1.96 
6.79 205943_at TDO2 0.07 
0.51 206110_at HIST1H3H 0.23 
1.90 206396_at SLC1A1 1.25 
0.82 206441_s_at COMMD4 1.06 
10.49 206643_at HAL 0.18 
0.84 207046_at HIST2H4A 0.56 
1.96 207122_x_at SULT1A2 1.27 
0.72 207156_at HIST1H2AG 0.31 
1.88 207254_at SLC15A1 0.41 
2.06 207574_s_at GADD45B 0.74 
1.28 207667_s_at MAP2K3 1.29 
0.76 207842_s_at CASC3 1.16 
2.90 208228_s_at FGFR2 1.44 
0.72 208583_x_at HIST1H2AJ 0.60 
0.47 208955_at DUT 1.84 
0.71 209053_s_at WHSC1 1.63 
1.60 209304_x_at GADD45B 0.76 
0.81 209680_s_at KIFC1 1.50 
1.42 209760_at KIAA0922 1.02 
0.49 209932_s_at DUT 1.49 
1.88 209980_s_at SHMT1 2.95 
0.61 210052_s_at TPX2 1.78 
1.90 210168_at C6 0.25 
1.28 210177_at TRIM15 0.50 
0.62 210387_at HIST1H2BG 0.06 
1.97 210473_s_at GPR125 1.09 
4.59 210587_at INHBE 2.40 
0.69 210766_s_at CSE1L 1.63 
1.25 210885_s_at TRIM15 0.81 
3.08 211026_s_at MGLL 0.40 
0.72 211165_x_at EPHB2 0.63 
2.67 211357_s_at ALDOB 0.33 
2.12 211385_x_at SULT1A2 1.36 
11.25 211548_s_at HPGD 0.62 
0.75 212020_s_at MKI67 1.37 
0.73 212021_s_at MKI67 1.80 
0.69 212022_s_at MKI67 2.10 
0.74 212115_at HN1L 1.01 
0.77 212145_at MRPS27 1.92 
0.80 212405_s_at KIAA0859 0.83 
0.43 212554_at CAP2 0.93 
0.76 212892_at ZNF282 1.50 
0.45 212922_s_at SMYD2 1.20 
0.79 213008_at FANCI 2.00 
0.74 213186_at DZIP3 1.08 
0.71 213226_at CCNA2 2.73 
1.37 213300_at ATG2A 0.65 
0.63 213301_x_at TRIM24 1.20 
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0.80 213454_at CORT 2.52 
0.76 213599_at OIP5 1.40 
1.73 213632_at DHODH 1.47 
3.97 213664_at SLC1A1 1.13 
1.76 213695_at PON3 0.30 
0.87 214197_s_at SETDB1 1.24 
0.37 214290_s_at HIST2H2AA3 0.17 
0.43 214469_at HIST1H2AE 0.10 
0.70 214472_at HIST1H3D 0.26 
0.56 214710_s_at CCNB1 1.48 
0.59 215177_s_at ITGA6 1.79 
0.78 215195_at PRKCA 0.52 
2.35 215299_x_at SULT1A1 1.33 
1.26 215499_at MAP2K3 1.14 
1.82 215723_s_at PLD1 0.66 
0.74 215779_s_at HIST1H2BG 0.13 
2.98 217238_s_at ALDOB 0.28 
4.69 217521_at NA 0.31 
0.49 217678_at SLC7A11 1.38 
3.04 217739_s_at NAMPT 0.91 
0.75 217774_s_at HSPC152 0.98 
1.39 218045_x_at PTMS 1.77 
0.64 218257_s_at UGCGL1 1.38 
0.39 218280_x_at HIST2H2AA3 0.17 
0.62 218355_at KIF4A 1.84 
0.87 218399_s_at CDCA4 2.49 
0.71 218594_at HEATR1 1.32 
0.78 218619_s_at SUV39H1 1.13 
0.49 218638_s_at SPON2 0.30 
0.60 218662_s_at NCAPG 2.49 
0.74 218663_at NCAPG 2.95 
0.61 218755_at KIF20A 2.46 
1.68 218931_at RAB17 0.35 
0.69 218979_at RMI1 1.62 
1.51 219313_at GRAMD1C 0.44 
0.65 219345_at BOLA1 0.77 
6.34 219410_at TMEM45A 0.58 
1.56 219450_at C4orf19 0.56 
0.76 219502_at NEIL3 3.27 
3.06 219954_s_at GBA3 1.00 
0.85 220060_s_at C12orf48 2.14 
1.75 220528_at VNN3 0.34 
0.86 220668_s_at DNMT3B 1.52 
0.85 221064_s_at UNKL 1.43 
1.38 221614_s_at RPH3AL 2.42 
0.81 222039_at KIF18B 1.51 
0.59 33323_r_at SFN 0.68 
0.73 35820_at GM2A 0.41 
2.38 43427_at ACACB 1.32 
2.14 57539_at LIME1 1.29 
 
 
Discriminative probe sets of 2b from 1a (n=70) 
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1a/2b Probe set 
Gene 
symbol IMM/SEN 
0.70 200916_at TAGLN2 1.06 
0.53 200998_s_at CKAP4 0.95 
0.37 201266_at TXNRD1 0.65 
0.75 201353_s_at BAZ2A 0.62 
0.56 201377_at UBAP2L 0.91 
1.42 201432_at CAT 0.98 
1.48 201968_s_at PGM1 1.36 
1.98 202025_x_at ACAA1 0.90 
0.57 202220_at KIAA0907 0.64 
0.66 202244_at PSMB4 1.07 
0.72 202261_at VPS72 1.18 
2.10 202309_at MTHFD1 1.59 
0.68 202396_at TCERG1 1.54 
0.57 202779_s_at UBE2S 2.09 
0.73 202809_s_at INTS3 0.84 
0.62 202846_s_at PIGC 0.74 
0.76 202971_s_at DYRK2 0.49 
0.46 203429_s_at C1orf9 0.42 
0.32 204105_s_at NRCAM 0.93 
0.58 204744_s_at IARS 1.25 
2.39 204753_s_at HLF 1.94 
2.20 204755_x_at HLF 2.33 
1.72 204920_at CPS1 0.64 
1.83 205019_s_at VIPR1 0.25 
0.53 205807_s_at TUFT1 0.51 
0.25 205830_at CLGN 1.08 
0.70 206052_s_at SLBP 1.40 
0.02 206239_s_at SPINK1 0.41 
1.79 206535_at SLC2A2 1.99 
1.96 208369_s_at GCDH 1.47 
0.65 208684_at COPA 0.64 
0.65 208693_s_at GARS 1.53 
0.41 208700_s_at TKT 2.25 
0.62 209053_s_at WHSC1 1.63 
0.77 209054_s_at WHSC1 1.40 
0.05 209220_at GPC3 0.62 
0.75 209326_at SLC35A2 0.48 
0.61 209678_s_at PRKCI 1.19 
0.21 210519_s_at NQO1 1.29 
0.73 210927_x_at JTB 0.92 
0.64 211761_s_at CACYBP 1.21 
0.68 211944_at BAT2D1 0.80 
0.53 212160_at XPOT 1.55 
0.66 212296_at PSMD14 1.56 
0.67 212334_at GNS 0.58 
0.70 212556_at SCRIB 1.38 
0.63 213165_at CEP350 0.54 
0.24 213194_at ROBO1 1.15 
0.25 213222_at PLCB1 1.62 
0.72 213302_at PFAS 1.58 
0.62 213671_s_at MARS 1.44 
0.76 213947_s_at NUP210 1.89 
1.55 213988_s_at SAT1 0.67 
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0.78 214061_at WDR67 2.65 
2.77 214142_at ZG16 1.86 
2.38 214274_s_at ACAA1 0.79 
2.04 216381_x_at AKR7A3 1.36 
0.72 217678_at SLC7A11 1.38 
0.65 218336_at PFDN2 1.05 
0.57 218361_at GOLPH3L 0.62 
1.85 218544_s_at RCL1 1.53 
0.75 218586_at C20orf20 1.71 
0.61 219060_at C8orf32 2.06 
0.64 219862_s_at NARF 1.42 
1.64 220108_at GNA14 0.60 
7.87 220432_s_at CYP39A1 0.42 
0.63 221486_at ENSA 0.72 
0.67 221884_at EVI1 0.92 
0.78 41220_at SEPT9 1.30 
3.29 57539_at LIME1 1.29 
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(2008), doi:10.1016/j.canlet.2008.10.048Cellular senescence is a process leading to terminal growth arrest with characteristic mor-
phological features. This process is mediated by telomere-dependent, oncogene-induced
and ROS-induced pathways, but persistent DNA damage is the most common cause. Senes-
cence arrest is mediated by p16INK4a- and p21Cip1-dependent pathways both leading to ret-
inoblastoma protein (pRb) activation. p53 plays a relay role between DNA damage sensing
and p21Cip1 activation. pRb arrests the cell cycle by recruiting proliferation genes to facul-
tative heterochromatin for permanent silencing. Replicative senescence that occurs in
hepatocytes in culture and in liver cirrhosis is associated with lack of telomerase activity
and results in telomere shortening. Hepatocellular carcinoma (HCC) cells display inactivat-
ing mutations of p53 and epigenetic silencing of p16INK4a. Moreover, they re-express telo-
merase reverse transcriptase required for telomere maintenance. Thus, senescence bypass
and cellular immortality is likely to contribute signiﬁcantly to HCC development. Onco-
gene-induced senescence in premalignant lesions and reversible immortality of cancer
cells including HCC offer new potentials for tumor prevention and treatment.
 2008 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Senescence is an evolutionary term meaning ‘‘the pro-
cess of becoming old”; the phase from full maturity to
death characterized by accumulation of metabolic prod-
ucts and decreased probability of reproduction or survival
[1]. The term ‘‘cellular senescence” was initially used by
Hayﬂick and colleagues to deﬁne cells that ceased to divide
in culture [2]. Today, cellular senescence is recognized as a
response of proliferating somatic cells to stress and dam-
age from exogenous and endogenous sources. It is charac-
terized by permanent cell cycle arrest. Senescent cells also
display altered morphology and an altered pattern of gene
expression, and can be recognized by the presence ofand Ltd. All rights reserved.
herche INSERM-Uni-
iot, Grenoble 38000,
6 54 94 54.
urk).
turk et al., Senescencesenescence markers such as senescence-associated
b-galactosidase (SABG), p16INK4A, senescence-associated
DNA-damage foci and senescence-associated heterochro-
matin foci (for a review see Ref. [3]). This cellular response
has both beneﬁcial (anti-cancer) and probably deleterious
(such as tissue aging) effects on the organism. Most of
our knowledge of cellular senescence is derived from
in vitro studies performed with ﬁbroblasts, and some epi-
thelial cells such as mammary epithelial cells. Animal
models are increasingly being used to study cellular senes-
cence in vivo. Telomerase-deﬁcient mouse models lacking
RNA subunit (TERC/) have been very useful in demon-
strating the critical role of telomeres in organ aging and tu-
mor susceptibility [4]. Other mouse models including
tumor suppressor gene-deﬁcient and oncogene-expressing
mice were also used extensively.
Compared to other tissues and cancer models, the role
of senescence in liver cells and its implications in hepato-
cellular carcinogenesis have been less explored. One ofand immortality in hepatocellular carcinoma, Cancer Lett.
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As hepatocytes can not divide in cell culture, the study of
their replicative senescence mechanisms is not easy. Nev-
ertheless, these cells are able to quit their quiescent state
in vivo and proliferate massively in response to partial
hepatectomy or liver injury [5]. This capacity can be ex-
plored to study in vivo senescence of hepatocytes using ro-
dent models. Studies with clinical samples indicate that
hepatocyte senescence occurs in vivo in patients with
chronic hepatitis, cirrhosis and HCC [6–8]. In contrast to
the paucity of studies directly addressing cellular senes-
cence, the critical role of telomere shortening (as a feature
associated with replicative senescence) in cirrhosis and
HCC development is well established [9]. Telomeres in nor-
mal liver show a consistent but slow shortening during
aging. In contrast, hepatocyte DNA telomere shortening is
accelerated in patients with chronic liver disease with
shortest telomeres described in cirrhotic liver and HCC.
Telomerase-deﬁcient mice have also been used elegantly
to demonstrate the critical roles of telomerase and telo-
meres in liver regeneration and experimentally induced
cirrhosis [10,11]. A major accomplishment in recent years
was the demonstration of critical role played by senes-
cence for the clearance of ras-induced murine liver carci-
nomas following p53 restoration [12].
Despite a relatively important progress, the mecha-
nisms of hepatocellular senescence and the role of cellular
immortality in HCC remain ill-known issues. As one of the
rare tissues with ample clinical data on senescence-related
aberrations, liver may serve as an excellent model to fur-
ther explore the relevance of cellular senescence in human
biology. Moreover, a better understanding of senescence
and immortality in hepatic tissues may help to develop
new preventive and therapeutic approaches for severe li-
ver diseases such as cirrhosis and HCC. Here we will review
recent progress on senescence and immortality mecha-
nisms with a speciﬁc emphasis on hepatocellular
carcinogenesis.2. Senescence pathways
Cellular senescence has long been considered as a
mechanism that limits the number of cell divisions (or
population doublings) in response to progressive telomere
shortening. Most human somatic cells are telomerase-deﬁ-
cient because of the repression of telomerase reverse
transcriptase (TERT) expression. Therefore, proliferating
somatic cells undergo progressive telomere DNA erosion
as a function of their number of cell divisions. This form
of senescence is now called as replicative or telomere-
dependent senescence (Fig. 1).
Human chromosome telomere ends are composed of
TTAGGG repeats (5–20 kb) in a DNA-protein complex
formed by six telomere-speciﬁc proteins, called ‘‘shelterin”
[13]. Telomeric DNA has a structure called ‘‘t-loop” which
is formed as a result of invasion of the single stranded G-
rich sequence into the double-stranded telomeric tract.
Since the 1930s, it has been known that telomeres, with
telomere-binding proteins, prevent genomic instability
and the loss of essential genetic information by ‘‘capping”Please cite this article in press as: M. Ozturk et al., Senescence
(2008), doi:10.1016/j.canlet.2008.10.048chromosome ends. They are also indispensable for proper
recombination and chromosomal segregation during cell
division. Telomeres become shorter with every cell divi-
sion in somatic cells, because of replication complex’s
inability to copy the ends of linear DNA, which also makes
them a ‘‘cell cycle counter” for the cell [14]. Telomeres are
added to the end of chromosomes with a complex contain-
ing the RNA template TERC and the reverse transcriptase
TERT [15]. Most somatic cells lack telomerase activity be-
cause the expression of TERT is repressed, in contrast to
TERC expression. The lack of sufﬁcient TERT expression in
somatic cells is the main cause of telomere shortening dur-
ing cell replication. This telomerase activity also helps to
maintain telomere integrity by telomere capping [15].
The loss of telomeres has long been considered to be the
critical signal for senescence induction. It is now well
known that telomere-dependent senescence is induced
by a change in the protected status of shortened telomeres,
whereby the loss of telomere DNA contributes to this
change [16]. The loss of telomere protection or any other
cause of telomere dysfunction results in inappropriate
chromosomal end-to-end fusions through non-homolo-
gous end joining or homologous recombination DNA repair
pathways [17]. These DNA repair pathways are used prin-
cipally to repair double-strand DNA breaks (DSBs). Thus, it
is highly likely that the open-ended telomere DNA is
sensed as a DSB by the cell machinery when telomere
structure becomes dysfunctional. Accordingly, dysfunc-
tional telomeres elicit a potent DSB type DNA damage re-
sponse by recruiting phosphorylated H2AX, 53BP1, NBS1
and MDC1 [18].
Telomere-dependent senescence is not the only form of
senescence. At least two other forms of telomere-indepen-
dent senescence are presently known: (1) oncogene-in-
duced senescence; and (2) reactive oxygen species (ROS)-
induced senescence (Fig. 1).
Oncogene-induced senescence had initially been identi-
ﬁed as a response to expression of Ras oncogene in normal
cells ([19], for a recent review see [20]). The expression of
oncogenic Ras in primary human or rodent cells results in
permanent G1 arrest. The arrest was accompanied by accu-
mulation of p53 and p16INK4a, and was phenotypically
indistinguishable from cellular senescence. This landmark
observation suggested that the onset of cellular senescence
does not simply reﬂect the accumulation of cell divisions,
but can be prematurely activated in response to an onco-
genic stimulus [19]. In 10 years following this important
discovery, telomere-independent forms of senescence have
become a new focus of extensive research leading to the
recognition of senescence as a common form of stress re-
sponse. Moreover, oncogene-induced senescence is now
recognized as a novel mechanism contributing to the ces-
sation of growth of premalignant or benign neoplasms to
prevent malignant cancer development [21]. In addition
to Ras, other oncogenes including Raf, Mos, Mek, Myc
and Cyclin E also induce senescence [20]. Conversely, the
loss of PTEN tumor suppressor gene also leads to senes-
cence [22]. Similar to telomere-dependent senescence,
oncogene-induced senescence is also primarily a DNA
damage response (Fig. 1). Experimental inactivation of
DNA damage response abrogates Ras-induced senescenceand immortality in hepatocellular carcinoma, Cancer Lett.
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Fig. 1. DNA damage and p53 activation play a central role in different senescence pathways. DNA damage (often in the form of double-strand breaks)
activate upstream kinases (ATM and ATR) leading to p53 phosphorylation by CHK1 and CHK2 kinases. Phosphoryated p53 is released from MDM, and
stabilized in order to induce senescence arrest or apoptosis (not shown here).
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and oncogene-induced senescence are established follow-
ing DNA hyper-replication immediately after oncogene
expression. Senescent cells arrest with partly replicated
DNA, where DNA replication origins have ﬁred multiple
times, prematurely terminated DNA replication forks and
DNA double-strand breaks are present [23,24].
ROS-induced senescence, the other telomere-indepen-
dent senescence pathway is gaining importance (for a re-
cent review see Ref. [25]). Mitochondria are the major
intracellular sources of ROS which are mainly generated
at the respiratory chain. Therefore, ROS have been sus-
pected for many years as cellular metabolites involved in
organismal aging [26]. ROS are also generated in the cyto-
plasm by the NOX family of enzymes [27]. Experimental
induction of ROS accumulation in cells (for example by
mild H2O2 treatment or glutathione depletion) induces
senescence-like growth arrest in different cell types,
whereas anti-oxidant treatment can inhibit senescence
[25]. More importantly, ROS have been identiﬁed as critical
mediators of both telomere-dependent and oncogene-in-
duced senescence. Telomere-dependent senescence arrestPlease cite this article in press as: M. Ozturk et al., Senescence
(2008), doi:10.1016/j.canlet.2008.10.048is accelerated in cells grown under high O2 conditions. In-
versely, cells grown under low O2 conditions display in-
creased lifespan ([28], see Ref. [25]). ROS also play a
critical role in Ras-induced senescence [29,30].
Currently, mechanisms of ROS-induced senescence are
not fully understood. It is generally accepted that oxidative
stress and ROS eventually cause DNA damage, whereby
DNA damage response may contribute to senescence
induction. The relationship between mitochondrial dys-
function, ROS, DNA damage and telomere-dependent
senescence has recently been demonstrated [31]. However,
ROS may also induce modiﬁcations in the cellular signaling
pathways resulting in senescence arrest. For example, ROS
induce senescence in hematopoietic stem cells by activat-
ing p38 MAPK [32].
Whether induced by telomere dysfunction, DNA repli-
cation stress following oncogene activation, or ROS accu-
mulation, DNA damage is one of the common steps in
the generation of senescence arrest via p53 activation
(Fig. 1). Upstream checkpoint kinases, such as ATM or
ATR are activated in response to DNA damage in the form
of double-stand breaks. These kinases phosphorylateand immortality in hepatocellular carcinoma, Cancer Lett.
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phosphorylate p53. Phosphorylation of p53 results in its
activation by the displacement of the MDM2 protein. Crit-
ical involvement of this p53 activating pathway has been
reported for both telomere-dependent [33], and onco-
gene-induced senescence [34].
Other mechanisms of senescence that are apparently
not driven by DNA damage should also be discussed here.
Of particular interest is the INK4 locus encoding two inhib-
itors of cyclin-dependent kinases (p16INK4a, p15INK4b), and
ARF, a p53 regulatory protein (for a review see Ref. [35]).
p16INK4a and p15INK4b connect some senescent initiating
signals to the retinoblastoma (Rb) pathway, independent
of p53 activation. These proteins are easily activated in cell
culture and induce senescence arrest. Cells that escape
senescence often display inactivation of p16INK4a, and
sometimes p15INKb and ARF either by homozygous deletion
or by shutting-down gene expression. A prominent role for
p16INK4a in senescence and tumor suppression in humans
has emerged, despite some confusion due to the fact that
a relatively small DNA segment encodes the 3 proteins of
the INK4 locus. p16INK4a is activated during telomere-
dependent and oncogene-induced senescence [19,36].
Moreover, its expression is induced in aging tissues [37].
The mechanisms of regulation of p16INK4a expression are
not well known. Although individual components of INK4
locus can respond independently to positively – (for exam-
ple to Ras) or negatively – (for example c-Myc) acting sig-
nals, the entire INK4 locus might be coordinately regulated
by epigenetic mechanisms (reviewed in Ref. [35]).
A very recent addition to the list of senescence mecha-
nisms is to be qualiﬁed as ‘‘senescence induced by secreted
proteins”. It was reported many years ago that TGF-b is a
mediator of oncogene-induced senescence [38]. This
mechanism of induction is of particular interest, because
it suggests that not only intrinsic cellular factors, but also
extracellular or secreted proteins can induce senescence.
Recent discovery of several other secreted proteins, includ-
ing IGFBP7 and IL6 as autocrine/paracrine mediators of
oncogene-induced senescence arrest, provide strong sup-
port for an extracellularly induced form of senescence
[39–41]. This new form of senescence regulation is remi-
niscent of the so called active apoptosis induction by death
ligands. Thus, an active form of cellular senescence in-
duced by ‘‘aging ligands” could be a major physiological
regulator of tissue/organism aging.
3. Cyclin-dependent inhibitors as commonmediators of
senescence arrest
We have already stated that senescence and apoptosis
share interesting similarities. Another similarity between
these cellular processes is the convergence of different
pathways in a common place to induce the same cell fate,
independent of the initial signal. Similarly to caspase acti-
vation, prior to apoptosis induction by different stimuli,
most if not all senescence pathways result in the activation
of cyclin-dependent kinase inhibitors (CDKIs) in order to
induce permanent cell cycle arrest. Senescent cells accu-
mulate at G1 phase of the cell cycle due to an inability toPlease cite this article in press as: M. Ozturk et al., Senescence
(2008), doi:10.1016/j.canlet.2008.10.048enter into S phase in order to initiate DNA synthesis. The
transition of proliferating cells from G1 to S phase requires
the release of E2F factors from their inhibitory partner ret-
inoblastoma protein (pRb) following phosphorylation by
cyclin-dependent kinases (CDKs), in particular by CDK4/
CDK6 and CDK2 at this stage of the cycle [35]. The senes-
cence arrest is mediated by inhibition of pRb phosphoryla-
tion by CDK4 and CDK2. The activities of these enzymes are
controlled by different mechanisms, but the major proteins
involved in the control of senescence arrest are CDKIs. Al-
most all known CDKIs have been reported to be implicated
in senescence arrest, but three of them are best character-
ized: p16INK4a and p15INK4b which inhibit CDK4/CDK6, and
p21Cip1 which inhibits CDK2 (Fig. 2).
p21Cip1 is one of the main targets of p53 for the induc-
tion of cell cycle arrest following DNA damage [42]. Path-
ways that generate DNA damage response and p53
activation use p21Cip1 as a major mediator of cellular
senescence to control pRb protein [43]. Exceptionally,
p21Cip1 can be activated by p53-independent pathways to
induce senescence [44].
The Rb protein plays two important and complemen-
tary roles that are necessary to initiate and to permanently
maintain the cell cycle arrest in senescent cells. pRb pro-
teins ﬁrstly contribute to the exit from the cell cycle by
arresting cells at G1 phase, as expected [45]. In senescent
cells, this exit is complemented with a dramatic remodel-
ing of chromatin through the formation of domains of fac-
ultative heterochromatin called SAHF [46–48]. SAHF
contain modiﬁcations and associated proteins characteris-
tic of transcriptionally silent heterochromatin. Prolifera-
tion-promoting genes, such as E2F target genes are
recruited into SAHF in a pRb protein-dependent manner.
This recruitment is believed to contribute to irreversible
silencing of these proliferation-promoting genes [49].
4. Senescence of hepatocytes and chronic liver disease
Hepatocytes in the adult liver are quiescent cells, they
are renewed slowly, approximately once a year, as esti-
mated by telomere loss which is 50–120 bp per year in
healthy individuals [50,51]. However, the liver has an ex-
tremely powerful regenerative capacity, as demonstrated
experimentally in rodents, and as observed in patients
with chronic liver diseases [5]. This regenerative capacity
is due mostly to the ability of mature hepatocytes to prolif-
erate in response to a diminution of total liver mass either
experimentally, or following exposure to viral and non vir-
al hepatotoxic agents. In addition, the adult liver seems to
harbor hepatocyte-progenitor cells (<0.10% of total hepato-
cyte mass) that are able to restore liver hepatocyte popula-
tions [52]. However, hepatocytes, like any other somatic
cells, do not have unlimited replicative capacity, due to
the lack of telomerase activity that is needed to avoid telo-
mere shortening during successive cell divisions. This is
best exempliﬁed by decreased hepatocyte proliferation in
liver cirrhosis stage of chronic liver diseases [53], providing
in vivo evidence for the exhaustion of hepatocyte prolifer-
ation capacity. Senescence mechanisms in hepatocytes and
in liver tissue are not well known. However, a limitedand immortality in hepatocellular carcinoma, Cancer Lett.
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numerous descriptive in vivo studies in liver tissue provide
sufﬁcient evidence that hepatocytes can undergo senes-
cence type changes.
In vitro senescence in hepatocytes: as stated earlier,
limited proliferative capacity of somatic cells is controlled
by replicative senescence. The experimental study of repli-
cative senescence is done traditionally by serial culture of
primary cells. Initially observed in ﬁbroblasts, this phe-
nomenon has also been well understood in some epithelial
cells, mammary epithelial cells in particular [54]. On the
other hand, our knowledge of hepatocyte replicative senes-
cence is highly limited. In contrast to in vivo conditions,
mature hepatocytes are extremely resistant to cell prolifer-
ation in cell culture. Usually, more than 99.9% of adult liver
hepatocytes do not divide and can only be maintained in
culture for a few weeks at most. A small progenitor-type
cell population (so called small hepatocytes) has been
shown to proliferate in vitro, but they usually stop growing
at passages 5–7, with an ill-deﬁned senescence-like pheno-
type [55].
Fetal hepatocytes display better proliferation capacity
in culture. A few studies have shown that these fetal cells
enter replicative senescence, as shown by senescence-
associated b-galactosidase assay (SABG) at population dou-
bling (PD) 30–35 [55]. This is accompanied by progressive
shortening of telomeres down to 6 kbp, as these cells like
adult hepatocytes lack telomerase activity. However, it was
possible to immortalize these fetal hepatocytes by stablePlease cite this article in press as: M. Ozturk et al., Senescence
(2008), doi:10.1016/j.canlet.2008.10.048expression of TERT [55]. Such immortalized cells have been
expanded beyond known senescence barriers (>300 PD).
In vivo senescence in liver tissue: in contrast to in vitro
studies, in vivo senescence of human hepatocytes is better
known. Indeed, the liver is one of the rare tissues where
in vivo evidence for senescence has been convincingly
and independently demonstrated by different investigators
[6–9]. Replicative senescence (as tested by SABG assay)
displayed a gradual increase from 10% in normal liver, to
84% in cirrhosis ([6,7]. It was also detected in 60% HCCs
[6]. It has also been demonstrated that telomere shorten-
ing in cirrhosis is restricted to hepatocytes and this hepa-
tocyte-speciﬁc shortening was correlated with SABG
staining [7].
Potential mechanisms of senescence in hepatocytes and
the liver: as presented in detail in the previous section,
multiple pathways of senescence have been described in
different experimental systems. Key molecules that are al-
ready involved in senescence arrest have also been sum-
marized. The published data on different senescence
pathways in the liver is fragmented and control mecha-
nisms involved in hepatocyte senescence are not com-
pletely understood. Therefore, existing data on
hepatocellular senescence together with potential mecha-
nisms that may be involved in this process will be
presented.
For reasons previously described, almost nothing is
known about molecular mechanisms involved in replica-
tive senescence and immortalization of hepatocytes in cul-and immortality in hepatocellular carcinoma, Cancer Lett.
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immortalization in vitro. Thus, ectopically expressed TERT
may induce hepatocyte immortalization. However, as the
published data using TERT immortalization is scarce, it is
highly likely that the immortalization of hepatocytes is
not an easy task even with a well-established protocol that
works with other epithelial cell types such as mammary
epithelial cells. The mechanisms of in vitro senescence
induction in hepatocytes are also mostly unknown. Rapid
induction of a senescence arrest in cultured hepatocytes
suggests that these cells display robust telomere-indepen-
dent senescence-inducing systems that are functional
in vitro. However, they remain to be discovered. It is highly
likely that, similar to other somatic cells, p53 and RB path-
ways in general, and some CDKIs in particular are also in-
volved in hepatocyte senescence, but the evidence is
lacking for the time being.
Telomere shortening during aging is slow (55–120 base
pairs per year) and stabilizes at mid age in healthy liver, so
that the loss of telomeric DNA does not reach a level to in-
duce telomere dysfunction and DNA damage response
[50,51]. Other forms of telomere-independent senescence
such as ROS-induced senescence may also be rare under
normal physiological conditions. On the other hand, telo-
mere loss is accelerated in chronic liver disease to reach
lowest levels in the cirrhotic liver [7,51]. Therefore, one
plausible mechanism involved in cirrhosis is probably telo-
mere-dependent senescence, or replicative senescence.
The relevance of replicative senescence to liver tissue aging
has been demonstrated experimentally using telomerase-
deﬁcient mice. Late generation telomerase-deﬁcient mice
display critically shortened telomeres and an impaired li-
ver growth response to partial hepatectomy. A subpopula-
tion of telomere-shortened hepatic cells displayed
impaired proliferative capacity that is associated with
SABG activity [11,56]. On the other hand, it has been re-
ported that mouse liver cells are highly resistant to exten-
sive telomere dysfunction. Conditional deletion of the
telomeric protein TRF2 in hepatocytes resulted in telomer-
ic accumulation of phospho-H2AX and frequent telomere
fusions, indicating loss of telomere protection. However,
there was no induction of p53 and liver function appeared
unaffected. The loss of TRF2 did not compromise liver
regeneration after partial hepatectomy. Liver regeneration
occurred without cell division involving endoreduplication
and cell growth, thereby circumventing the chromosome
segregation problems associated with telomere fusions.
Thus, it appears that hepatocytes display intrinsic resis-
tance to telomere dysfunction, although they are appar-
ently vulnerable to severe telomere loss [57].
Hepatocyte senescence that is observed in severe
chronic liver diseases such as cirrhosis may also be induced
by telomere-independent pathways. Chronic liver injury
observed under such conditions is accompanied with
inﬂammation, cell death, and oxidative stress [58–60].
Some of the etiological factors such as HCV and alcohol in-
duce mitochondrial dysfunction may result in ROS accu-
mulation [61,62]. Thus, ROS-induced senescence may also
occur during cirrhosis, although this has not yet been re-
ported. The status of DNA damage in chronic liver disease
is less well-known. 8-Hydroxydeoxyguanosine, an indica-Please cite this article in press as: M. Ozturk et al., Senescence
(2008), doi:10.1016/j.canlet.2008.10.048tor of DNA lesions produced by ROS, was reported to be in-
creased in chronic liver disease [63]. On the other hand, the
upregulation of DNA repair enzymes in cirrhosis has also
been reported [64]. Increased DNA repair activity in cirrho-
sis which may reﬂect increased DNA damages as a conse-
quence of chronic liver injury, but also inhibition of DNA
damage responses such as senescence were observed. Ta-
ken together, these observations suggest that the primary
cause of senescence in cirrhotic patients is telomere dys-
function and that ROS may also play additional roles.
Among senescence-related proteins, p16INK4a and
p21Cip1 expression was found to be high in cirrhosis, as
compared to normal liver and tumor tissues [65], suggest-
ing that these major senescence-inducing proteins accu-
mulate in the cirrhotic liver. Promoter methylation of
these CDKIs was also studied. Chronic liver disease sam-
ples displayed lower levels of methylation as compared
to HCCs [66]. Thus, the progression of chronic liver disease
towards cirrhosis is accompanied with a progressive acti-
vation of different CDKIs, as expected.5. Senescence pathway aberrations and telomerase
reactivation in hepatocellular carcinoma
As stated earlier, p53 and retinoblastoma (Rb) pathways
play a critical role in senescence arrest as observed in dif-
ferent in vitro and in vivo models. Indirect evidence sug-
gests that these pathways may also be important in
hepatocellular senescence. The accumulation of p21 and
p16 in cirrhotic liver tissues has been reported indepen-
dently by different reports. On the other hand, HCC rarely
develops in liver tissues absent of chronic liver disease.
More than 80% of these cancers are observed in patients
with cirrhosis [9]. As the appearance of proliferating malig-
nant cells from this senescence stage requires the bypass of
senescence, the status of both p53 and RB pathways in HCC
is of great importance in terms of molecular aspects of
hepatocellular carcinogenesis.
HCC is one of the major tumors displaying frequent p53
mutations [67,68]. The overall p53 mutation frequency in
HCC is around 30%. Both the frequency and the spectrum
of p53 mutations show great variations between tumors
from different geographical areas of the World. A hotspot
mutation (codon 249 AGG? AGT) has been linked to
exposure to aﬂatoxins which are known to be potent
DNA damaging agents (for a review see Ref. [67]).
Although, it is unknown whether aﬂatoxins are able to
generate a DNA damage-dependent senescence response
in hepatocytes, their association with DNA damage and
p53 mutation provides indirect evidence for such an abil-
ity. Other p53 mutations described in HCCs from low aﬂa-
toxin areas may similarly be correlated with other DNA
damaging agents, such as ROS which are known to accu-
mulate in the livers of patients with chronic liver diseases,
including cirrhosis.
Another player of senescence arrest, the p16 gene is
rarely mutated in HCC, but its epigenetic silencing by pro-
moter methylation is highly frequent in this cancer. More
than 50% of HCCs display de novo methylation of the pro-
moter of CDKN2A gene, encoding p16 protein, resulting inand immortality in hepatocellular carcinoma, Cancer Lett.
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Rb pathways in the same set of HCCs with different etiolo-
gies have been analyzed [69]. Retinoblastoma pathway
alterations (p16 INK4a, p15INK4b or RB1 genes) were present
in 83% of HCCs, whereas p53 pathway alterations (p53 or
ARF genes) were detected in only 31% of tumors. Altera-
tions in both Rb and p53 pathways were present in 30%
of HCCs. Thus, it appears that either the Rb and/or the
p53 pathway are affected in the great majority of HCCs,
and that both pathways are affected in at least one third
of these tumors. Unfortunately, p53 and p16INK4a aberra-
tions observed in HCC have not yet been studied in relation
to senescence aberrations. However, these observations
provide supporting evidence on the critical role of senes-
cence-controlling pathways in the development of HCC.
The lack of telomerase activity in normal and cirrhotic
liver correlates with progressive loss of telomere
sequences ending up with a senescence arrest. The
emergence of malignant hepatocytes from this senes-
cence-dominated cirrhotic milieu would require not only
the bypass of senescence, but also a way of survival despite
critically shortened telomeres. Additionally, the prolifera-
tive expansion of neoplastic cells in order to form
sustained tumor masses would require telomeres at a min-
imal length required to maintain intact chromosomal
structures.
Many studies showed that telomerase activity is a hall-
mark of all human cancers, including 80–90% of HCCs
[70–72]. It is currently unclear how the TERT expression
is repressed and released in normal hepatocytes and HCC
cells, respectively. The integration of HBV DNA sequences
into TERT gene provides evidence for a virus-induced
deregulation of TERT expression, but this appears to rarely
occur, as only four cases have been reported thus far [73–
75]. Hbx and PreS2 proteins may upregulate TERT expres-
sion [76,77]. The molecular mechanisms involved in TERT
suppression in somatic cells and its reactivation in cancer
cells are ill-known. The TERT promoter displays binding
sites for a dozen of transcriptional regulators: estrogen
receptor, Sp1, Myc and ER81 acting positively, and vitamin
D receptor, MZF-2, WT1, Mad, E2F1 and SMAD interacting
protein-1 (SIP1, also called ZEB-2 or ZFHX1B) acting nega-
tively [78]. Despite high telomerase activity, telomeres in
HCC were repeatedly found to be highly shortened
[65,79,80]. However, 30 telomere overhangs were found
to be increased in nearly 40% HCCs [80]. Moreover, the
expression of several telomeric proteins is increased in
HCC [80,81].
Another ill-known aspect of TERT activity in HCC cells is
the cellular origin of these malignant cells. It is presently
unclear whether HCC arises from mature hepatocytes
which lack telomerase activity, or stem/progenitor cell-like
cells that may already express TERT at sufﬁcient levels to
maintain telomere integrity. In the non-tumor area sur-
rounding the cancer tissue, telomerase activity could not
be detected, or was detected at very low levels.
The importance of telomerase activity in HCC
development has been studied experimentally using telo-
merase-deﬁcient mouse model. These mice show in-
creased susceptibility to adenoma development (tumor
initiation), but they are quite resistant to fully malignantPlease cite this article in press as: M. Ozturk et al., Senescence
(2008), doi:10.1016/j.canlet.2008.10.048tumor development [82]. Likewise, telomerase deletion
limits the progression of p53-mutant HCCs with short telo-
meres [83]. These observations suggest that the aberra-
tions affecting telomerase activity and senescence
controlling genes such as p53 may cooperate during hepa-
tocellular carcinogenesis.
In summary, HCC is characterized by mutational inacti-
vation of p53, a major player in DNA damage-induced
senescence. In addition, p15INK4b, p16INK4a, p21Cip1 CDKIs
are often inactivated in this cancer mostly by epigenetic
mechanisms involving promoter methylation. These
changes may play a critical role in the bypass of senescence
that is observed in most cirrhosis cases, allowing some ini-
tiated cells to escape senescence control and proliferate. In
the absence of telomerase activity such cells would proba-
bly not survive due to telomere loss. However, since more
than 80% of HCCs display telomerase activity, it is highly
likely that the telomerase reactivation, together with the
inactivation of major CDKIs, plays a critical role in HCC
development by conferring premalignant or malignant
cells the ability to proliferate indeﬁnitely (Fig. 3). However,
cellular immortality is not sufﬁcient for full malignancy
[84]. Thus, senescence-related aberrations that are ob-
served in HCC cells, may confer a partial survival advan-
tage that would need to be complemented by other
genetic or epigenetic alterations.6. Senescence as an anti-tumor mechanism in
hepatocellular carcinoma
Senescence in normal somatic cells and tissues is ex-
pected. How about cancer cells and tumors? Initial studies
using different cancer cell lines provided ample evidence
for the induction of senescence by different genetic as well
as chemical or biological treatments [85]. Thus, it appeared
that cancer cells, immortalized by deﬁnition, do have a
hidden senescence program that can be revealed by differ-
ent senescence-inducing stimuli. These studies provided
preliminary evidence for considering senescence induction
as an anti-cancer therapy. The in vivo relevance of these
observations and expectations became evident only very
recently. Senescence was observed in tumors or pre-neo-
plastic lesions. SABG activity as well as several other senes-
cence markers were detected in lung adenomas, but not in
adenocarcinomas observed in oncogenic Ras ‘‘knock-in”
mice [86]. Ras-driven mouse T-cell lymphomas entered
senescence after drug therapy, when apoptosis was
blocked [87]. The ﬁrst direct evidence of cellular senes-
cence in humans was reported for the melanocytic nevus
[88].
Senescence response of HCC cells was not the subject of
intensive study until very recently. Therefore the potential
role of senescence in these tumors is less well understood.
Treatment of HCC cell lines with 5-aza-2-deoxycytidine in-
duced the expression of p16INK4a, hypophosphorylation of
pRb and G1 arrest associated with positive SABG staining
[89]. Recent ﬁndings indicate that senescence induction
is a powerful mechanism of HCC regression. Xue et al. ex-
pressed H-ras oncogene and suppressed endogenous p53
expression in mouse hepatoblasts which produced massiveand immortality in hepatocellular carcinoma, Cancer Lett.
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However, these tumors regressed rapidly upon restoration
of p53 expression. Tumor regression was due to differenti-
ation and massive senescence induction, followed by im-
mune-mediated clearance of senescent cells. These
observations may indicate that oncogene-induced senes-
cence is also involved in HCC. On the other hand, HCCs in-
duced by tet-regulated c-Myc activation in mouse liver
cells differentiate into mature hepatocytes and biliary cells
or undergo senescence [90]. Thus, senescence induction
may also be relevant to oncogene inactivation in HCC. In
this regard, c-Myc down-regulation and senescence induc-
tion in several HCC cell lines as a response to TGF-b was
observed (S. Senturk, M. Ozturk, unpublished data).
So far, all the reported examples of senescence induc-
tion in HCC cells are in the form of a telomere-independent
permanent cell cycle arrest. Until recently, it was unknown
whether replicative senescence could also be induced in
immortal cancer cells. Ozturk et al. reported recently that
immortal HCC cells can revert spontaneously to a replica-
tive senescence phenotype [91]. Immortal HCC cells gener-
ated progeny that behaved, in vitro, similar to normal
somatic cells. Such senescence-programmed progeny
lacked telomerase activity due to TERT repression (proba-
bly mediated by SIP1 gene), and displayed progressive
telomere shortening in cell culture, resulting in senescence
arrest. It will be interesting to test whether such spontane-
ous reversal of replicative immortality is involved in wellPlease cite this article in press as: M. Ozturk et al., Senescence
(2008), doi:10.1016/j.canlet.2008.10.048known tumor dormancy and/or spontaneous tumor
regression.
7. Concluding remarks
Cellular senescence has gained great interest in recent
years following the demonstration that it also occurs
in vivo. It is also highly interesting that senescence can
be mediated by a large number of pathways and mole-
cules, as is the case for apoptosis. Recent ﬁndings that
implicate secreted molecules in senescence induction
strongly suggest that cellular senescence is not just a cellu-
lar event, but also a physiologically relevant process for the
whole organism. In terms of tumor biology, oncogene-in-
duced senescence that may serve as anti-tumor mecha-
nism in pre-neoplastic lesions underlines its clinical
relevance. On the other hand, induced or spontaneous
senescence that is observed in cancer cells is promising
to explore new approaches for tumor prevention and treat-
ment. The role of senescence bypass and cellular immortal-
ity in hepatocellular carcinogenesis is not well deﬁned.
But, many ﬁndings (inactivation of senescence-mediator
genes such as p53, p16INK4a and p15INK4b, as well as reacti-
vation of TERT) indicate that senescence mechanisms and
their aberrations are critically involved in HCC. We may
expect that this ﬁeld will attract more attention in coming
years for a better deﬁnition of senescence implications in
hepatocellular carcinogenesis.and immortality in hepatocellular carcinoma, Cancer Lett.
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